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Zusammenfassung 
Während der Embryogenese, bestimmen koordinierte Abfolgen weitreichender 
transkriptioneller Änderungen und die Reorganisation des Chromatins die Zelltyp-
Spezifizierung. Pionertranskriptionsfaktoren stellen in diesem Prozess eine entscheidende 
Rolle, bei der Programmierung des Epigenoms und der Rekrutierung weiterer 
regulatorischer Faktoren, dar. Der LIM-homeodomain Transkriptionsfaktor Isl1 ist 
entscheidend für die frühe Entwicklung des Herzens und fungiert als Marker der kardialen 
Vorläuferzellen des sogenannten „second heart field“. Allerdings sind, durch die frühe 
embryonale Letalität von Isl1-Knockout Mäusen, Studien zur Rolle von Isl1 in späteren 
Phasen der Herzentwicklung unmöglich. Dadurch bleiben die Funktion von Isl1 in der 
epigenetischen Regulation der second heart field Entwicklung und die zugrundeliegenden 
Mechanismen weitgehendst ungeklärt.  
Im Zuge unserer Studie konnten wir, mittels eines Isl1-hypomorphen Mausmodells, Isl1 als 
kritischen Faktor für die kardiale Entwicklung während der späten embryonalen Entwicklung 
identifizieren. Mittels high-throughput sequencing und unter Verwendung eines Isl1-
Knockout Mausmodells und des Isl1-hypomorphen Mausmodells in Kombination mit einem 
gerichteten kardialen Differenzierungssystem, konnten wir ein regulatorisches Netzwerk in 
kardialen Vorläuferzellen identifizieren, deren Derivate durch Isl1 organisiert sind. Mit Hilfe 
von Analysen des genomweiten Profilings von Isl1-Bindestellen und von ATAC-
Sequenzierungsdaten konnten wir Isl1 als entscheidenden Faktor der frühen Kardiogenese 
identifizieren. Weiterhin konnten wir zeigen, dass Isl1 mit Brg1 und Baf60c interagiert. Isl1 
induziert zusammen mit dem Brg1-Baf60c-basiertem SWI/SNF Komplex 
Genexpressionsprogramme in kardialen Vorläuferzellen und unterstützt die Zell-
Spezifizierung durch die Organisation des Genome.  
Abschließend konnten wir Isl1 als entscheidenden Pionertranskriptionsfaktor in der 
kardialen Zelldifferenzierung charakterisieren. Diese Erkenntnisse gewähren Einblicke in die 
molekularen Mechanismen der Kardiogenese und eröffnen somit neue Möglichkeiten für ein 
besseres Verständnis der kardialen Entwicklung.  
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Abstract 
Coordinated series of large-scale transcriptional changes and chromatin reorganization drive 
cell type specification and differentiation during embryogenesis. In this process, pioneer 
transcription factors play key roles in programming the epigenome and facilitating 
recruitment of additional regulatory factors. Isl1, a LIM-homeodomain transcription factor, 
marks the second heart field and plays a key role in early cardiac development. However, the 
early embryonic lethality of Isl1 knockout mouse makes it impossible to study the role of Isl1 
at later stages of mouse heart development. The role of Isl1 in epigenetic regulation during 
second heart field development and the mechanisms behind are still not clear.  
In this study, using an Isl1 hypomorphic mouse model, we found Isl1 is critical for cardiac 
development even at the later stages of embryonic development. To search for the 
downstream targets of Isl1 during cardiogenesis, we performed RNA-Sequencing with an Isl1 
knockout mouse model and the Isl1 hypomorphic mouse model, together with a mESC-
based directed cardiac differentiation system. In combination with ChIP in mESC-derived 
cardiac progenitor cells and in mouse embryos followed by high-throughput sequencing, we 
identified a regulatory gene network in cardiac progenitor cells and their derivatives 
organizing by Isl1.  
To investigate the molecular mechanism underlying the role of Isl1 in second heart field 
development, we firstly revealed that Isl1 interacts with Brg1 and Baf60c in cardiac 
progenitor cells by co-immunoprecipitation. We further performed ATAC-sequencing in 
mESC-derived cardiac progenitor cells and in mouse embryos. Analysis of ATAC-sequencing 
data, combined with genome-wide profiling of Isl1 binding in mESC-derived cardiac 
progenitor cells and in mouse embryos, we identified that Isl1 acts as a pioneer factor during 
cardiogenesis. Moreover, we found Isl1 might recruit Brg1 to its target sites and works 
cooperatively with the Brg1-Baf60c-based SWI/SNF complex to reorganize the chromatin 
landscape of target genes with critical functions in cardiac development, thus inducing gene 
expression programs in cardiac progenitors and promoting cardiac cell fate specification. 
In conclusion, our study highlights a pioneering function of Isl1 in cardiac lineage 
commitment and provides exciting novel insights into the molecular machinery orchestrating 
cardiogenesis. 
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1. Introduction 
1.1 Heart development 
In vertebrates, the heart is the first organ to form and is crucial to supply the embryo with 
nutrients and oxygen while removing metabolic waste. Therefore, the normal formation and 
function of the heart are essential for fetal life (Bruneau 2013). So far, numerous studies 
have defined the process of heart morphogenesis. Mouse heart development resembles that 
of the human, and thus has been supplied as a good model for understanding human 
cardiogenesis and congenital heart disease (CHD). A better understanding of heart 
development might in the long run have an impact on clinical management of CHD and help 
to generate efficient therapies. 
1.1.1 Mouse heart development 
In mouse embryos, myocardial cells are derivatives of the mesoderm, which emerges from 
the primitive streak during gastrulation (Buckingham, Meilhac et al. 2005). At around 
embryonic day 6.5 (E6.5), cardiac progenitor cells leave the primitive streak and migrate in 
an anterior-lateral direction to positions under the head folds, forming two groups of cells 
on either side of the midline (Figure 1A) (Buckingham, Meilhac et al. 2005). The cells then 
extend across the midline to form the cardiac crescent where differentiated myocardial cells 
are now observed (E7.5) (Figure 1B) (Buckingham, Meilhac et al. 2005). The region of the 
crescent, which fuses at the midline to form the primitive cardiac tube, is termed the first 
heart field (FHF, shown in red in Figure 1) (Vincent and Buckingham 2010). The second 
population of cells, which resides medially and posteriorly to the first heart field at E7.5, and 
later locates behind the heart tube, is referred to as the second heart field (SHF, shown in 
green in Figure 1) (Vincent and Buckingham 2010, Xin, Olson et al. 2013). The FHF is the 
source of the early left ventricle (LV) whereas the SHF gives rise to the outflow tract (OFT) 
and the right ventricle (RV), and both populations contribute to the atria (Dyer and Kirby 
2009, Vincent and Buckingham 2010, Buckingham 2016). 
One of the key steps in this refinement was the identification of Islet 1 (Isl1) as a SHF marker 
(Schoenwolf 2000, Waldo, Kumiski et al. 2001, Cai, Liang et al. 2003, Vincent and 
Buckingham 2010). According to marker gene expression and their contribution to the heart, 
the SHF is further divided into two main subdomains: anterior SHF (aSHF, shown in dark 
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green in Figure 1C) and posterior SHF (pSHF, shown in light green in Figure 1C) (Vincent and 
Buckingham 2010). The aSHF is marked by expression of Fgf8, Fgf10, and Tbx1 and mainly 
contributes to the right ventricle and outflow tract myocardium progenitors (Robert G.Kelly 
2001, Xu, Morishima et al. 2004). In contrast, the pSHF cells contribute to the atria at the 
venous pole of the heart, expressing Isl1, but not the aSHF marker genes (Galli, Dominguez 
et al. 2008, Vincent and Buckingham 2010). 
 
 
Figure 1 Overview of mouse heart development (modified from (Buckingham, Meilhac et 
al. 2005, Meilhac, Lescroart et al. 2014, Zaffran, Robrini et al. 2014, Santini, Forte et al. 
2016)) 
Different stages in cardiac morphogenesis. FHF and SHF cells and their descendants are shown in red 
and green, respectively. Solid arrows indicate ongoing rearrangement of FHF and SHF cells. (A) 
Myocardial progenitor cells originate in the primitive streak (PS), from where they migrate to the 
anterior of the embryo at about E6.5. (B) Formation of the cardiac crescent (CC), with the second 
heart field (SHF) lying medial to it. (C) FHF cells form the primary heart tube, with SHF cells being 
added to the poles of the primary heart tube. At E8.0, frontal and lateral views showing the heart 
tube and subdomains of the SHF, including aSHF (anterior second heart field, in dark green) and pSHF 
(posterior SHF, in light green). (D) At E9.0, frontal and lateral views of the heart region showing 
looped heart tube. Dashed arrows indicate migration of cardiac neural crest cells to the heart. (E and 
F) The chambered hearts at E10.5 (E) and E14.5 (F) are shown, with lineage contributions to the heart 
from the FHF (first heat field), SHF (second heart field), cardiac neural crest (CNC) and proepicardium 
(PE). PA: pharyngeal arch; OT: outflow tract; RA: right atrium; RV: right ventricle; LA: left atrium; LV: 
left ventricle; Ao: aorta; PT: pulmonary trunk; Epi: epicardium. 
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The early FHF-derived cardiac tube provides a scaffold for subsequent growth. The primary 
heart tube grows by division of existing cardiomyocytes and by addition of the SHF 
myocardial progenitors to the arterial pole, where blood is pumped out the heart, and to the 
venous pole, where blood enters the heart. As the heart tube elongates, it undergoes a 
rightward looping and subsequently ballooning, result in formation of the four-chambered 
heart (Buckingham, Meilhac et al. 2005, Xin, Olson et al. 2013). During later stages, the 
mature shape of the heart is generated by differentiation of cardiac cell populations and 
extensive remodeling of the heart, resulting in a well‐developed heart with distinct in‐ and 
outflow tracts, cardiac valves separating the different compartments, and a mature 
conduction system (Scheuermann and Boyer 2013) (Figure 1). 
1.1.1.1 Proepicardium 
During heart development, in addition to the cells of FHF and SHF, there are other two cell 
populations also contribute to the formation of the heart: proepicardium (PE) and the 
cardiac neural crest (CNC) (Laugwitz, Moretti et al. 2008, Vincent and Buckingham 2010, 
Santini, Forte et al. 2016). Proepicardium (shown in yellow in Figure 1D) is a transitory 
structure, which arises from the lateral plate mesoderm (LPM) and forms at the posterior 
end of the heart tube between E8.5 and E9.5. Proepicardial cells subsequently undergo an 
epithelial-to-mesenchymal transition (EMT) and invade the myocardium (Rickert-Sperling, 
Kelly et al. 2015, Meilhac and Buckingham 2018). Proepicardium gives rise to the epicardium 
which covers the external surface of the heart, smooth muscle cells associated with coronary 
arteries and cardiac fibroblasts (Maya-Ramos, Cleland et al. 2013, Rickert-Sperling, Kelly et 
al. 2015) (Figure 3B). Wt1 (Wilms Tumor 1), Tbx18 (T-Box 18) and Tcf21 (Transcription Factor 
21) are usually used as PE markers, even though they are also expressed in other tissues 
(Maya-Ramos, Cleland et al. 2013, Meilhac and Buckingham 2018). Another two PE markers, 
Scx (Scleraxis BHLH Transcription Factor) and Sema3D (Semaphorin 3D) are more specifically 
expressed in the PE and epicardium (Maya-Ramos, Cleland et al. 2013). 
1.1.1.2 Cardiac neural crest 
Cardiac neural crest (CNC) (shown in purple in Figure 1D) originate from the neural tube. 
CNC cells migrate to the pharyngeal arches and a subset continues to migrate through the 
anterior SHF into the outflow tract, playing a critical role in the remodeling of the outflow 
tract region. Interactions between neural crest cells and the anterior SHF affect the behavior 
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of both cell populations and their contributions to the heart (Vincent and Buckingham 2010). 
Fate mapping studies in both quail/chick chimeras and mouse embryos showed that CNC 
contributes to the aortopulmonary septum and valve formation which leads to the 
separation of the distal OFT into aorta and pulmonary trunk (Karen Waldo 1998, Xiaobing 
Jiang 2000). Moreover, the CNC plays a key role in the development of pharyngeal arch 
arteries and also gives rise to the cardiac ganglia (Kirby and Hutson 2010). Pax3 is a vital 
regulator of CNC and serves as a marker of CNC cells in mouse embryos (S.J. Conway 1997, 
Jun Li 2000). 
1.1.1.3 Chamber septation and valves formation 
In mouse embryos, the first anatomic features of septation are seen at E10.5, when a 
distinct ridge appears in the atrial roof (the primary atrial septum) (Anderson, Spicer et al. 
2014). During E11.5, this muscular septum extends through the cavity of the initially 
common atrial chamber, carrying on its leading edge a mesenchymal cap (MC), which arises 
through epithelial-to-mesenchymal transition (EMT) from the endocardium overlying the 
cap. With continuing growth of the muscular primary atrial septum, this mesenchymal cap 
approaches, and then fuses with, the superior endocardial cushion of the atrioventricular 
(AV) canal (Robert H Anderson 2003, Anderson, Spicer et al. 2014). The endocardial cushions 
contain mesenchymal cells that are derived from the endocardium through EMT. This 
primary atrial septum partially septates the atrial chamber and leaves a gap (the ostium 
primum) between the mesenchymal cap (MC) and the AV canal. The MC then merges 
anteriorly with the AV cushions and posteriorly with the dorsal mesenchymal protrusion 
(DMP) to fill the ostium primum. The DMP comes from the SHF and bulges into the atrial 
chamber as a mesenchymal protrusion. These mesenchymal tissues are later muscularised 
to form sturdy septum. While the ostium primum is closing, the upper margin of the primary 
atrial septum dissolves, creating a second opening (the ostium secundum) between the right 
and left atria. The ostium secundum is later sealed by a muscular septum (the secondary 
atrial septum), which is formed by part of the atrial roof that folds inward. The primary and 
secondary atrial septum then fuses to complete the septation of atrial chamber (Robert H 
Anderson 2003, Lin, Lin et al. 2012). Along with the atrial septum formation, an 
interventricular muscular septum emerges within the ventricular chamber (Robert H 
Anderson 2003). The interventricular septum (IVS) forms by outgrowth of two adjacent cell 
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populations in a small segment of the left and right ventricles (Bruneau 2013). It fuses with 
atrioventricular cushions, dividing the ventricular chamber into left and right ventricles (Lin, 
Lin et al. 2012). In addition, a subset of endocardial cushion cells in the atrioventricular canal 
(AVC) develops into atrioventricular (mitral and tricuspid) valves, whereas the OFT 
endocardial cushions give rise to semilunar (aortic and pulmonic) valves. The formation of 
heart valves ensures the blood flows in one direction from the atria to ventricles and then to 
the arteries (Lin, Lin et al. 2012). 
1.1.1.4 Trabeculation 
During vertebrate cardiac chamber maturation, ventricular myocardium undergoes 
trabeculation which is a process forming highly organized sheet-like muscular structures, 
termed trabeculae, in the inner surface of the ventricular wall. This is a result of the 
extrusion and expansion of differentiated cardiomyocytes into the lumen of the ventricular 
chambers (Liu, Bressan et al. 2010, Samsa, Yang et al. 2013). In mouse, the trabeculation 
occurs at approximately E9.5 and forms a mature trabeculated network at around E14.5 (Liu, 
Bressan et al. 2010, Samsa, Yang et al. 2013), increasing the myocardial surface area to 
facilitate the uptake of oxygen and nutritions (Meilhac and Buckingham 2018). Trabeculae 
are no longer required when the coronary vascular system develops, so they undergo 
compaction at the later stages (Meilhac and Buckingham 2018). 
1.1.2 Congenital heart disease 
Congenital heart disease (CHD) is the most common cause of major congenital anomalies, 
representing a major global health problem (Denise van der Linde, Konings et al. 2011). In 
man, CHD occurs in 0.5%-1% of live births, with similar prevalence all over the world (Harris 
2011, Kernell, Sydsjö et al. 2014, Triedman and Newburger 2016). CHD is usually referred to 
as abnormality in cardiac structures or associated vessels which are of functional significance 
(van der Bom, Zomer et al. 2011). It is classified into two main groups: acyanotic and 
cyanotic CHD (Figure 2). Infants with cyanotic CHD appear a bluish color of the skin and 
mucous membranes, due to the mixing of large amount of oxygenated and deoxygenated 
blood, while infants with acyanotic CHD initially do not (Bruneau 2008, Abramzon, Bosaleh 
et al. 2019). Acyanotic CHD includes ventricular septal defect (VSD), atrial septal defect 
(ASD), and patent ductus arteriosus (PDA), and so on. Like acyanotic CHD, cyanotic CHD also 
contains many different types of CHD, such as Tetralogy of Fallot (ToF), Persistent truncus 
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arteriosus (PTA) and Transposition of the great arteries (TGA). Here I summarized some of 
the common types of CHD. 
 
Figure 2 Common types of congenital heart disease (adapted from (Abramzon, Bosaleh et 
al. 2019)) 
Graphical representation shows the characteristics of some of the main defects with acyanotic and 
cyanotic CHD. RA: Right atrium; LA: Left atrium; RV: Right ventricle; LV: Left ventricle; A: Aorta; PA: 
Pulmonary artery; VSD: ventricular septal defect; ASD: atrial septal defect; PDA: Patent ductus 
arteriosus; ToF: Tetralogy of Fallot; PTA: Persistent truncus arteriosus; TGA: Transposition of the 
great arteries. 
 
1.1.2.1 Ventricular septal defect and atrial septal defect (VSD and ASD) 
VSD and ASD are the most common CHD in newborns. They are result from incomplete 
cardiac chamber septation during heart development. The hole in the atrial or ventricular 
septum leads to communications between the left and right atria or ventricles, respectively 
(Garg 2006, Midgett and Rugonyi 2014). The presence of a VSD can result in pulmonary 
hypertension as more blood needs to be pumped to the pulmonary vessels and can force the 
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left ventricle to work harder to pump the needed blood to the body (Garg 2006, Midgett and 
Rugonyi 2014). Moreover, VSDs are commonly associated with other types of CHD, such as 
Patent ductus arteriosus (PDA) (Abramzon, Bosaleh et al. 2019). In addition, VSDs sometimes 
undergo spontaneous closure shortly after birth. In contrast, ASD is generally the most 
frequent CHD found in adults, especially in women (Hoffman and Kaplan 2002, Abramzon, 
Bosaleh et al. 2019). 
1.1.2.2 Patent ductus arteriosus (PDA) 
Patent ductus arteriosus (PDA) is one of the common CHDs, which occurs when the ductus 
arteriosus that supposed to close after birth does not close (Midgett and Rugonyi 2014). 
Ductus arteriosus (DA) is a normal connection between the aorta and the pulmonary artery 
when babies are developing in the uterus. During pregnancy, it is not necessary for blood to 
circulate through the fetus’s lungs because oxygen is provided through the placenta. 
However, when the baby is born, the blood must receive oxygen from the lungs and this hole 
is supposed to close. When it fails to close, the oxygenated blood from the aorta will mix 
with deoxygenated blood from the pulmonary artery. PDA can increase blood pressure in 
the pulmonary arteries causing pulmonary hypertension (Midgett and Rugonyi 2014). 
1.1.2.3 Tetralogy of Fallot (ToF) 
Tetralogy of Fallot (ToF) is the most common cyanotic CHD. It is a combination of four 
congenital abnormalities, including (1) right ventricular outflow tract obstruction, such as 
pulmonary stenosis, narrowing of the pulmonary valve opening; (2) VSD; (3) overriding aorta 
(OA), an OFT alignment defect, in which the aorta is shifted slightly to the right and lies 
directly above the VSD; and (4) RV hypertrophy, in which muscular wall of the RV is thicken 
due to the overworking (Abramzon, Bosaleh et al. 2019). Frequent associated defects can be 
found in ToF patients such as ASD, right aortic arch, and coronary artery anomalies 
(Abramzon, Bosaleh et al. 2019).  
1.1.2.4 Persistent truncus arteriosus (PTA) 
Persistent truncus arteriosus (PTA) is another kind of cyanotic CHD. It results from the failed 
division of the pulmonary artery and the aorta during fetal development, in which the single 
common arterial trunk usually overrides the interventricular septum (Mavroudis 2015). In 
most cases, it is associated with other CHD defects, especially VSD. The deoxygenated blood 
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from the RV and the oxygenated blood from the LV mix together when they are ejected out 
into the common trunk, going to both the body and the lungs. Therefore, it makes the heart 
to work harder and is risky of pulmonary hypertension (Midgett and Rugonyi 2014). 
1.1.2.5 Transposition of the great arteries (TGA) 
Transposition of the great arteries (TGA) is one of the most common and severe cyanotic 
CHD in neonates (Abramzon, Bosaleh et al. 2019). It is principally a result of failed OFT 
rotation (Neeb, Lajiness et al. 2013). In TGA, The aorta and pulmonary artery are fully 
septated but the positioning of them is reversed, with the aorta arising from the RV and the 
pulmonary trunk arising from the left ventricle (LV) (Neeb, Lajiness et al. 2013). It leads to 
the heart pumps the deoxygenated blood in RV from the body again to the body through the 
aorta; while pumps the oxygenated blood in LV from the lungs to the lungs again through 
the pulmonary artery. TGA is often associated with other CHDs, such as ASD, VSD and PDA 
(Martins and Castela 2008). In this case, the mixing of oxygenated blood and deoxygenated 
blood by other defects is beneficial, since they provide at least some oxygen to the body. 
TGA causes high mortality rate without treatment, thus surgical treatment is usually needed 
(Abramzon, Bosaleh et al. 2019). 
1.1.3 Cell types and cardiac lineages in mammalian heart 
The heart is predominantly made up of epicardium, endocardium, and myocardium, as well 
as cardiac fibroblasts (Doetschman and Azhar 2012). Epicardium is the outermost layer of 
the heart, whereas endocardium is the innermost layer. In the middle is the myocardium, 
which forms the muscular walls of the heart (Lin, Lin et al. 2012). The epicardial cells are 
derived from the proepicardium, some of which subsequently undergo epithelial-to-
mesenchymal transition (EMT) and give rise to cardiac fibroblasts and smooth muscle cells in 
coronary arteries (Ramón Muñoz-Chápuli 2002). The endocardium contains a large group of 
endothelial cells, which are mainly derived from the cardiogenic mesoderm. Moreover, the 
endothelial cells also form the interior lining of blood vessels and surround the cardiac valves 
(Xin, Olson et al. 2013). The myocardium is primarily constituted with cardiomyocytes, which 
originate from the cardiogenic mesoderm (Doetschman and Azhar 2012). The cardiac 
conduction cells mainly consist of purkinje fiber and pacemaker cells (Doetschman and Azhar 
2012). They are specialized cardiomyocytes that generate and conduct electrical impulses 
(Xin, Olson et al. 2013). In addition, cardiac neural crest cells mostly contribute to the aortic 
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smooth muscle cells in distal outflow tract region, to the septum between the aortic and 
pulmonary trunks and valves, and autonomic nervous system cells in the heart (Meilhac 
2012, Kloesel, DiNardo et al. 2016). These types of cells all work together to form the 
functional heart.  
 
Figure 3 Origins and lineage relationships of cardiac cell types (adapted from (Mikawa and 
Takashi 1999, Meilhac 2012, Chong, Forte et al. 2014)) 
Schematic diagram summarizes the lineage tree of cardiac cell types, which derive from three origins: 
cardiogenic mesoderm, cardiac neural crest and the proepicardium. (A) Cells from the cardiogenic 
mesoderm, containing precursors of the endocardium and myocardium. Conduction cells are 
specialized cardiomyocytes (CM), including the pacemaker cells and purkinje fibres. (B) Cells from 
cardiac neural crest and the proepicardium. Cardiac neural crest cells mainly contribute to the 
smooth muscle of the aortic and pulmonary trunks, and the pharyngeal arch arteries, to the septum 
between the aortic and pulmonary trunks and valves, and to the ganglia of the developing heart. 
Proepicardium gives rise to the epicardium. A subset of these cells, termed epicardial-derived cells 
(EPDCs), mainly differentiates into the coronary smooth muscle cells, as well as cardiac fibroblasts. 
 
Interestingly, studies from different labs suggest that, with respect to lineage diversification, 
different cardiac cell types arise from a common progenitor (Kattman, Huber et al. 2006, 
Moretti, Caron et al. 2006, Wu, Fujiwara et al. 2006, Bu, Jiang et al. 2009). Moreover, the 
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work from Moretti et al. revealed the existence of multipotent Isl1+ cardiovascular 
progenitors (Moretti, Caron et al. 2006), which can generate the three major cell types of 
the heart: cardiomyocytes, smooth muscle and endothelial cells (Moretti, Caron et al. 2006, 
Wu, Fujiwara et al. 2006, Laugwitz, Moretti et al. 2008, Bu, Jiang et al. 2009) (Figure 4). 
 
Figure 4 Cellular hierarchy of cardiac progenitors and their lineage specification (adapted 
from (Moretti, Caron et al. 2006, Wu, Fujiwara et al. 2006, Laugwitz, Moretti et al. 2008)) 
Isl1+ cardiovascular progenitors are multipotent which can give rise to all three major cell types in the 
heart (Moretti, Caron et al. 2006). Nkx2.5+ progenitor cells are reported to be bipotent (Wu, Fujiwara 
et al. 2006) or multipotent (Ma, Zhou et al. 2008). However, lineage reconstruction from single cell 
analysis shows that Nkx2.5+ cells are primed to cardiomyocyte lineage (DeLaughter, Bick et al. 2016, 
Jia, Preussner et al. 2018). 
 
1.1.4 Signaling pathways in cardiac development 
Signaling pathways and networks orchestrated by signaling molecules play key roles in 
regulating cardiac morphogenesis. Perturbation of signaling molecules during cardiogenesis 
leads to congenital heart defects. Over the past years, a number of studies have identified 
key signaling pathways controlling cardiogenesis, such as Wnt, Bmp, FGF, Hedgehog and 
Notch signaling pathways (Figure 5). 
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Figure 5 Illustration showing the core features of Wnt, FGF, BMP, Hh, and Notch signaling 
pathways (Rochais, Mesbah et al. 2009) 
This simplified schema summarizes the key steps from ligand binding to target gene transcription for 
each signaling pathway (Rochais, Mesbah et al. 2009). Details are described in the context in sub-
sections of each pathway. 
 
1.1.4.1 Wnt signaling pathway 
Wnt signaling pathway is a key pathway during development and it plays multiple roles in 
regulating cellular behavior including proliferation, differentiation, cell migration, and cell 
polarity (Tian, Cohen et al. 2010). It consists of canonical Wnt signaling pathway and 
noncanonical Wnt signaling pathway.  
In canonical Wnt signaling pathway (also called, Wnt/β-catenin signaling pathway), binding 
of Wnt ligands to the Fzd (Frizzled)-LRP5/6 receptor complex allows the activation of the 
intracellular effector DSH (Disheveled), which results in the uncoupling of β-catenin from a 
multiprotein degradation complex composed of APC (adenomatous polyposis coli), Axin, and 
GSK3β (glycogen synthase kinase 3β). β-catenin then translocates to the nucleus and, in 
association with LEF/TCF, activates target gene transcription. Binding of Wnt ligand to 
receptors can be blocked by its binding to secreted FRZB (frizzled-related molecules). 
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Canonical Wnt pathway has been reported to play diverse roles during heart development 
which will lead to different effects depending on the time of action (Gessert and Kuhl 2010, 
Buikema, Zwetsloot et al. 2014). Canonical Wnt signaling initially promotes cardiogenesis, 
but later is inhibitory as progenitors begin to differentiate into various cardiac derivatives 
(Naito, Shiojima et al. 2006, Kwon, Arnold et al. 2007, Bruneau 2013). Cell culture studies of 
cardiac differentiation revealed that canonical Wnt activation induces nascent mesoderm 
from pluripotent stem cells, but once mesoderm is induced, inhibition of canonical Wnt 
signaling is necessary for cardiac specification and prolonged Wnt/β-catenin activation 
inhibits cardiac differentiation and instead, induces other lineages (Kattman, Witty et al. 
2011, Xiaojun Lian 2012, Burridge, Matsa et al. 2014, Loh, Chen et al. 2016, Sadahiro, Isomi 
et al. 2018). Consistently, inhibition of Wnt/β-catenin signaling results in failure of ESCs to 
generate Flk1+ mesodermal precursors and subsequent mature mesodermal lineages 
(Lindsley, Gill et al. 2006). 
In addition to playing earlier roles in mesoderm development, canonical Wnt signaling also 
promotes cardiac progenitor cell proliferation and plays an inhibitory role in later 
cardiomyocyte differentiation (Cohen, Tian et al. 2008). In vivo activation of β-catenin 
signaling in Isl1+ progenitors of the SHF leads to their massive accumulation, inhibition of 
differentiation, and outflow tract (OFT) morphogenic defects (Qyang, Martin-Puig et al. 
2007). Wnt2 was also shown to regulate the expansion of cardiac progenitor cells in the 
posterior SHF through canonical Wnt pathway (Tian, Yuan et al. 2010). In contrast, the 
expression of secreted Wnt antagonists Crescent, which competes with Fzd for Wnt binding 
via its homology to the Fzd extracellular domain, and Dkk1, which inhibits canonical Wnt 
signaling by causing Lrp5/6 receptor internalization, induces cardiac gene expression and the 
appearance of beating cardiomyocytes in noncardiogenic mesoderm in chick and Xenopus 
embryos (Marvin MJ 2001, Valerie A. Schneider 2002). Moreover, tissue-specific deletion of 
β-catenin in the SHF with Isl1-Cre results in nearly complete loss of the right ventricle, 
suggesting β-catenin is required for right ventricle formation (Kwon, Arnold et al. 2007, 
Kwon, Cordes et al. 2008).  
Noncanonical Wnt signaling pathway consists of two signaling pathways. One is downstream 
of DSH and the other one is independent of DSH. In the first pathway, activated DSH 
promotes small G protein (Rac and Rho) activation, leading to the activation of JNK (c-Jun N-
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terminal kinase) and ROCK (Rho-associated kinase). Ultimately, the ATF/CREB complex is 
activated and results in target gene transcription. The second pathway, called Wnt/Ca2+ 
pathway, results in intracellular Ca2+ release and activation of the Ca2+/CamK2 (calmodulin-
dependent kinase 2) and the PKC (protein kinase C) pathways. 
Two noncanonical Wnt ligands, Wnt5a and Wnt11, are expressed at the arterial pole of the 
heart as SHF cells migrate through on their way to the right ventricle, and mice with 
homozygous mutations of Wnt5a or Wnt11 have outflow tract defects consistent with those 
caused by disruption of the SHF (Tian, Cohen et al. 2010, Sinha, Li et al. 2015, van Vliet, Lin et 
al. 2017). Wnt5a and Wnt11 were reported to promote cardiac differentiation and inhibit 
the proliferation of SHF progenitor cells (Terami, Hidaka et al. 2004, Koyanagi, Haendeler et 
al. 2005, Koyanagi, Iwasaki et al. 2009, Abdul-Ghani, Dufort et al. 2011, Cohen, Miller et al. 
2012, Bisson, Mills et al. 2015). They are co-required for repressing canonical Wnt signaling 
in SHF progenitors and promote SHF progenitor development cooperatively (Cohen, Miller et 
al. 2012, Bisson, Mills et al. 2015). In addition, Wnt2 is strongly expressed in the early 
developing murine heart, and was reported to be essential for efficient cardiomyocyte 
differentiation from ES cells through JNK/AP-1 pathway (Onizuka, Yuasa et al. 2012). 
1.1.4.2 FGF signaling pathway 
In FGF (Fibroblast Growth Factors) signaling pathway, binding of FGF ligands leads to the 
autophosphorylation of the FGF receptor tyrosine kinase, allowing interaction of the FRS2α 
docking protein and subsequent activation of the GRB2/SOS (growth factor receptor-bound 
protein 2/Son of sevenless) complex. Activated SOS, a guanine nucleotide exchange factor, 
in turn, activates the small G protein RAS, triggering a cascade of phosphorylation leading to 
the successive activation of RAF, MEK, and mitogen-activated protein kinase (ERK) kinases. 
p-ERK phosphorylates target transcription factors (including Ets family members) to activate 
gene expression. Sprouty blocks the phosphorylation cascade by interacting with the 
FRS2α/GRB2/SOS complex. 
FGFs are among the critical signals controlling communications within and between 
developing cardiac progenitors (Urness, Bleyl et al. 2011). The human/mouse FGF family 
comprises 22 members (Itoh, Ohta et al. 2016). Among them, FGF ligands implicated in 
second heart field development include Fgf3, Fgf8, Fgf10 and Fgf15 (Francou, Saint-Michel et 
al. 2013). Fgf8 is the best understood one among these FGFs regulating cardiovascular 
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development. Fgf8 signaling was shown to promote SHF proliferation and inhibit myocardial 
differentiation in chick SHF explants (Hutson, Zeng et al. 2010). Studies from two 
independent groups showed that Fgf8 deletion in the SHF leads to severe truncations of the 
right ventricle and the outflow tract (Ilagan, Abu-Issa et al. 2006, Park, Ogden et al. 2006), 
indicating the critical role of Fgf8 in SHF development. It was later reported that the role of 
mesodermal Fgf8 and Fgf10 overlaps during SHF and pharyngeal arch arteries (PAA) 
development, highlighting the sensitivity of cardiovascular development to FGF dosage 
(Watanabe, Miyagawa-Tomita et al. 2010). Moreover, Fgf3 and Fgf10 also function 
redundantly and are dosage sensitively required during cardiovascular development (Urness, 
Bleyl et al. 2011). In addition, targeted disruption of Fgf15 in mouse embryos leads to OFT 
alignment defects and reduced cell proliferation within the OFT myocardium, indicating that 
Fgf15 is required for proper morphogenesis of cardiac outflow tract (Vincentz, McWhirter et 
al. 2005). 
1.1.4.3 BMP signaling pathway 
In the BMP (Bone Morphogenetic Proteins) signaling pathway, BMP ligands bind to a 
receptor complex composed of type 1 and type 2 BMP receptors. Upon receptor activation, 
Smad proteins (Smad1/5/8) are phosphorylated and associate with a coactivator Smad 
(Smad 4). The resulting Smad complex enters the nucleus and activates target gene 
expression. BMP signaling can be inhibited by the secreted proteins NOG (Noggin), CHORD 
(Chordin) and intracellular Smad proteins (Smad 6/7). 
BMPs are a group of signaling molecules that belongs to the Transforming Growth Factor-β 
(TGFβ) superfamily of proteins (Wang, Green et al. 2014). A lot of studies implicate the role 
of BMP signaling in regulating cardiogenesis of different species, such as chicken (Birgit 
Andre´e 1998), mouse (Liu, Selever et al. 2004, Wang, Greene et al. 2010), zebrafish (Emma 
de Pater 2012) and Xenopus (Shi, Katsev et al. 2000). Bmp2 acts as a cardiac specification 
factor that elicits ectopic expression of the early cardiac markers Nkx2.5 and Gata4, when it 
is ectopically expressed in chicken (Birgit Andre´e 1998). In SHF explants from chick embryos, 
Bmp2 decreases SHF proliferation and promotes myocardial differentiation (Hutson, Zeng et 
al. 2010). Bmp4 was shown to be required for outflow tract septation and branchial arch 
artery remodeling in mouse embryos (Liu, Selever et al. 2004). Bmp2 and Bmp4 were 
reported to control the timing of progenitor gene silencing in OFT myocardium by regulating 
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the expression of miRNAs in mouse embryos (Wang, Greene et al. 2010). Bmp10 is another 
Bmp member, shown to be essential in regulating cardiac growth and chamber maturation 
in mouse embryos (Chen, Shi et al. 2004). Bmp10 is also required for maintaining normal 
expression levels of several key cardiogenic factors (including Nkx2.5 and Mef2c) in the 
developing myocardium at mid-gestation (Chen, Shi et al. 2004) and works in axis with 
myocardin (Myocd) in this process (Huang, Elicker et al. 2012). In Xenopus, BMP signaling is 
also required for heart formation as well as maintenance of Nkx2.5 expression (Shi, Katsev et 
al. 2000). In zebrafish, Pater et al. reported that Bmp signaling activity is strictly controlled 
during cardiomyocyte differentiation, since it is required to induce cardiac differentiation of 
cardiac progenitors but dispensable and even deleterious once differentiation is initiated 
(Emma de Pater 2012). They further illustrated that smad6a is expressed in the cardiac fields 
and linear heart tube to inhibit Bmp signaling (Emma de Pater 2012). 
1.1.4.4 Hedgehog signaling pathway 
The Hh (Hedgehog) signaling pathway is one of the key regulators of metazoan 
development. In this pathway, the Patched receptor inhibits activity of the transmembrane 
protein Smo (Smoothened) in the absence of Hh ligand. The Cos2/Fu/SuFu (Costal-
2/Fused/Suppressor of fused) complex is thus able to convert the transcription factor GLI 
into a repressor form (GLIR). In the presence of Hh ligand, Hh binds to Patched and thereby 
releases the inhibition of SMO. SMO blocks the Cos2/Fu/SuFu complex, leading to the 
generation of the activator form of GLI (GLIA) that translocates to the nucleus to drive target 
gene transcription.  
Three different Hedgehog proteins-SHH (Sonic hedgehog), IHH (Indian hedgehog), and DHH 
(Desert hedgehog), exist in vertebrates. Among them, SHH is the most understood one in 
heart development. In mouse embryos, loss of Shh causes several cardiac abnormalities, 
including ventricular hypoplasia, septation defects and outflow tract shortening (Tsukui T 
1999, Washington Smoak, Byrd et al. 2005). Mice ablated of Smo using Isl1-Cre exhibit 
cardiovascular defects similar to those observed in Shh null mice, defining a spatial 
requirement for hedgehog signaling within Isl1 expression domains for aortic arch and 
outflow tract formation (Lin, Bu et al. 2006). In chick embryos, inhibition of Shh leads to 
reduced SHF proliferation and pulmonary atresia, suggesting that Shh maintains proliferation 
in SHF progenitors and is required for normal arterial pole formation (Dyer and Kirby 2009). 
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1.1.4.5 Notch signaling pathway 
In Notch signaling pathway, interaction of Notch receptor with transmembrane ligand 
proteins (Ser, Serrate; Del, Delta; Jag, Jagged) in a neighboring cell triggers the proteolytic 
cleavage of Notch by TACE (tumor necrosis factor (TNF) α-converting enzyme) and γ-
secretase. This cleavage releases the Notch intracellular domain (NICD) and allows its 
translocation to the nucleus. NICD forms a transcriptional complex with RBPJκ 
(recombination signal binding protein Jκ) to activate target genes. 
The Notch signaling pathway is an ancient and highly conserved signaling pathway that plays 
important roles in development. It is also involved in multiple processes during vertebrate 
cardiogenesis. Analysis of standard and endothelial-specific Notch1 and RBPJk mutants 
shows that trabeculation is severely impaired and only primitive, poorly organized 
trabeculae can be observed in these mutants (Grego-Bessa, Luna-Zurita et al. 2007). 
Functional analysis reveals the requirement of the transcription factor Hey2 (Hes related 
family BHLH transcription factor with YRPW motif 2) (Kokubo, Miyagawa-Tomita et al. 2004) 
or the synergistic functions of Hey1 and Hey2 (Kokubo, Miyagawa-Tomita et al. 2005) or Heyl 
(Hey1 and Hey-like protein) in valve development (Fischer, Steidl et al. 2007). Endothelial-
specific deletion of Jag1 (Jagged1) in mice results in cardiovascular defects, displaying right 
ventricular hypertrophy, overriding aorta, ventricular septal defects, coronary vessel 
abnormalities and valve defects and loss of Jag1 disrupts EMT during endocardial cushion 
formation (Hofmann, Briot et al. 2012). Moreover, conditional inactivation of Jag1 in second 
heart field tissues results in OFT and aortic artery defects resembling those seen in patients 
with congenital heart disease (CHD), indicating that Jag1 is an essential Notch ligand in the 
SHF (High, Jain et al. 2009, MacGrogan, Nus et al. 2010).  
1.1.5 Transcriptional factors involved in heart development 
The expression of Mesp1 is one of the known earliest sign toward cardiovascular 
development (Yumiko Saga 2000). Mesp1 promotes the expression of cardiac transcription 
factors while repressing genes that maintain pluripotency (Bondue 2008). As cardiac 
precursors migrate away from the primitive streak to form the cardiac crescent, Mesp1 is 
downregulated while genes encoding cardiac transcription factors are activated (Y. Saga 
1996, Paige, Plonowska et al. 2015). Here I summarized some of the representative 
transcriptional factors involved in heart development. 
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1.1.5.1 GATA binding factors 
Among the six GATA family transcription factors, Gata1, Gata2 and Gata3 are sub-classified 
as “hematopoietic GATA factors”, while Gata4, Gata5 and Gata6 are “cardiac GATA factors”, 
due to their priming roles in different systems  (Tremblay, Sanchez-Ferras et al. 2018).  
Gata4 is one of the earliest transcription factors expressed in mouse cardiac cells. It can be 
detected in the precardiac mesoderm as early as primitive streak stage (around E7.0) in 
mouse embryos and expands subsequently to more structures such as myocardium, 
endocardium, endocardial cushion and septum tissues, and persists in myocardium even 
after birth (Heikinheimo, Scandrett et al. 1994). Homozygous Gata4-deficient mice arrest in 
development between E7.0 and E9.5 and die short after, because of severe defects including 
the loss of a ventral heart tube resulting from a failure in lateral to ventral folding. In detail, 
in the absence of Gata4, the failed migrating of cardiac precursors to the ventral midline 
leads to forming of cardiac structures in bilateral side of the embryo, which is called cardia 
bifida (Kuo, Morrisey et al. 1997, Molkentin, Lin et al. 1997). However, studies from chimera 
mice suggest that the cardiac defects are secondary due to ventral patterning defects, 
resulting from lacking of Gata4 in the visceral endoderm, rather than the mesoderm (Narita, 
Bielinska et al. 1997, Watt, Battle et al. 2004). Analysis of mouse embryos with Gata4 
deficiency in different tissues reveals important activities of Gata4 in proepicardium 
development, chamber formation, generation of the endocardial cushions, and septation of 
the OFT (Watt, Battle et al. 2004, Zeisberg, Ma et al. 2005, Rivera-Feliciano, Lee et al. 2006). 
Moreover, Gata4 was reported to act as a pioneer factor which can bind its target DNA 
sequences within condensed chromatin (Cirillo, Lin et al. 2002). In mouse heart, Gata4 
shapes the chromatin environment and regulates gene expression by recruiting the histone 
acetyltransferase P300, which deposits H3K27ac deposition at cardiac enhancers to 
stimulate transcription (He, Gu et al. 2014). 
In addition, data from Gata5-/- mice suggest a role of Gata5 in endocardial cell differentiation 
and cardiac valve formation (Laforest, Andelfinger et al. 2011). Gata6 inactivation in vascular 
smooth muscle cells (VSMCs) leads to perinatal lethality and cardiovascular defects, 
including interrupted aortic arch and persistent truncus arteriosus, suggesting a role of 
Gata6 in regulating morphogenetic patterning of the cardiac outflow tract and aortic arch 
(Lepore, Mericko et al. 2006). Gata4, Gata5 and Gata6 interact with each other (Laforest and 
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Nemer 2011) and have partially redundant roles in the regulation of heart development 
(Holtzinger and Evans 2007, Peterkin, Gibson et al. 2007). They also work cooperatively with 
other cardiac transcription factors in regulation of cardiac gene expression in the developing 
heart, such as Nkx2.5, Tbx5, Tbx20, Mef2c, Srf and so on (Durocher, Charron et al. 1997, 
Stennard, Costa et al. 2003, He, Kong et al. 2011, Schlesinger, Schueler et al. 2011). 
Mutations of GATA4, GATA5 or GATA6 in human all lead to CHD, including cardiac septal 
defects and OFT defects, which are consistent with the phenotypes observed in the mouse 
models (Garg, Kathiriya et al. 2003, Kodo, Nishizawa et al. 2009, Wei, Bao et al. 2013). 
1.1.5.2 T-box transcription factors 
Among T‐box gene family members, Tbx1, Tbx2, Tbx3, Tbx5, Tbx18, and Tbx20 are expressed 
and have functions in the developing heart. 
Tbx1 is expressed in the mesoderm and endoderm of the pharyngeal arches, and OFT in 
mouse (Xu, Morishima et al. 2004, Maeda, Yamagishi et al. 2006). Lineage tracing 
experiments have demonstrated that these Tbx1-positive cells contribute extensively to 
myocardial wall and endothelium of the OFT, and some contribute to the myocardium of the 
right ventricle, suggesting that Tbx1 expressed mainly in the SHF (Xu, Morishima et al. 2004). 
Tbx1 is required for normal development of the pharyngeal arch arteries in a gene dosage-
dependent manner. Deletion of one copy of Tbx1 affects the development of the fourth 
pharyngeal arch arteries, whereas homozygous mutation severely disrupts the pharyngeal 
arch artery system, which phenocopies the cardiac defects observed in DiGeorge syndrome 
in human (Elizabeth A. Lindsay 2001). Tbx1 was later reported to be required for posterior 
SHF cells to contribute to the arterial and venous poles of the heart tube (Rana, Theveniau-
Ruissy et al. 2014), providing an explanation for the occurrence of venous pole defects seen 
in DiGeorge syndrome. In addition, Fgf8 and Fgf10 act downstream of Tbx1 in the SHF, while 
Foxc1 and Foxc2 act upstream of the Tbx1-FGF cascade (Hu, Yamagishi et al. 2004, Xu, 
Morishima et al. 2004, Seo and Kume 2006) (Figure 5). Moreover, Tbx1 regulates the balance 
between myocardial proliferation and differentiation in the SHF through Isl1, Hod and 
Nkx2.6 (Liao, Aggarwal et al. 2008). 
Tbx2 and Tbx3 are expressed in the non-chamber myocardium of the atrioventricular canal 
(AVC) and are redundantly required for AVC patterning by repressing chamber myocardial 
genes (Christoffels, Burch et al. 2004, Harrelson, Kelly et al. 2004, Christoffels 2012). Tbx2 is 
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expressed in the OFT as well, and misexpression of Tbx2 impairs deployment of SHF derived 
progenitor cells to the OFT and also leads to defects in OFT remodeling in mouse embryonic 
heart (Harrelson, Kelly et al. 2004, Dupays, Kotecha et al. 2009). Whereas, Tbx3 is expressed 
in the cardiac conduction system as well, and is required for its specification (Bakker, 
Boukens et al. 2008). Interestingly, Tbx3 is reported to be required for mouse OFT 
development, even though it is supposed not to express in the OFT, through an indirect way, 
by regulation of intercellular signaling pathways coordinating proliferation and deployment 
of the SHF (Mesbah, Harrelson et al. 2008). 
Both Tbx5 and Tbx20 play roles in the cardiac chamber formation.  Tbx5 is expressed in the 
inflow tract, atria, AV cushion, and left ventricle, appearing to be restricted to the FHF-
derived region (Benoit G. Bruneau, Malcolm Logan et al. 1999). By contrast, Tbx20 is 
primarily expressed in the outflow tract and the right ventricle during heart chamber 
formation, which are derived from the SHF (Koshiba-Takeuchi, Morita et al. 2016). Mice with 
Tbx20 complete knockdown showed defects in heart formation, including hypoplasia of the 
outflow tract and right ventricle (Takeuchi, Mileikovskaia et al. 2005, Koshiba-Takeuchi, 
Morita et al. 2016). In the developing heart, Tbx5 and Tbx20 are complementarily expressed 
in the left and right ventricle, respectively (Takeuchi 2003, Plageman and Yutzey 2004).  In 
humans, mutations in TBX5 are related to Holt-Oram syndrome (Basson, Bachinsky et al. 
1997, Li, Newbury-Ecob et al. 1997, Benoit G. Bruneau, Malcolm Logan et al. 1999), while 
mutations in TBX20 result in ASD, ToF, PTA and so on (Kirk 2007, Posch 2010, Pan, Geng et 
al. 2015, Huang, Wang et al. 2017). Moreover, Tbx5 and Tbx20 act in combination with 
Nkx2.5 and Gata4 to promote the specification of chamber myocardium (Paige, Plonowska 
et al. 2015). In mice, Tbx5 and Gata4 regulate the expression of connexin 30.2, which is 
required for slow conduction in the atrioventricular node (Munshi, McAnally et al. 2009). 
Tbx18 is expressed in the proepicardium (PE), in the epicardium, and sinus venosus region in 
mouse (Florian Kraus 2001). Expression domains of Tbx18 are adjacent but distinct from 
Nkx2.5 and Isl1 expression domains. It is required for the venous pole formation in the heart 
(Christoffels, Mommersteeg et al. 2006). 
1.1.5.3 Hand1 and Hand2 
In mice, Hand1 (eHand) and Hand2 (dHand) are involved in ventricular chamber formation. 
After cardiac looping, they are preferentially expressed in the left ventricle and right 
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ventricle, derivatives of the first and second heart fields, respectively (Tiffani Thomas 1998). 
Mice that lack Hand2 die at E10.5 from right ventricular hypoplasia and vascular defects 
(Deepak Srivastava 1997, Yamagishi, Olson et al. 2000, Tsuchihashi, Maeda et al. 2011). In 
contrast, embryos homozygous for Hand1 deletion displayed defects in the left ventricle and 
endocardial cushions, and exhibited dysregulated ventricular gene expression (McFadden, 
Barbosa et al. 2005). Moreover, Hand1 acts downstream of Nkx2.5 during cardiac 
morphogenesis (Harvey 1997, McFadden, Barbosa et al. 2005), whereas Hand2 is a direct 
downstream target of Gata4 and Isl1 (D.G. McFadden 2000, Caputo, Witzel et al. 2015) 
(Figure 5). 
1.1.5.4 Nkx2.5 
The homeobox gene Nkx2.5 (also called Csx), a homolog of Drosophila tinman, is one of the 
earliest known markers of vertebrate heart development (R.J. Schwartz 1999). Nkx2.5 can be 
detected in the early cardiac crescent at E7.5. As development proceeds, Nkx2.5 is expressed 
in almost all the cardiac regions derived from both first and second heart fields, including left 
ventricle, outflow tract and right ventricle, as well as atria and sinus venosus. Nkx2.5 is also 
detected in the pharyngeal region. However, Nkx2.5 deletion in the pharyngeal endoderm 
does not affect heart formation, which may be result from the compensation of endodermal 
expression of Nkx2.3 and Nkx2.6. In contrast, mesodermal deletion of Nkx2.5 showed a 
hypoplastic outflow tract and right ventricle and an arrested looping heart tube, as seen in 
Nkx2.5 null mouse embryos, leading to embryonic lethality at around E10.5 (I Lyons 1995, M. 
Tanaka 1999, Zhang, Nomura-Kitabayashi et al. 2014). These studies indicate that Nkx2.5 is 
pivotal for early heart formation in mouse embryos.  
Nkx2.5 acts genetically upstream of multiple genes essential for heart development, 
including some cardiac transcription factors, such as Mef2c, Hand1 and Myocd (M. Tanaka 
1999, Ueyama, Kasahara et al. 2003). Isl1 is also reported to be a downstream target of 
Nkx2.5 but is negatively regulated (Dorn, Goedel et al. 2015, Colombo, de Sena-Tomas et al. 
2018) (Figure 5).  
1.1.5.5 Mef2c 
Among the four Mef2 transcription factor family members (Mef2a, -b, -c, and -d), Mef2c is 
the most extensively studied in heart development. Studies in mouse embryos showed that 
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Mef2c is required for looping of the cardiac tube, development of the right ventricle, and 
expression of a subset of cardiac genes, such as Hand2, Mlc1a and cardiac α-actin (Qing Lin 
1997). Moreover, deletion of Mef2c causes embryonic lethal in mouse at around E10.5 (Lin, 
Schwarz et al. 1997). Mice with Mef2c deleted in the anterior second heart field (aSHF) 
display cardiac defects similar with the ones observed in human CHD (Qiao, Wang et al. 
2017, Lu, Wang et al. 2018), such as tetralogy of Fallot (ToF), great arteries (d-TGA) with VSD; 
or double-outlet right ventricle (DORV), indicating an essential role of Mef2c in OFT 
alignment (Barnes, Harris et al. 2016). Interestingly, a recent publication further 
demonstrated that cardiovascular development and survival in mouse require Mef2c 
function in the myocardial but not the endothelial lineage (Materna, Sinha et al. 2019). 
Mef2c works cooperatively with other cardiac transcription factors in regulating cardiac gene 
expression, such as Gata4, Nkx2.5 and Tbx5 (Nemer 2000, Vincentz, Barnes et al. 2008, 
Ghosh, Song et al. 2009). Moreover, Mef2c is a direct downstream target of Isl1, Gata4 and 
Nkx2.5 (M. Tanaka 1999, Dodou, Verzi et al. 2004, Wang, Li et al. 2016) (Figure 6). 
 
Figure 6 Cardiac gene regulatory networks (Paige, Plonowska et al. 2015) 
The diagram shown is a brief overview of a subset of known transcription factor interactions and 
signaling pathways that drive the differentiation of first heart field (FHF; orange) and second heart 
field (SHF; blue) cardiac progenitor cells (CPCs) during development. Factors colored by both orange 
and blue represent regulators of both FHF and SHF. Arrows indicate increased expression of one 
transcription factor or signaling molecule because of activity of another transcription factor. Signaling 
pathways that activate expression of certain transcription factors are shown in red.  
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Spatiotemporal and quantitative regulation of cardiac transcription factors must occur in a 
precise manner to ensure fine regulation of downstream targets (Bruneau 2002). Although 
networks of interacting transcription factors are being defined (Figure 6), the full 
complement of their target genes is still not clear, nor is how these factors are integrated at 
the level of chromatin to activate transcriptional programs (Bruneau 2013). 
 
1.2 Isl1 
1.2.1 Protein structure of ISL1 
Islet1 (Isl1) is a LIM-homeodomain transcription factor. The gene encoding Isl1 contains six 
exons, and is located on chromosome 13 in mouse and chromosome 5 in human (Karlsson, 
Thor et al. 1990). Like other members in the LIM-homeodomain transcription factor family, 
ISL1 contains a pair of closely spaced N-terminal LIM domains followed by a central 
homeodomain (HD); in addition, ISL1 also contains a LBD domain (Figure 7) (Bhati, Lee et al. 
2012). ISL1 binds DNA through its homeodomain while its LIM domains usually act as a 
protein-protein interaction motif (Karlsson, Thor et al. 1990, Bach 2000). LBD domain 
mediates the interaction of ISL1 with LIM-Homeodomain (LHX) proteins. For example, ISL1 
interacts with LDB1 through its LIM domains and with LHX3 through its LBD domain, in the 
regulation of motor neurons specification (Gadd, Bhati et al. 2011). Although the LIM 
interaction domain of LDB1 (LDB1LID) and the LIM binding domain of ISL1 (ISL1LBD) share low 
levels of sequence homology, they bind LHX3 in an identical manner (Mugdha Bhati 2008). In 
addition, ISL1 LBD domain can also mediate an intramolecular interaction with LIM domains 
of ISL1 (ISL1LIM1+2), even though in a low affinity, to inhibit DNA binding, with inhibition being 
relieved by interaction of the LIM domains with another binding partner, such as LDB1LID 
(Figure 7) (Gadd, Jacques et al. 2013). 
32 
 
 
Figure 7 Schematic diagram of ISL1 domains and the intermolecular and intramolecular 
interactions (adapted from (Bhati, Lee et al. 2012, Gadd, Jacques et al. 2013)) 
(A) Diagram shows domains of mouse ISL1 protein. Numbers refer to the mouse proteins with the 
domain boundaries as defined in SWISS-PROT (Bhati, Lee et al. 2012). (B) The intramolecular 
interaction between ISL1LIM1+2 and ISL1LBD could impose steric effects on the homeodomain, 
impacting DNA binding. (C) When LDB1LID binds ISL1, the intramolecular interaction is displaced, and 
this inhibition would be released. (D) Cofactor exchange mechanism. When ISL1 approaches the 
binary LDB1/LHX3 complex the intramolecular interaction between ISL1LIM1+2 and ISL1LBD may 
facilitate the formation of an intermediate ternary complex in which the N- and C-terminal halves of 
ISL1LBD and LDB1LID contact different molecules to enable ISL1 to efficiently displace 
LDB1LID/LHX3LIM1+2 and generate the ternary complex in a stepwise manner (Gadd, Jacques et al. 
2013). HD: homeodomain; LBD: LIM binding domain; LID: LIM interaction domain; N and C: the N- 
and C-terminal halves of ISL1LBD and LDB1LID domains. 
 
1.2.2 Expression and function of Isl1 during development 
Genetic studies have demonstrated that Isl1 plays essential roles during embryogenesis. A 
better visualization of Isl1 expression profile provides further insight into its potential roles 
during development. Previous studies have revealed expression of Isl1 in multiple tissues 
and cell types, including normal adult islet cells (Karlsson, Thor et al. 1990), pancreas 
(Ahlgren, Pfaff et al. 1997), heart progenitor cells (Schoenwolf 2000, Cai, Liang et al. 2003, 
Sun, Liang et al. 2007), hindlimb (Yang, Cai et al. 2006), cochlear epithelium of the inner ear 
(Radde-Gallwitz, Pan et al. 2004), retina (Elshatory, Everhart et al. 2007), nervous system 
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(Samuel L. Pfaff 1996, Sun, Dykes et al. 2008), thyroid gland (Westerlund, Andersson et al. 
2008) and so on. 
Isl1 regulates gene expression by binding through its homeodomain to AT-rich consensus 
elements containing a core TAAT motif (YTAATGR) (Karlsson, Thor et al. 1990, Drucker 1995, 
Golzio, Havis et al. 2012). ISL1 is originally identified as a protein that binds to an insulin gene 
enhancer and regulates its expression (Karlsson, Thor et al. 1990). Initial experiments 
localized Isl1 to the islet cells, suggesting a possible role for this protein in the regulation of 
insulin gene expression and/or islet cell development (Karlsson, Thor et al. 1990, M Wang 
1994). In pancreas, Isl1 is also expressed in the mesenchymal cells surrounding the dorsal 
lobe, and plays an important role in pancreas development (Ahlgren, Pfaff et al. 1997). Isl1 
also functions as a positive regulator of proglucagon gene transcription in the endocrine 
pancreas (Drucker 1995). Later people found that Isl1 is also expressed in the central and 
peripheral nervous system (M Wang 1994, Zhuang, Zhang et al. 2013). It is required for the 
generation of motor neurons (Pfaff, Mendelsohn et al. 1996) and has essential roles in 
multiple aspects of motor neuron development, including motor neuron cell body 
localization, motor column formation and axon growth (Liang, Song et al. 2011). A recent 
study revealed a temporal requirement for Isl1 in multiple aspects of sympathetic neuron 
development (Zhang, Huang et al. 2018).  In addition, Isl1 is also involved in the regulation of 
other cell types and organs, such as dentition (Mitsiadis 2003) and external genitalia (Ching, 
Infante et al. 2018). Importantly, more and more studies have determined that Isl1 is critical 
in heart development.  
1.2.3 Expression and function of Isl1 during heart development 
With an Isl1-nlacZ mouse line and co-immunostaining for Isl1 and lineage markers, Sun et al. 
reported the detailed expression pattern of Isl1 in mouse heart (Sun, Liang et al. 2007) 
(Figure 8). They showed that Isl1 is expressed in distinct subdomains of the heart and in 
diverse cardiovascular lineages although Isl1 expression is downregulated in most cardiac 
progenitors as they differentiate (Sun, Liang et al. 2007), which is consistent with the earlier 
studies (Schoenwolf 2000, Cai, Liang et al. 2003). Cai et al. showed that Isl1 is detectable in 
the cardiac progenitor cells at the early cardiogenic crescent stages (around E7.0) (Cai, Liang 
et al. 2003). At this stage, Isl1-expressing cells are contiguous with, but medial and dorsal 
to, Mlc2a-expressing cells, which is one of the earliest markers for differentiated 
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cardiomyocytes (Cai, Liang et al. 2003) (Figure 8A). Studies demonstrate that Isl1 expressing 
progenitors migrate into the heart shortly following fusion of cardiac primordia (Park, Ogden 
et al. 2006, Sun, Liang et al. 2007). At E8.5, Isl1 is actively expressed in outflow tract and 
partially in the right atria and right ventricle, but not in the remaining myocardium (Figure 
8B). By E9.0, most Isl1 progenitors have migrated into the heart. Isl1 is asymmetrically 
expressed in the right atria, and becomes progressively confined to a subdomain within the 
right atria, in the region of the cardiac pacemaker (Figure 8C-G). At E11.5 and E13.5, Isl1 is 
observed in outflow tract and in the region of the sinoatrial (SA) and atrioventricular (AV) 
nodes. At E14.5, Isl1-nlacZ expression is still detected in subdomains within the outflow 
tract, aorta, pulmonary artery, venous valves, atrial septum, and in regions corresponding to 
those of the sinoatrial and atrioventricular nodes, and in clusters of cells in the region of 
cardiac ganglia (Figure 8G). At postnatal day 3, Isl1-nlacZ expression is observed in the region 
of the sinoatrial node (SAN) and at the base of the aorta/pulmonary artery, but less 
extensively, with the exception of cardiac ganglia which still exhibits strong expression (Sun, 
Liang et al. 2007). Moreover, they also showed that Isl1 expressing cells not only contribute 
to myocardial lineages, but also contribute to endothelial and vascular smooth muscle 
lineages including smooth muscle of the coronary vessels by co-immunostaining of ISL1 with 
MF20 (myosin heavy chain 1E, MYH1E), CD31 (also called platelet endothelial cell adhesion 
molecule, PECAM1) and α-smooth muscle actin (α-SMA) (Sun, Liang et al. 2007). 
 
Figure 8 Isl1 expression profile in mouse heart (adapted from (Cai, Liang et al. 2003, Sun, 
Liang et al. 2007)) 
(A) Embryos were stained with double whole-mount in situ hybridization, utilizing probes 
for Isl1 (green) and Mlc2a (red) mRNAs at E7.0 and E7.5 (Cai, Liang et al. 2003). (B-G) Analysis of β-
galactosidase expression in Isl1-nlacZ knock-in embryos using X-gal staining at E8.5-E14.5 and 
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representative corresponding sections. The arrow in (E) indicates X-gal-positive cells within the 
endocardium of the outflow tract (Cai, Liang et al. 2003, Sun, Liang et al. 2007). LA: left atria; LV: left 
ventricle; OT: outflow tract; RA: right atria; RV: right ventricle; PA: pulmonary artery; Ao: aorta; SAN: 
sinoatrial node. 
 
In the course of cardiogenesis, Isl1 marks the second heart field progenitors (Cai, Liang et al. 
2003). The key role of Isl1 in SHF development is evident from genetic studies in mice, 
showing that Isl1-deficient mouse embryos are embryonic lethal due to lacking of all 
structures derived from the SHF including the right ventricle, the outflow tract and large 
portions of the atria, since Isl1 is required for proliferation, survival, migration of SHF CPCs 
and their differentiation into different cardiac lineages (Cai, Liang et al. 2003, Moretti, Caron 
et al. 2006, Kwon, Qian et al. 2009). Isl1 was later shown to play a key role in survival, 
proliferation, and function of pacemaker cells as well (Liang, Zhang et al. 2015). In Xenopus, 
Isl1 was reported to be necessary for heart morphogenesis, cardiac marker gene expression, 
and vasculogenesis (Brade, Gessert et al. 2007), whereas in zebrafish isl1 is required to 
complete the cardiomyocyte differentiation process at the venous pole (de Pater, Clijsters et 
al. 2009).  
Isl1 is known to cooperate with other transcriptional factors such as Gata4 and Tbx20, to 
regulate a cascade of transcriptional events involving its downstream target genes, such 
as Mef2c, Myocd, Shh, Fgf10 and Bmp4 that collectively control lineage specification of the 
cardiac progenitors (Dodou, Verzi et al. 2004, Vincent and Buckingham 2010, Golzio, Havis et 
al. 2012, Watanabe, Zaffran et al. 2012). In addition, Isl1 also works in concert with other 
cofactors, such as epigenetic regulators and signaling molecules, in regulating cardiac 
development and cardiac lineage differentiation. For example, Isl1 and Ldb1 works together 
to orchestrate a network for transcriptional regulation and coordination in three 
dimensional space, driving cardiac progenitor cell differentiation and heart development 
(Caputo, Witzel et al. 2015). In addition, the LIM protein Ajuba binds Isl1 and represses its 
transcriptional activity, which is required to downregulate the expression of key 
transcription factors in the SHF such as Mef2c, and to enable Isl1 to suppress its own 
expression (Witzel, Jungblut et al. 2012). Pacheco-Leyva et al. reported that Cited2 and Isl1 
interact physically and cooperate to promote embryonic stem cell (ESC) differentiation 
toward cardiomyocytes (Pacheco-Leyva, Matias et al. 2016). Jmjd3 (Jumonji domain-
containing protein 3) also physically interacts with Isl1 to alter the cardiac epigenome, 
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instructing gene expression changes that drive cardiac differentiation (Wang, Li et al. 2016). 
These cofactors act together with Isl1 in a coordinated manner to keep the proper 
spatiotemporal regulation during cardiac differentiation and heart development. Despite the 
critical role of Isl1 in cardiac development and disease, detailed insights into its molecular 
mode of action are critically missing. 
1.2.4 ISL1 and CHD 
As a key transcription factor in regulating cardiac development, ISL1 is involved in congenital 
heart disease (CHD). Genetic variation in ISL1 is associated with risk of non-syndromic CHD 
has been revealed through a 2-stage case-control study in white and black/African American 
populations (Stevens, Hakonarson et al. 2010). This study identified eight genic and flanking 
ISL1 single nucleotide polymorphisms (SNPs) (rs6867206, rs4865656, rs6869844, rs2115322, 
rs6449600, IVS1+17C>T, rs1017, rs6449612) that are significantly associated with complex 
CHD (Stevens, Hakonarson et al. 2010). Later the same conclusion was shown and different 
ISL1 variants were found to be associated with CHD in a Chinese cohorts (Lang, Tian et al. 
2013, Luo, Sun et al. 2014). The rs3762977 and IVS1+17C>T variants of ISL1 were identified 
to be closely associated with the risk of developing ventricular septal defects (VSD) through a 
study enrolled with 512 congenital VSD patients and 612 healthy controls (Lang, Tian et al. 
2013). Another SNP (rs1017) in ISL1 contributes to the risk of CHD in Chinese Han people 
(Luo, Sun et al. 2014). In addition, a study among 389 infants born with tetralogy of Fallot 
(ToF) or d‐transposition of the great arteries (d‐TGA) found that ISL1 haploinsufficiency is 
associated with d‐TGA (Osoegawa, Schultz et al. 2014). A recent study revealed a novel 
heterozygous ISL1 mutation (c.409G > T or p.E137X) that contributes to congenital heart 
defects, by analyzing a cohort of CHD patients and healthy controls (Ma, Wang et al. 2018).  
 
1.3 Pioneer transcription factors 
A transcription factor (TF) is a protein that controls the rate of transcription of genetic 
information from DNA to messenger RNA, by binding to a specific DNA sequence (Karin 
1990, Latchman 1997). The function of transcription factors is to regulate “turn on and off”-
genes in order to make sure that they are expressed in the right cell at the right time and in 
the right amount throughout the life of the cell and the organism. Therefore, transcription 
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factors are responsible for the spatial and temporal fine-tuning of transcriptional programs. 
Although they recognize and bind to specific DNA sequences, the recruitment of 
transcription factors is also dependent on the chromatin landscape (Tanaka, Tawaramoto-
Sasanuma et al. 2004). In eukaryotes, genomic DNA is tightly packaged into a higher order 
chromatin structure. Thus, chromatin structure becomes a general obstacle for eukaryotic 
transcription by blocking the access of the basic RNA polymerase machinery, as well as most 
transcription factors (Iwafuchi-Doi 2019). In the context of embryonic development and cell 
differentiation, many TFs initiate the assembly of transcriptional complexes at specific 
enhancers, which in turn trigger nucleosome repositioning so as to increase accessibility for 
other factors (Spitz and Furlong 2012). Biochemical and genomic studies indicate that such a 
group of factors can be considered ‘‘pioneers’’ by virtue of their ability to engage target DNA 
sites in closed chromatin prior to the apparent engagement, opening, or modification of the 
site by other factors (Iwafuchi-Doi and Zaret 2014). This ‘‘pioneer’’ function was first 
identified in yeast (Almer, Rudolph et al. 1986) and subsequently at the mouse albumin 
enhancer during endoderm development (Gualdi, Bossard et al. 1996, Bossard and Zaret 
1998). And this subset transcription factors are called “pioneer transcription factors” or 
“pioneer factors” (Iwafuchi-Doi 2019) (Figure 9). 
 
Figure 9 Chromatin binding by pioneer factors (adapted from (Iwafuchi-Doi and Zaret 2016, 
Zaret, Lerner et al. 2016)) 
Chromatin is depicted as consisting of open domains and closed domains. Pioneer factors (green 
blobs) are able to target the closed domains, whereas non-pioneer factors (gray blobs) are typically 
dependent upon pioneers for binding there (black arrow). The green arrows depict transient, on-and-
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off association with chromatin as the factors scan the different domains; the red bars indicate 
the factors being impeded from scanning certain domains. 
 
In recent years, more key transcription factors have been identified as pioneer transcription 
factors, such as FOXA (Forkhead box A), GATA1/2/3/4, OCT3/4 (Octamer-binding 
transcription factor 3/4), SOX2 (SRY (sex determining region Y)-box 2), KLF4 (Kruppel like 
factor 4), PAX7 (Paired box 7), ASCL1 (Achaete-scute family BHLH transcription factor 1), P53 
(Tumor protein p53), and so on (Cirillo, Lin et al. 2002, Nili, Field et al. 2010, May, Soneji et 
al. 2013, Soufi, Garcia et al. 2015, Park, Guilhamon et al. 2017, Mayran, Khetchoumian et al. 
2018). Although these pioneer factors belong to diverse structural classes of transcription 
factors and show different binding repertoires in different cell types, for example, SOX2 
binds different target subsets in mouse cortex and spinal cord (Hagey, Zaouter et al. 2016), 
they have the common activities (Figure 10). Firstly, they scan the nucleosomal DNA in 
closed chromatin for their target sequences and then bind to their recognition sites 
(Iwafuchi-Doi and Zaret 2014, Iwafuchi-Doi and Zaret 2016, Iwafuchi-Doi 2019). The ability to 
target closed chromatin is based on the inherent capacity of pioneer factors to recognize 
their target DNA sequences on the nucleosome, either by full or partial motif recognition 
(Cirillo, McPherson et al. 1998, Iwafuchi-Doi and Zaret 2016). 
The FOXA family of transcription factors has been most extensively studied in mechanistic 
depth by biochemical, genetic, and genomic studies. The binding domains of FOXA 
transcription factors possess a “winged helix” structure, which binds to one side of a DNA 
helix and leaves the other side of DNA to bind a nucleosome core particle (Clark, Halay et al. 
1993, Cirillo, McPherson et al. 1998, Zaret, Caravaca et al. 2010). This structural similarity to 
linker histones H1/H5 allows FOXA transcription factors to access closed chromatin (Clark, 
Halay et al. 1993, Zaret, Caravaca et al. 2010). As the second step of pioneering activity, 
pioneer factors locally open chromatin structure and create a permissive state for gene 
regulation. In contrast to the chromatin binding step, the molecular mechanisms underlying 
the chromatin opening step remain to be determined for most pioneer factors. FOXA 
pioneer factors have the intrinsic ability to open chromatin by themselves as the C-terminal 
domain of FOXA can bind directly to core histone proteins and is required for opening 
chromatin (Cirillo, Lin et al. 2002). However, for some pioneer factors, they can recruit 
chromatin remodelers and achieve chromatin opening. For example, OCT4 recruits the 
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chromatin remodeler BRG1 and establishes accessible chromatin structure in pluripotent 
stem cells (King and Klose 2017). Once chromatin is open, pioneer factors can recruit 
cofactors (for example, transcription factors, chromatin modifiers, histone variants, and 
repressors) and allow their access to the site for gene and epigenetic regulation (Iwafuchi-
Doi and Zaret 2014, Zaret and Mango 2016, Iwafuchi-Doi 2019). 
 
Figure 10 Activities of pioneer factors (adapted from (Zaret and Mango 2016, Iwafuchi-Doi 
2019)) 
Pioneer factors can scan nucleosomal DNA for their target sites in closed chromatin (top). Opening 
chromatin and increased residence time at targeted sites allow for cooperative interactions with 
chromatin remodelers and more stable binding (middle). Binding of pioneer factors and cofactors can 
lead to activated sequences (bottom left) with open chromatin features (green flags) and a state of 
competence to be expressed or direct transcriptional activity, or repressed sequences (bottom right) 
with closed chromatin features (red flags). 
 
In the context of embryonic development, pioneer factors start being expressed in the early 
stages and play a role in establishing competence for specific cell fates (Iwafuchi-Doi and 
Zaret 2014, Zaret and Mango 2016, Iwafuchi-Doi 2019). Genetics and genomics studies 
demonstrate the role of pioneer factors in cell programming and reprogramming. FOXA 
pioneer factors have the ability to specify liver fate by altering chromatin organization after 
binding nucleosomal target-DNA sequences (Cirillo, Lin et al. 2002). PAX7 specifies 
intermediate pituitary melanotrope cell identity through pioneer activity (Budry, Balsalobre 
et al. 2012). NeuroD1 (Neurogenic differentiation factor 1) and ASCL1 (also known as 
MASH1), have also been suggested to have pioneer activity during neural development 
(Wapinski, Vierbuchen et al. 2013, Pataskar, Jung et al. 2016). The three pluripotency factors 
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OCT4, KLF4 and SOX2 have pioneer activity on a global scale by widely affecting the 
epigenome beyond their initial binding sites (Soufi, Donahue et al. 2012, Soufi, Garcia et al. 
2015). In addition, the aberrant activation or inhibition of pioneer factors can compromise 
large-scale chromatin structure and ultimately human health (Iwafuchi-Doi 2019). In many 
forms of cancer, pioneer factors are misregulated, mutated, or their genomic locus 
amplified; alternatively, the binding sites of pioneer factors are mutated (Jozwik and Carroll 
2012). Although more key transcription factors have been identified as pioneer transcription 
factors, the molecular mechanisms behind their special properties are only beginning to be 
revealed (Iwafuchi-Doi 2019). Understanding the pioneering mechanisms will help us to 
precisely control cell fate for research and therapeutic purposes. 
 
1.4 Epigenetic regulation 
1.4.1 Chromatin structure 
In the nucleus of eukaryotes, DNA is packaged as chromatin. The nucleosome is the 
fundamental unit of chromatin and it is composed of an octamer of the four core histones 
(H2A, H2B, H3 and H4,) around which 147 base pairs of DNA are wrapped (Kouzarides 2007). 
Each of the histone proteins consists of a structured core and an unstructured tail domain. 
These histone tails are the most common sites of post-translational modifications (Biswas, 
Voltz et al. 2011). H1 histone associates with the linker DNA located between the 
nucleosomes. Nucleosome spacing determines chromatin structure, which can be broadly 
divided into “closed chromatin” and “open chromatin” (Figure 11). “Closed chromatin” is 
condensed and usually associated with relative transcriptional repression. In contrast, “open 
chromatin” is a state which allows proteins governing transcription to access the DNA and 
effect RNA synthesis (Gillette and Hill 2015). Chromatin structure and gene accessibility to 
transcriptional machinery are regulated by modifications to both DNA and histone tails 
(Handy, Castro et al. 2011). 
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Figure 11 Schematic representation shows the organization and packaging of genetic 
materials (adapted from (Yan, Matouk et al. 2010)) 
Schematic diagram shows different levels of chromatin compaction. DNA is wrapped around a cluster 
of histone proteins to form nucleosomes. Nucleosome is represented by DNA wrapped around eight 
histone proteins, H2A, H2B, H3, and H4. H1 serves as a linker protein. Histone tails are shown 
protruding from histone proteins and histone modifications are shown with round balls. 
Nucleosomes are further organized to create open and closed regions of chromatin, which in turn 
create three-dimensional structures that encompass different levels of gene organization in the 
chromosomes packed into a cell nucleus.  
 
1.4.2 Epigenetic control mechanisms 
In 1940s, Waddington first proposed the term “epigenetics” by combining the words 
“epigenesis" and “genetics”, which was defined as the study of heritable changes in gene 
expression, that are not a result of changes in the DNA sequence, but rather due to 
alterations related to the packaging (thereby altering DNA accessibility) and/or translation of 
genetic information (Morris 2001, Bird 2007, Goldberg, Allis et al. 2007, Lorenzen, Martino 
et al. 2012, Vallaster, Vallaster et al. 2012). Over the past decade, epigenetics has become an 
important and rapidly expanding field of research in Biology (Portela and Esteller 2010, 
Ponchel and Burska 2016). Chromatin structure can be dynamically regulated by three 
classes of chromatin regulators: DNA methylation (Me) by DNA modifiers, histone 
modification by histone modifiers, and chromatin organization by chromatin remodelers 
(Chang 2012). They are reported in a lot of publications to play a central role in various 
biological processes, including stem cell fate decision (Lunyak and Rosenfeld 2008), cell 
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proliferation and differentiation (Srinageshwar, Maiti et al. 2016, Marroncelli, Bianchi et al. 
2018), embryonic development (Hemberger, Dean et al. 2009) and diseases (Portela and 
Esteller 2010). Here I only focus on the chromatin organization by chromatin remodelers. 
1.4.2.1 Chromatin remodelers 
Chromatin remodeling is widely used to describe changes in chromatin structure that occur 
during regulatory processes (Aalfs and Kingston 2000). It can occur independently or in 
concert with other events, such as transcription (Aalfs and Kingston 2000). The complexes 
that relocate nucleosomes or alter the structure of nucleosomes are called “chromatin 
remodelers” or “chromatin remodeling complexes”. 
The chromatin remodeling complexes are primarily made up of a single ATPase and multiple 
associated subunits (Hota and Bruneau 2016). The core catalytic subunit is the ATPase 
subunit. On the basis of the sequence and structure of the core ATPase subunit, the ATP-
dependent chromatin remodeling complexes are divided into four major subfamilies (Figure 
12A): ISWI (imitation switch), CHD (chromo domain helicase DNA-binding), INO80 (inositol 
requiring 80)/SWR (SWI2/SNF2 related), and SWI/SNF (switch/sucrose non-fermentable) 
subfamilies (Ho and Crabtree 2010, Mazina and Vorobyeva 2016, Clapier, Iwasa et al. 2017). 
With energy derived from ATP hydrolysis, these complexes work on chromatin remodeling in 
a variety of ways (Figure 12B): (A) nucleosome assembly: factors, especially those belonging 
to the ISWI and CHD subfamily remodelers, participate in the random distribution of newly 
formed nucleosomes, as well as their maturation and arrangement into regularly-spaced 
chromatin structures; (B) Chromatin access: factors that mainly belong to the SWI/SNF 
family mediate DNA accessibility by repositioning nucleosomes, ejecting octamers or evicting 
histone dimers; (C) Nucleosome editing: factors of the INO80 subfamily change nucleosome 
composition by exchanging canonical and variant histones (like H2AZ).  
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Figure 12 Domain structure of the core ATPase subunits and functional classification of the 
chromatin remodeling complexes (adapted from (Manelyte and Langst 2013, Hota and 
Bruneau 2016, Clapier, Iwasa et al. 2017, Sokpor, Castro-Hernandez et al. 2018)) 
(A) Diagram shows the domain organization of the catalytic subunits of ISWI, CHD, INO80/SWR and 
SWI/SNF subfamilies of chromatin remodelers. All of these subunits are SNF2 family proteins. They 
all contain an ATPase domain, which consists of DEXDc and HELICc domains, with each subfamily 
possessing additional domains. For example, ISWI proteins harbor a C-terminal SANT domain as well 
as SANT-like ISWI (SLIDE) and HAND domains. CHD proteins are defined by the presence of tandem 
N-terminal chromo domains, with some family members containing N-terminal plant homeodomain 
(PHD) domains. INO80R/SWR proteins notably contain a split ATPase domain, with a spacer between 
the DEXDc and HELICc domains. By contrast, SWI/SNF proteins are defined by the presence of an N-
terminal helicase-SANT (HSA) domain and a C-terminal bromo domain. Image is adapted from 
(Manelyte and Langst 2013, Hota and Bruneau 2016). (B) Summary of the ways of actions of 
chromatin remodelers. The core ATPase subunits are depicted in pink; additional subunits in 
different complexes are depicted in green, brown and blue, respectively. Image is adapted from 
(Clapier, Iwasa et al. 2017, Sokpor, Castro-Hernandez et al. 2018). In addition, to avoid of confusion, 
“CHD” represents “chromo domain helicase DNA-binding” only in 1.4.2.1 part, whereas in the other 
parts of this thesis, “CHD” refers to “congenital heart disease”. 
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1. The ISWI subfamily remodeling complex 
The ISWI subfamily of remodeling complexes contains one catalytic subunit and one or more 
accessory subunits. In mammals, the core ATPase subunit of this complex is SNF2H or SNF2L. 
They are functionally distinct and are found in different complexes, as distinguished by their 
accessory subunits. SNF2L is present in the NURF (nucleosome remodeling factor) and CERF 
(CECR2-containing remodeling factor) complexes, whereas SNF2H is present in the NoRC 
(nucleolar remodeling complex), WICH (WSTF ISWI chromatin remodeling complex), ACF 
(chromatin-assembly factor), RSF (remodeling and spacing factor) and CHRAC (chromatin 
accessibility complex) complexes (Hota and Bruneau 2016, Sokpor, Castro-Hernandez et al. 
2018). NURF complexes and NoRC are involved in transcriptional activation and repression. 
By contrast, ACF, CHRAC and WICH complexes are required for the regulation of chromatin 
structure (including nucleosome assembly and spacing), the replication of DNA through 
heterochromatin and the segregation of chromosomes (Dirscherl and Krebs 2004, Ho and 
Crabtree 2010). 
2. The CHD subfamily remodeling complex 
The CHD subfamily of chromatin remodeling complexes contains core ATPase subunits of 
CHD proteins, which comprises nine chromo domain containing members (Figure 12). These 
CHD proteins are subdivided into 3 groups according to their structural properties. Group I of 
CHD proteins contain CHD1 and CHD2. They can act as monomeric units to directly regulate 
chromatin and transcription (Sokpor, Castro-Hernandez et al. 2018). CHD3 and CHD4 are 
members of Group II of CHD proteins. They are core catalytic components (ATPases) of the 
nucleosome remodeling deacetylase NuRD complex, which contain histone deacetylases 
(HDACs) and function as transcriptional repressors (Ho and Crabtree 2010). Group III CHD 
proteins contain CHD5-9, in which CHD7 is the most extensively studied one. Mutations in 
CHD7 result in CHARGE syndrome in humans, which is characterized by coloboma of the 
eyes, heart defects, choanal atresia, severe retardation of growth and development, and 
genital and ear abnormalities (Vissers, van Ravenswaaij et al. 2004). 
3. The INO80 remodeling complex 
The INO80/SWR complexes are characterized by the presence of a conserved split ATPase 
domain (Figure 12). Similar with the other remodeling complexes, they also contain core 
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ATPase subunits and some associated subunits. In mammals, the core catalytic subunits 
include INO80, P400 and SRCAP (homologues of yeast SWR1). They work together with other 
subunits to play a role in different biological processes, such as transcriptional regulation 
and DNA damage repair (Ho and Crabtree 2010). 
4. The SWI/SNF remodeling complex 
The SWI/SNF subfamily is one of the most-studied subfamilies of chromatin remodeling 
complexes. It is conserved from yeast to mammals. In mammals, SWI/SNF complexes are 
known as brahma-associated factor (BAF) complexes. The ATPase subunit of BAF complex is 
encoded by two homologs, BRM (Brahma) and BRG1 (brahma-related gene 1), and only one 
of them is present in each complex, which gives rise to a diversity of stable assemblies that 
differ between cell types and that have distinct functions (Wang, Xue et al. 1996, Lessard, 
Wu et al. 2007). BRG1 and BRM are associated with different promoters during cellular 
proliferation and differentiation, and in response to specific signaling pathways by 
preferential interaction with certain classes of transcription factors. They may direct distinct 
cellular processes by recruitment to specific promoters through protein-protein 
interactions that are unique to each ATPase (Kadam and Emerson 2003).  
In addition to the core ATPase unit BRG1/BRM, BAF complex contains a lot of associated 
subunits. The BAF complex composition undergoes progressive changes during the process 
of development and in different cell types (Wang, Xue et al. 1996, Lessard, Wu et al. 2007) 
(Figure 13). For example, the BAF complex in mouse embryonic stem cell (ESC), called esBAF, 
is defined by the presence of BRG1 but not BRM, and BAF155 but not BAF170 (Ho, Ronan et 
al. 2009). It is essential for ESC self-renewal and pluripotency, and is a critical component 
and regulator of the core transcriptional network of ES cells (Ho, Jothi et al. 2009, Ho, Ronan 
et al. 2009). When ESCs differentiate into neuronal progenitors, the esBAF complex 
undergoes several subunit exchanges: it incorporates BRM and excludes BAF60B, which is 
now called npBAF, to differentiate it from the BAF complexes in other cell types. As neural 
progenitors exit the cell cycle, the BAF45a/53a subunits, which are necessary and sufficient 
for neural progenitor proliferation, are replaced by the homologous BAF45b, BAF45c, and 
BAF53b. Preventing the subunit switch impairs neuronal differentiation, indicating that this 
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molecular event is essential for the transition from neural stem/progenitors to postmitotic 
neurons (Lessard, Wu et al. 2007). 
 
Figure 13 Tissue/cell-type-specific assemblies of BAF complexes (adapted from (Ho and 
Crabtree 2010))  
Schematic diagram shows the tissue/cell-type specific subunits of BAF complexes. All of the subunits 
form the whole complex by occupying specific positions, as in a jigsaw puzzle. The domains that 
enable the subunits to interact with DNA are depicted at the surface of each protein. The BAF 
complex in embryonic stem cells (ESCs) is called esBAF; in neuronal progenitors, npBAF; and in 
neurons, nBAF. In cardiac progenitors, the composition of the BAF complex is also distinct and 
recently is characterized by proteomic analysis (Hota, Johnson et al. 2019), unlike the other BAF 
complexes shown. In some cases, key transcription factors that work in cooperation with BAF 
complexes (such as OCT4 and SOX2 in ESCs, CREST in neurons and GATA4 and TBX5 in cardiac 
progenitors) are depicted.  
 
Recently, using immunoprecipitation with mass spectrometry, Hota et al. determined the 
dynamic composition of BAF complexes during mammalian cardiac differentiation, 
identifying several cell-type specific subunits. For example, ESC-derived BRG1 complexes 
were enriched for BRD9, GLTSCR1L, BCL7B/C, BAF155 and BAF60A, consistent with previous 
reports (Kidder, Palmer et al. 2009, Ho and Crabtree 2010, Kadoch and Crabtree 2013), while 
BRG1 partners in mesoderm (PDE4D, CRABP2, ARID1B), cardiac progenitor cells (BAF60B/C, 
POLYBROMO-1, BAF200, BAF47, BCL7A, BRD7, and BAF45A) and cardiomyocytes stages 
(BAF170, BAF60C, BAF57, SS18l1, BAF45C, WDR5, and CC2D1B) were also identified (Hota, 
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Johnson et al. 2019). There is a fine balance in the composition of the BAF complex, and 
perturbation of one subunit extends to the association of other subunits in the complex, and 
different subunits or isoforms substitute for the absence of one or more subunits, for 
example, both BAF60A and BAF60B substitute for the lack of BAF60C, and depletion of 
BAF45C is balanced by enrichment of BAF45A, which indicating that subunit switching and 
substitution in BAF complex composition could be an important mechanism in cardiac 
lineage specification (Hota, Johnson et al. 2019). 
Tissue-specific BAF complexes have been reported to interact with a variety of transcription 
factors in different cell types, allowing the complexes to take on context-dependent 
functions arising from their different interaction partners (Ho and Crabtree 2010). For 
example, ectopic expression of Baf60c but not Baf60a, in coordination with the transcription 
factors Gata4 and Tbx5, is sufficient to induce the development of beating cardiomyocytes 
from non-cardiogenic mesoderm in the developing embryos (Takeuchi and Bruneau 
2009).  BAF complexes can function as both transcriptional activators and repressors and can 
even switch between these two modes of action at the same gene (Chi, Wan et al. 2003, Ho 
and Crabtree 2010).  
1.4.2.2 Roles of BAF complex in cardiac development and diseases 
BAF complex components are essential for multiple stages of cell differentiation during heart 
development, for heart formation and postnatal heart function (Figure 14) (Hota and 
Bruneau 2016). Among all the subunits in BAF complex, BRG1 and BAF60C, in particular, 
have crucial roles in multiple transcriptional regulatory pathways.  
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Figure 14 Roles of BAF chromatin remodeling complex in heart development (adapted 
from (Hota and Bruneau 2016)) 
Stages of mammalian heart development are pictured, with mouse embryonic day (E) indicated 
below. Key demonstrated roles for specific chromatin-remodeling factors are positioned at relevant 
stages below the developmental timeline. LA, left atrium; LV, left ventricle; RA, right atrium; RV, right 
ventricle. 
 
Brg1, also known as Smarca4, is ubiquitously expressed in the developing mouse embryos 
from unfertilized egg, two-cell, four-cell, morula, and blastocyst stages (Bultman, Gebuhr et 
al. 2000, Singh, Foley et al. 2017). Brg1 is highly expressed in mouse embryos and is 
downregulated in adult cardiomyocytes (Chang 2012). Brg1 homozygous (Brg1-/-) mouse die 
during the peri-implantation stage of development (Bultman, Gebuhr et al. 2000). In 
contrast, heterozygous loss of Brg1 in mouse results in dilated and disorganized ventricles, 
ventricular septal defects (VSDs) and a double outlet right ventricle, anomalies that resemble 
human congenital heart defects, indicating that Brg1 is haploinsufficient in mouse heart 
(Takeuchi, Lou et al. 2011). 
In the developing mouse heart, Brg1 is critical for cardiac morphogenesis and regulation of 
cardiac gene expression programs. During cardiac differentiation, Brg1 is essential for 
modulating active and repressive chromatin states during mesoderm lineage commitment, 
in particular the activation of developmentally important enhancers (Alexander, Hota et al. 
2015). Brg1 is also a crucial regulator of cardiomyocyte gene expression and differentiation, 
and its dosage is critical during mouse and zebrafish heart development (Takeuchi, Lou et al. 
2011, Hota, Johnson et al. 2019). In mouse embryos, Brg1 represses the expression of 
Adamts1 in the endocardium and endocardial specific loss of Brg1 leads to trabeculation 
defects (Stankunas, Hang et al. 2008). Moreover, Brg1 deletion in the myocardium leads to 
thin compact myocardium and fails to form an interventricular septum (Hang, Yang et al. 
2010). It was further shown that Brg1 promotes myocardial cell proliferation by maintaining 
Bmp10 and suppressing p57kip2 expression in mouse embryos (Hang, Yang et al. 2010). In 
addition, Brg1 is required for the formation and differentiation of neural crest cells (NCCs), 
which are essential for the formation of pharyngeal arch arteries and the cardiac outflow 
tract. Brg1 maintains a NCC progenitor pool by promoting proliferation and inhibiting 
apoptosis, facilitates NCC maturation to vascular smooth muscle cells and regulates neural 
crest cell migration to the outflow tract (Wei Li, Yiqin Xiong et al. 2012). 
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Baf60c, also called Smarcd3, is a subunit of BAF complex. Baf60c is initially restricted to the 
developing heart, as early as E7.5. In the looping heart tube (E8.5-E9.0), Baf60c expression is 
more pronounced at the poles of the heart, which will give rise to the outflow tract 
anteriorly and to the atria posteriorly. Baf60c is also expressed in myotome of somites, 
dorsal neural tube, and limb bud mesenchyme from E9.5 onwards (Lickert, Takeuchi et al. 
2004). Baf60c is highly expressed in the heart at the early stages of embryonic development 
but gradually downregulated at the postnatal stages (Nakamura, Koshiba-Takeuchi et al. 
2016). Mouse embryos with reduced levels of Baf60c showed defective cardiac 
differentiation and severe heart defects including outflow tract defects, impaired trabecular 
formation and hypoplastic atrium and right ventricle (Lickert, Takeuchi et al. 2004). 
Conditional deletion of Baf60c in cardiomyocytes resulted in postnatal dilated 
cardiomyopathy with impaired contractile function (Sun, Hota et al. 2017).  
BAF complexes orchestrate many aspects of heart development, and genetically interact 
with cardiac transcription factors to finely modulate cardiac gene expression (Hang, Yang et 
al. 2010, Takeuchi, Lou et al. 2011). Congenital heart defects in humans can result from 
haploinsufficiency of transcription factors such as TBX5, NKX2.5, and GATA4 (Bruneau 2008). 
Brg1 interacts with these factors to regulate cardiac gene expression and Baf60c can 
enhance interactions between transcription factors and Brg1, at least when overexpressed in 
cell culture, suggesting that Baf60c may function as a bridge between the BAF complex and 
select cardiac transcription factors (Lickert, Takeuchi et al. 2004, Wang 2012). Genetically, 
Brg1 interacts with cardiac transcription factors in a dose-dependent manner to regulate 
heart development in mice and disrupting the balance between Brg1 and disease-causing 
cardiac transcription factors, including Tbx5, Tbx20 and Nkx2.5, causes severe cardiac 
anomalies (Takeuchi, Lou et al. 2011). Baf60c, together with the cardiac transcription factors 
Tbx5, Nkx2.5 and Gata4, can induce non-cardiac mesoderm to differentiate into 
cardiomyocytes, suggesting that Baf60c may have a central function in the specification of 
cardiac fate in addition to its later role in cardiac morphogenesis (Takeuchi and Bruneau 
2009, Wang 2012).  
Targeting subunits and domains of chromatin remodelers is currently being evaluated as a 
therapeutic strategy in the prevention and treatment of human diseases. Chromatin 
remodelers harbor epigenetic reader domains that may serve as novel drug targets (Längst 
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and Manelyte 2015). JQ1 molecule, inhibiting BRD4 protein through its bromo domain, was 
the first discovered inhibitor, which is already in clinical trials (Delmore, Issa et al. 2011, 
Längst and Manelyte 2015). Brm and Brg1 bromo domains are also potentially drugable with 
specific Pfi-3 inhibitor (http://www.thesgc.org) (Längst and Manelyte 2015). Moreover, 
HDACs and PARP1, which interact with Brg1, are therapeutic targets for cardiac hypertrophy, 
as pharmacological inhibition of their activities or genetic mutations of class I HDACs and 
PARP1 in mice reduce hypertrophy. Upregulation of Brg1 is observed in heart tissues 
obtained from patients with hypertrophic cardiomyopathy, and the level of Brg1 
upregulation correlates strongly with the severity of hypertrophy and MHC switch (Hang, 
Yang et al. 2010). Deletion of Brg1 in adult hearts which prevents stress-induced Brg1 
reactivation, reduces cardiac hypertrophy, abolishes cardiac fibrosis, and reverses the 
pathological MHC switch (Chang 2012), indicating that Brg1-based BAF complex may act as a 
target for treating cardiac hypertrophy and failure. 
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2. Objectives 
The work on Isl1 described in the introduction has demonstrated that Isl1 is crucial for early 
heart development. However, still many questions remain. In this study, we want to address 
the following questions regarding the role of Isl1 in second heart field (SHF) development: 
1. What is the genome wide binding profile of Isl1 during cardiogenesis? What are Isl1 
primary downstream targets in a genome-wide view during SHF development? 
To elucidate the role of Isl1 in greater details during SHF development, we firstly want to 
investigate the downstream targets of Isl1. To achieve this aim, we selected the mESC-based 
in vitro cardiac differentiation approach and Isl1 knockout mouse as model systems. mESC-
based in vitro cardiac differentiation strategy offers a powerful tool to generate large 
amount of cardiac progenitor cells with high homogeneity and makes it easier to observe 
cardiac differentiation at different time points. Moreover, Isl1 knockout mouse lines help us 
to explore the regulatory network of Isl1 in vivo. Furthermore, ChIP-Seq can help us to 
identify the genome wide binding profile of Isl1 during cardiogenesis. In combination of 
RNA-Seq and ChIP-Seq techniques, we hope to identify Isl1 directly regulated downstream 
targets during cardiogenesis in a genome-wide view. 
2. What is the role of Isl1 in epigenetic regulation during SHF development? 
After identifying the transcriptional regulatory network of Isl1, our next aim is to investigate 
how these genes are regulated? Transcriptional regulation is associated with chromatin 
landscape. Pioneer transcription factors are capable of reorganizing the chromatin state and 
play critical roles in cell fate control during embryonic development (Zaret and Mango 2016). 
As a transcription factor, we hypothesize that Isl1 could function as a pioneer factor in 
regulating SHF development. To investigate whether Isl1 acts as a pioneer factor and the role 
of Isl1 in epigenetic regulation during SHF development, we plan to use biochemical and 
molecular approaches in this study. Co-immunoprecipitations can help to identify Isl1 
working partners in this process. ATAC-Seq combined with ChIP-Seq analysis in both mESC-
derived CPCs and embryonic tissues should be possible to clarify the role of Isl1 in organizing 
chromatin landscape at its target sites. 
Altogether, we hypothesize that Isl1 could work as a pioneer factor to reshape the chromatin 
landscape in regulating a transcriptional gene network during SHF development. 
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3. Results 
3.1 Isl1 regulates cardiogenesis in CPCs by directly targeting a 
large group of downstream targets  
3.1.1 Generation of Isl1 KO ESC line 
To investigate the role of Isl1 during cardiogenesis using the cell culture system, we 
generated a mouse embryonic stem cell (mESC) line with Isl1 deletion using CRISPR-Cas9 
technique. Gene editing was done in Nkx2.5-GFP mESC line (Wu, Fujiwara et al. 2006, Hsiao, 
Yoshinaga et al. 2008) which expresses GFP specifically in cardiac progenitor cells and later in 
cardiomyocytes, driven by a cardiac-specific enhancer together with a Nkx2.5 base promoter 
(Figure 15A-B). This allows us to check cardiac differentiation efficiency and sort cardiac 
progenitor cells and cardiomyocytes by flow cytometry. Exons 1-4 of Isl1 were deleted, 
covering the LIM1, LIM2 and Homeodomain (HD) of ISL1 protein. The knockout (KO) 
efficiency was checked by Western blot which showed Isl1 is efficiently deleted (Figure 15C).  
 
Figure 15 Generating Isl1 KO ESC lines by CRISPR-Cas9 technique 
(A) Strategy for generating Isl1 KO ESC lines by CRISPR-Cas9 technique. Exons 1-4 were deleted by 
guide1 and guide2 and primers 1-3 were used for genotyping. (B) Genotyping of Isl1 KO lines by PCR. 
KO band is 915bp amplified by primers1 and 3 and WT band is 476bp amplified by primers1 and 2. (C) 
Western Blot to check Isl1 knockout efficiency in CPCs. α-Tubulin was used as loading control. 
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3.1.2 Establishing in vitro mESC-based cardiac differentiation protocol 
Embryonic stem cells (ESCs) are pluripotent which can undergo differentiation in vitro to 
generate derivatives of the three primary germ layers and hence potentially all the cell types 
present in the body. In most cases, the in vitro differentiation recapitulates the stepwise 
stages of embryological development for the cell types of interest. To explore the role of Isl1 
during cardiac differentiation, we used a directed differentiation method of mESCs into 
cardiomyocytes in which the mesoderm (MES), cardiac progenitor cells (CPCs), and 
cardiomyocytes (CMs) were sequentially induced (Figure 16A) (Kattman, Witty et al. 2011, 
Wamstad, Alexander et al. 2012) as a model system. In this protocol, ESCs were aggregated 
in petri dishes and cultured for 2 days in the absence of exogenous factors (days 0-2), 
subsequently treated with Activin A, BMP4, and VEGF for 40 hours to induce mesoderm 
under serum-free conditions (days 2-3.7), and then dissociated to a monolayer culture to 
differentiate into CPCs and CMs (days 3.7-10) under the induction of VEGF, bFGF and FGF10 
(Figure 16A). This directed cardiac differentiation protocol efficiently specified ESCs into 
mesoderm, CPCs and CMs at specific stages. By this system we can get roughly 75% cardiac 
progenitors at day5 (GFP positive cells; Figure 16B-C) and cardiomyocytes at day10 
(Wamstad, Alexander et al. 2012).  
 
Figure 16 Characterization of directed cardiac differentiation of mouse ESCs 
(A) Schematic representation of the differentiation process and timeline of directed CM 
differentiation protocol and stage collection. (B) Fluorescent images of day5 cultures for Nkx2.5-GFP 
reporter line. (C)  Flow cytometry analysis of GFP positive cells in negative control (E14 line) and 
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Nkx2.5-GFP lines (GFP transgenic line with E14 background) at day5. mESCs: mouse embryonic stem 
cells; MES: mesoderm cells; CPCs: cardiac progenitor cells; CM: cardiomyocytes. 
 
Based on marker gene expression analysis (Figure 17A-D), we picked four stages of 
differentiation that represent key cell types in the transition from pluripotent cells to 
cardiomyocytes: undifferentiated embryonic stem cells (ESCs) expressing pluripotency genes 
(Oct4, Sox2 and Nanog), cells expressing mesodermal markers (Brachyury, Mesp1 and Mesp2) 
(MES), cells expressing cardiac transcription factors (Nkx2.5, Isl1, Mef2c, Hand1/2 and 
Tbx5/20) but not yet beating (CPCs), and functional cardiomyocytes (CMs) with CM-specific 
gene expression (Tnnt2, Mlc2a and Mlc2v). 
 
Figure 17 Marker gene expression analyses at different stages of cardiac differentiation 
Marker genes expression measured by qPCR throughout directed cardiac differentiation protocol: (A) 
ESC markers; (B) MES markers; (C) CPC markers; and (D) CM marker genes. 
 
3.1.3 Isl1 KO ESC lines can differentiate into CPCs 
To check whether our Isl1 KO (Isl1-/-) lines generated with CRISPR-Cas9 technique can 
differentiate properly, we performed the directed cardiac differentiation and harvested cells 
at cardiac progenitor stage for fluorescence-activated cell sorting (FACS) and qPCR analysis 
(Figure 18). We can get around 60% GFP positive cells at day5 and Isl1 depletion did not 
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change the number of CPCs (Figure 18B). As expected, loss of Isl1 led to downregulation of 
known Isl1 target genes (Figure 18C). These results suggest that our Isl1 KO ESC lines are 
successfully generated and they can differentiate into cardiac progenitors by in vitro cardiac 
differentiation. 
 
Figure 18 Analysis of CPCs differentiated from control and Isl1 KO lines 
(A) Schematic diagram shows cardiac differentiation of control and Isl1 KO lines and FACS analysis at 
cardiac progenitor stage. (B) FACS results of CPCs from control and Isl1 KO lines. CPCs from E14 line 
are used as negative control. (C) qPCR to check some Isl1 known targets and some CPC marker genes. 
Data represent mean±SEM, n=3. 
 
3.1.4 Isl1 loss-of-function results in downregulation of a large number of genes 
critical for cardiogenesis in CPCs 
To identify downstream targets of Isl1 in CPCs, we performed RNA-Seq of sorted Nkx2.5-
GFP+ CPCs derived by differentiation of control or Isl1-/- Nkx2.5-GFP mESCs (Figure 19). We 
observed strong correlation between replicates for control and Isl1 KO samples, 
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demonstrating high reproducibility across experiments (Figure 19A). From the results, we 
identified 1014 differentially expressed genes (fold change > 1.5; log2 fold change < -0.58, > 
0.58; p value < 0.05) (Figure 19B). GO analysis of genes downregulated in the Isl1 KO CPCs 
revealed over-representation of GO terms linked to heart development, cardiac muscle 
contraction, sarcomere organization and outflow tract morphogenesis while upregulated 
genes are highly associated with regulation of transcription and multicellular organism 
development (Figure 19C). 
 
Figure 19 RNA-Seq data analysis in control and Isl1 KO CPCs 
(A) Principal component analysis (PCA) of RNA-Seq data from control and Isl1 KO CPCs (n=2), 
providing insights into the association between samples. (B) Volcano plot of RNA-Seq data from 
control and Isl1 KO CPCs (n=2). Each point represents an individual gene and all genes differentially 
expressed with fold change >1.5; log2 fold change < -0.58 and p value < 0.05 are highlighted in green 
(downregulated genes) and red (upregulated genes). (C) Heatmap of differentially regulated genes 
(782 downregulated and 232 upregulated genes with fold change > 1.5; log2 fold change < -0.58, > 
0.58 and p value < 0.05) in CPCs caused by Isl1 KO (n=2). Representative genes and enriched GO 
terms are presented on the right side. 
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3.1.5 Isl1 directly regulates a large amount of genes in CPCs 
To investigate whether Isl1 directly regulates these target genes, we harvested cardiac 
progenitor cells derived from mESCs through cardiac differentiation and performed 
chromatin immunoprecipitation followed by high-throughput sequencing (ChIP-Seq) to map 
the genome-wide binding of Isl1 in CPCs. ChIP-Seq analysis identified a lot of target genes 
directly regulated by Isl1 (Figure 20). Some are its known targets, such as Mef2c, Hand2, 
Myocd, as we expected. Interestingly, there are also a lot of new targets which have not 
been reported, such as signaling molecules Jag1 and Wnt2, cardiac transcription factor 
Gata4, and cardiomyocytes structural/contraction associated gene Mybpc3, Tnni1, Ryr2 
(Figure 20). 
 
Figure 20 Genome tracks of some representative Isl1 targets in CPCs 
Screenshots of RNA-Seq and ChIP-Seq data in CPCs showing genome tracks of some representative 
Isl1 target genes. 
 
Intersection of the RNA-Seq data to the ChIP-Seq data revealed more than 60% 
downregulated genes that were bound by Isl1 in CPCs and 56% upregulated genes with Isl1 
occupancy (Figure 21A and 21B). GO analysis of genes downregulated in the Isl1 KO CPCs 
that were bound by Isl1 revealed over-representation of GO terms linked to positive 
regulation of transcription and heart development while hemopoiesis and embryonic 
hindlimb morphogenesis for the common upregulated genes (Figure 21C and 21D). 
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Figure 21 Isl1 regulates a large group of genes associating with cardiogenesis in CPCs 
(A-B) Common genes of Isl1 bound genes and downregulated (A) or upregulated genes (B) caused by 
Isl1 loss-of-function in CPCs respectively. (C-D) Representative GO items for downregulated genes (C) 
and upregulated genes (D) with Isl1 binding in CPCs analyzed using DAVID 6.8. 
 
3.2 Isl1 is essential in regulating second heart field development in 
mouse embryos 
3.2.1 Isl1 knockout leads to significant gene expression changes at early stage 
of mouse embryonic development 
To gain insight into the molecular mechanisms underlying Isl1 function in cardiogenesis in 
vivo, we performed RNA-Seq (Figure 22) from dissected pharyngeal mesoderm/hearts of 
E8.5 Isl1 knockout embryos at which stage the Isl1+ cells are restricted in the cardiogenic 
region (Figure 8). 
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Figure 22 Analysis of RNA-Seq data from E8.5 Isl1 KO embryos 
(A) PCA plot of RNA-Seq data from E8.5 Isl1 KO and control embryos (n=4). (B) Volcano plot of RNA-
Seq data from E8.5 Isl1 KO embryos versus control (n=4). Each point represents an individual gene 
and all genes differentially expressed with fold change > 1.5; log2 fold change < -0.58 and p value < 
0.05 are highlighted in green (downregulated genes) and red (upregulated genes). (C) Heatmap of 
differentially regulated genes (334 downregulated and 235 upregulated genes with fold change >1.5; 
log2 fold change < -0.58, > 0.58 and p value < 0.05) in the cardiogenic region of Isl1 KO E8.5 embryos 
versus control (n=4). Representative genes and enriched GO terms are presented on the right side. 
 
The RNA-Seq results showed four replicates of control and four Isl1 KO samples clustered 
together very well and showed consistent results (Figure 22A). From the RNA-Seq data, we 
identified 569 differentially expressed genes in E8.5 Isl1 knockout embryos (fold change > 
1.5; log2 fold change < -0.58, > 0.58; p value < 0.05) (Figure 22B). Gene Ontology (GO) 
analysis revealed over-representation for GO terms linked to cardiac muscle contraction, 
heart development, atrial septum and OFT morphogenesis in genes downregulated in E8.5 
Isl1 knockout embryos, whereas genes involved in multicellular organism development and 
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transcription regulation were overrepresented in upregulated genes (Figure 22C). This is 
consistent with our results from Isl1 KO mESC-derived cardiac progenitor cells. 
3.2.2 Reduced level of Isl1 results in cardiac defects and deregulation of target 
genes in E10.5 Isl1 hypomorphic embryos 
The critical role of Isl1 in heart development has been demonstrated using an Isl1 KO mouse 
line. Isl1 KO embryos show early embryonic lethality (at around E10.5) (Cai, Liang et al. 2003, 
Yang, Cai et al. 2006). This severe phenotype makes it impossible to analyze the role of Isl1 in 
heart development at later stages during development. For this purpose, we utilized an Isl1 
hypomorphic mouse line (Liang, Song et al. 2011) which survives until birth. 
 
Figure 23 Reduced Isl1 expression leads to defects in cardiac morphogenesis 
Isl1 hypomorphic mice presented various degrees of cardiac outflow tract (OFT) defects with ASDs 
and VSDs. Here only representative images are shown (Thanks for our collaborators to provide this 
figure). (A) Histological analysis of Isl1 hypomorphic hearts at E17.5 showing ventricular septal defect 
(VSD, arrow) and PTA compared to control hearts. (B) 3D reconstruction of control and Isl1 
hypomorphic hearts showing PTA and VSD. Ao: Aorta; AoA: aortic arch; PA: pulmonary artery; LV: left 
ventricle; RV: right ventricle; VSD: ventricular septal defect; PTA: persistent truncus arteriosus. 
 
Histological analyses of Isl1 hypomorphic embryos at E17.5 revealed various degrees of 
cardiac outflow tract (OFT) septation abnormalities, including partial OFT septal defects with 
aortic stenosis and misalignment and persistent truncus arteriosus (PTA). Nearly all Isl1 
hypomorphic mice presented ventricular septal defects (VSDs) and atrial septal defects 
(ASDs) (Figure 23A). MRI and 3D reconstructions confirmed the presence of various cardiac 
outflow tract (OFT) abnormalities, VSDs and ASDs (Figure 23B). To conclude, reduced level of 
Isl1 in Isl1 hypomorphic mice led to cardiac defects as seen in human CHD patients, 
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suggesting Isl1 is also crucial for heart development at the later stages of embryonic 
development. 
 
Figure 24 Analysis of RNA-Seq data from E10.5 Isl1 hypomorphic embryos 
(A) PCA plot of RNA-Seq data from E10.5 Isl1 hypomorphic and control embryos (n=4). (B) Volcano 
plot of RNA-Seq data from E10.5 Isl1 hypomorphic embryos versus control (n=4). Each point 
represents an individual gene and all genes differentially expressed with fold change > 1.5; log2 fold 
change < -0.58 and p value < 0.05 are highlighted in green (downregulated genes) and red 
(upregulated genes). (C) Heatmap of differentially regulated genes (500 downregulated and 399 
upregulated genes with fold change > 1.5; log2 fold change < -0.58, > 0.58 and p value < 0.05) in the 
SHF of E10.5 embryos caused by reduced Isl1 expression (n=4). Representative genes and enriched 
GO terms are presented on the right side. 
 
To explore the molecular mechanisms responsible for the cardiac defects observed at later 
stages of heart development in Isl1 hypomorphic embryos, we isolated the OFT and RV of 
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E10.5 Isl1 hypomorphic embryos, structures derived from the Isl1+ SHF CPCs, still expressing 
Isl1, and when the phenotype is not so severe yet, to avoid secondary effect on gene 
expression changes. We performed RNA-Seq with 4 replicates for control and Isl1 
hypomorphic embryos, respectively. The RNA-Seq data showed consistent results of all the 
replicates (Figure 24A). From the results, we identified 899 deregulated genes caused by 
reduced level of Isl1 (fold change > 1.5; log2 fold change < -0.58, > 0.58; p value < 0.05) 
(Figure 24B). In addition to many transcriptional regulators of cardiac morphogenesis, we 
found significant overrepresentation of genes involved in cell adhesion and differentiation 
that have been shown to play key role in cardiac looping morphogenesis, cushion formation, 
neural crest addition, ventricular and OFT septation in the downregulated genes (Figure 
24C). Interestingly, we identified genes involved in erythroid development and hemogenic 
lineage specification in genes upregulated upon Isl1 loss (Figure 24C). Given the antagonistic 
relationship between hemangiogenic and cardiogenic mesoderm specification (Van Handel, 
Montel-Hagen et al. 2012), this might suggest that Isl1 is important for establishing cardiac 
fate and prevents the acquisition of hemogenic fate. 
3.2.3 ChIP-Seq analysis identified Isl1 primary downstream targets in vivo 
To investigate whether Isl1 directly regulates these downstream targets in vivo, we 
performed chromatin immunoprecipitation followed by high-throughput sequencing (ChIP-
Seq) to map the genome-wide binding of Isl1 in dissected cardiogenic regions of E8.25-E9.0 
embryos. The ChIP-Seq data identified 12,968 Isl1 direct targets. Intersection of our RNA-Seq 
data from E8.5 Isl1 KO embryos to this ChIP-Seq data revealed up to 60% downregulated 
genes that were bound by Isl1 in mouse cardiogenic region at E8.5 and more than 53% 
upregulated genes with Isl1 occupancy (Figure 25A and 25B). GO analysis of genes 
downregulated in the Isl1 KO embryos that were bound by Isl1 revealed over-representation 
of GO terms linked to heart development, cardiac muscle contraction, atrial septum and OFT 
morphogenesis, while multicellular organism development and cellular response to hypoxia 
for the common upregulated genes (Figure 25C and 25D). 
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Figure 25 Intersection of RNA-Seq and Isl1 ChIP-Seq data in mouse embryos 
(A-B) Common genes with Isl1 binding and downregulated (A) or upregulated (B) caused by Isl1 loss-
of-function in cardiogenic region of mouse embryos, respectively. (C-D) Representative GO items for 
downregulated genes (C) and upregulated genes (D) with Isl1 binding in mouse embryos analyzed 
using DAVID 6.8. 
 
3.3 Isl1 orchestrates a regulatory network driving cardiogenesis 
To get a better view of Isl1 regulatory network during cardogenesis, we compared our in vivo 
RNA-Seq and Isl1 ChIP-Seq datasets with the ones in mESC-derived CPCs (Figure 26). Analysis 
showed 71% of genes bound by Isl1 in ESC-derived CPCs were also bound in E8.25-E9.0 
embryos. Importantly, 75% of genes deregulated in E8.5 Isl1 knockout embryos were bound 
by Isl1, whereas 67% of genes deregulated in OFT and RV of E10.5 Isl1 hypomorphic embryos 
were bound by Isl1 (Figure 26). 
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Figure 26 Venn diagram showing Isl1 targets from different datasets 
Venn diagram representing the overlap of genes bound by Isl1 in E8.25-E9.0 embryos or ESC-derived 
CPCs (n=2) and differentially expressed in dissected pharyngeal mesoderm/hearts of E8.5 Isl1 
knockout embryos as well as OFT and RV of E10.5 Isl1 hypomorphic embryos (p value < 0.05) 
compared to control embryos (n=4). 
 
Gene network analysis uncovered distinct groups of Isl1 primary downstream targets (Figure 
27), e.g. (i) transcription factors, such as Mef2c and Myocd, known Isl1 downstream targets 
(Dodou, Verzi et al. 2004, Kwon, Qian et al. 2009), and other key regulators of SHF 
development, such as Tbx3, Tbx20, Eya1, Foxc1 (Vincent and Buckingham 2010); (ii) signaling 
molecules, such as Fgf10 (Golzio, Havis et al. 2012, Watanabe, Zaffran et al. 2012), and other 
key components of the Wnt, BMP and FGF signaling pathways; (iii) cardiomyocyte structural 
genes and genes involved in cardiac contraction, such as Myl2, Myl3, Ttn, Ryr2, Cacna1c, 
Tpm1, Tmod1 and Mybpc3. The observation that Isl1 binds to cardiomyocytes structural 
genes is consistent with the disrupted sarcomerogenesis in Isl1 hypomorphic embryos, but is 
somewhat surprising because cardiac structural genes are only highly expressed when Isl1 
transcription is turned off. 
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Figure 27 Isl1-regulatory gene network 
Gene regulatory networks orchestrated by Isl1 in mouse embryos identified in heart development 
associated genes using GeneMANIA and Cytoscape. 
 
GO analysis after intersection of the RNA-Seq data with ChIP-Seq data revealed 
overrepresentation of GO terms linked to heart development, cell adhesion and 
differentiation, atrial septum and outflow tract morphogenesis, as well as cardiac muscle 
fiber development and cardiac conduction (Figure 28A-C), consistent with the defects 
observed in Isl1 hypomorphic embryos. Importantly, we observed enrichment of GO terms 
involved in response to hypoxia in E8.5 embryos (Figure 28A), consistent with the critical role 
of Isl1 in regulating SHF progenitor cell function in response of spatial differences in 
oxygenation during cardiogenesis (Yuan, Qi et al. 2017).  
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Figure 28 GO terms enriched in Isl1 target genes 
(A-C) GO terms enriched in genes bound by Isl1 deregulated in E8.5 Isl1 knockout embryos (A), in 
E10.5 OFT+RV of Isl1 hypomorphic embryos (B), or in both E8.5 Isl1 knockout embryos and E10.5 
OFT+RV of Isl1 hypomorphic embryos (C). Examples of genes regulated and bound by Isl1 in (A), (B), 
(C), showing genome tracks of Isl1 ChIP-Seq and RNA-Seq reads, are presented on the right side of 
the panel. 
 
3.4 Baf60c is a key Isl1 downstream target 
3.4.1 Baf60c is directly regulated by Isl1 
We next want to clarify the subset of Isl1 primary downstream targets differentially 
regulated both in vitro and in vivo, so we further analyzed our RNA-Seq and ChIP-Seq 
datasets from both mESC-derived CPCs and the ones generated from embryonic tissues. We 
identified a group of genes directly regulated by Isl1 and deregulated in both systems (Figure 
29A). Among them, in addition to known Isl1 targets, such as Hand2 and Mef2c (Dodou, 
Verzi et al. 2004, Caputo, Witzel et al. 2015), we found many novel primary downstream 
targets with a role in cardiogenesis (Figure 29A). One of the targets, Baf60c (Smarcd3) 
(Figure 29A-B), a cardiac-specific component of the Brg1-based SWI/SNF chromatin 
remodeling complex, plays a crucial role in heart development (Lickert, Takeuchi et al. 2004, 
Sun, Hota et al. 2017, Hota, Johnson et al. 2019). Baf60c level was significantly decreased in 
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both Isl1 KO mESC-derived CPCs and in embryos (Figure 29A), confirming Baf60c as a primary 
downstream target of Isl1. In addition, Baf60c downregulation is further validated by qPCR 
results in Isl1 KO and control CPCs (Figure 29C).  
 
 
Figure 29 Baf60c is a key Isl1 downstream target 
(A) Heatmap of genes bound by Isl1 and deregulated in both RNA-Seq analysis of dissected 
pharyngeal mesoderm/hearts of wild-type and E8.5 Isl1 knockout embryos, and of control and Isl1 
KO Nkx2.5+ CPCs (log2 fold change < -0.58, > 0.58, p value < 0.05). Representative genes and enriched 
GO terms are presented on the right side. (B) Genome tracks of Isl1 ChIP-Seq and RNA-Seq on Baf60c 
in control and Isl1 knockout CPCs. (C) Relative mRNA expression of Isl1 direct targets in sorted CPCs 
of control and Isl1 KO lines. Data are mean±SEM, n=3.  
 
3.4.2 RNA-Seq analysis identified Baf60c regulated genes in CPCs 
To investigate the role of Baf60c in cardiac progenitor cells, we decided to generate mESC 
lines with Baf60c knockdown (KD). To establish Baf60c KD stable mESC lines, we packaged 
Baf60c shRNA into lentivirus and infected WT mESC lines following with puromycin selection. 
To check the differentiation and Baf60c KD efficiency of these cell lines, we performed 
cardiac differentiation and collected the cells at day5 for sorting of GFP+ CPCs by flow 
cytometry (Figure 30A). Baf60c is efficiently knocked down, as shown in qPCR results (Figure 
30B). Knockdown of Baf60c did not affect the differentiation of mESCs to CPCs, as seen by 
FACS analysis for Nkx2.5-GFP+ cells (Figure 30C). 
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Figure 30 Analysis of CPCs differentiated from control and Baf60c KD mESC lines 
(A) Scheme depicting directed cardiac differentiation and sample harvesting strategy. (B) qPCR for 
Baf60c to check the KD efficiency in sorted control and Baf60c KD CPCs. (C) Flow cytometry analysis 
of control and Baf60c KD CPCs. 
 
To address whether Baf60c plays a role in mediating Isl1 function in cardiogenesis, we 
performed RNA-Seq of sorted Nkx2.5-GFP+ CPCs derived by directed cardiac differentiation 
of control or Baf60c knockdown Nkx2.5-GFP mESCs (Figure 31). Principal component analysis 
(PCA) of the duplicates showed consistent results (Figure 31A). The RNA-Seq data identified 
878 downregulated genes and 893 upregulated genes following Baf60c depletion (fold 
change >1.5; log2 fold change < -0.58, > 0.58 and p value < 0.05) (Figure 31B). GO analysis of 
downregulated genes showed that Baf60c activates genes involved in cardiac muscle 
contraction, sarcomere organization and ion transport, while repressing genes involved in 
multicellular organism development and anterior/posterior pattern specification (Figure 
31C).  
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Figure 31 Analysis of RNA-Seq data in control and Baf60c KD CPCs 
(A) PCA plot of RNA-Seq data from control and Isl1 KO CPCs (n=2). (B) Volcano plot of RNA-Seq data 
from control and Baf60c KD CPCs (n=2). Each point represents an individual gene and all genes 
differentially expressed with fold change > 1.5; log2 fold change < -0.58 and p value < 0.05 are 
highlighted in green (downregulated genes) and red (upregulated genes). (C) Heatmap of 
differentially regulated genes (878 downregulated and 893 upregulated genes with fold change >1.5; 
log2 fold change < -0.58, > 0.58 and p value < 0.05) in CPCs caused by Baf60c KD (n=2). 
Representative genes and enriched GO terms are presented on the right side. 
 
3.4.3 Isl1 and Baf60c share common targets 
Next, to test whether Isl1 and Baf60c regulate common genes in CPCs, we compared the 
RNA-Seq data from controls, Baf60c KD CPCs and Isl1-/- CPCs. We found there are 432 
common genes differentially expressed following Isl1 or Baf60c depletion (Figure 32A, fold 
change > 1.5; log2 fold change < -0.58, > 0.58 and p value < 0.05). GO analysis of common 
deregulated genes showed that Isl1 and Baf60c activate genes involved in cardiac muscle 
contraction, sarcomere organization and heart development, while repressing genes 
involved in immune system process and cellular response to interferon-gamma (Figure 32B). 
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These results indicate that Baf60c may work in axis with Isl1 to promote chromatin 
reorganization at cardiomyocyte structural genes and cardiac contraction associated genes 
in CPCs. 
 
Figure 32 Isl1 and Baf60c share common target genes in CPCs 
(A) Venn diagram showing overlap of differentially regulated genes in sorted Isl1 knockout and 
Baf60c knockdown CPCs (fold change > 1.5; log2 fold change < -0.58, > 0.58 and p value < 0.05; n=2). 
(B) Heatmap of genes downregulated or upregulated in both Isl1 knockout and Baf60c knockdown 
versus control CPCs (fold change > 1.5; log2 fold change < -0.58, > 0.58 and p value < 0.05; n=2). 
Representative genes and enriched GO terms are presented on the right side. 
 
3.5 Isl1 works in concert with the Brg1-based SWI/SNF complex to 
regulate its target genes 
3.5.1 Isl1 interacts with Brg1 and Baf60c 
As mentioned above, Baf60c is a cardiac-specific subunit of the Brg1-based SWI/SNF 
complex, which plays an important role in heart development (Lickert, Takeuchi et al. 2004). 
To analyze whether Isl1 may also work unitedly with the Brg1-based SWI/SNF complex, we 
first analyzed whether Isl1 and Brg1 interact with each other. Co-immunoprecipitation 
experiments in ESC-derived CPCs revealed that Isl1 binds to both Brg1 and Baf60c (Figure 
33A). The binding of Isl1 to Brg1 was further validated in E8.25-E9.0 embryos (Figure 33B). 
The interaction of Isl1 and Brg1 in mESC-derived CPCs and in mouse embryos suggests Isl1 
may work together with Brg1/Baf60c complex in regulating cardiogenesis. 
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Figure 33 Isl1 interacts with Brg1/Baf60c complex 
(A) Co-IP showing interaction between Isl1 and Brg1/Baf60c in mESC-derived CPCs. (B) Co-IP showing 
interaction between Isl1 and Brg1 in mouse embryos. 30 embryos at E8.25-E9.0 were used for each 
IP. And immunoprecipitation was done by both Brg1 and Isl1 antibodies. 
 
3.5.2 The interaction of Isl1 with Brg1 does not depend on Baf60c 
Baf60c was reported to mediate interactions between cardiac transcription factors such as 
Tbx5, Nkx2.5, Gata4 and the Brg1 complex to drive cardiac specific gene expression (Lickert, 
Takeuchi et al. 2004, Takeuchi and Bruneau 2009). To test whether Baf60c promotes the 
binding of Isl1 to the Brg1 complex, we performed co-immunoprecipitation in control and 
Baf60 KD ESC-derived CPCs using Isl1 antibody, suggesting that, in contrast to Tbx5, Nkx2.5 
and Gata4, Baf60c does not mediate the association of Isl1 with the Brg1 complex in CPCs 
(Figure 34A), and vice versa (Figure 34B). Taken together, these results suggested that Isl1 
not only plays a role in regulating Baf60c but also works together with the Brg1-Baf60c 
complex during cardiogenesis. 
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Figure 34 Baf60c doesn’t mediate the interaction between Isl1 and Brg1 in CPCs and vice 
versa 
(A) Co-immunoprecipitation with anti-Isl1 antibody and Western blot analysis for Brg1 in control or 
Baf60c KD CPCs, showing that the interaction between Isl1 and Brg1 does not depend on Baf60c. (B) 
Co-immunoprecipitation with anti-Isl1 antibody and Western blot analysis for Baf60c in control or 
Brg1 KD CPCs, showing that the interaction between Isl1 and Baf60c does not depend on Brg1. α-
Tubulin was used as loading control. 
 
3.5.3 Co-occupancy of Isl1 and Brg1 in CPCs 
To further investigate how Isl1 and Brg1 work together in regulating cardiogenesis, we 
compared the ChIP-Seq data for Brg1 (Hota, Johnson et al. 2019) and Isl1 in CPCs. Analysis 
showed high co-occupancy of Brg1 and Isl1 at Isl1 binding sites, especially near the 
transcription start sites (TSS) of target genes (Figure 35A-C), such as Smarcd3, Tbx20, Wnt2 
and Ryr2, confirming our hypothesis that Isl1 works cooperatively with Brg1 in regulating its 
target genes during cardiogenesis. 
73 
 
 
Figure 35 Isl1 co-occupied with Brg1 on its target genes in CPCs 
(A) Venn diagram representing the overlap of Isl1 and Brg1 ChIP-Seq peaks (All peaks: left panel; 
peaks near TSS: right panel). (B) Average ChIP-Seq tag intensities at Isl1 peaks. (C) Examples of IGV 
snapshots showing co-occupancy of Isl1 and Brg1 on the target genes in CPCs. 
 
Furthermore, by analyzing the ChIP-Seq data with our RNA-Seq data in Isl1 KO CPCs, we 
found that 59.3% of the genes bound by Isl1 were bound by Brg1, while 44% of the genes 
deregulated by Isl1 loss-of-function were concomitantly bound by Isl1 and Brg1 (Figure 36). 
As Brg1/Baf60c complex is chromatin remodeler, these results led us to think that Isl1 may 
work together with the Brg1-Baf60c complex to regulate nucleosomal structure and 
expression of its target genes. 
 
Figure 36 A large subset of genes differentially regulated in Isl1 KO CPCs are co-bound by 
Isl1 and Brg1 
Venn diagram representing the overlap of genes bound by Isl1 and Brg1 (n=2) and differentially 
expressed in Isl1 KO CPCs (n=2). 
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3.5.4 Isl1 works cooperatively with Brg1 to regulate its target gene expression 
To investigate our hypothesis in vivo, we inactivated Brg1 (Bultman, Gebuhr et al. 2000) in 
SHF progenitor cells using an Isl1-Cre driver mouse line. We dissected the outflow tract and 
right ventricle, which are derived from the Isl1+ SHF progenitors, and analyzed the expression 
of Isl1 targets genes. qPCR expression analysis of dissected OFT and RV of E10.5 wild-type, 
Isl1-Cre+/-, Isl1-Cre+/-/Brg1fl/+ and Isl1-Cre+/-/Brg1fl/fl embryos revealed significant 
downregulation of Isl1 primary targets in Isl1-Cre+/-/Brg1fl/+ embryos and further decrease in 
Brg1-deficient embryos (Figure 37A). These results suggested that Brg1 regulates a common 
group of target genes with Isl1 during SHF development, and demonstrated a dosage 
requirement for Brg1 in regulating gene expression programs associating with SHF 
development, similar with the report that allelic balance between Brg1 and cardiac 
transcription factors Tbx5, Tbx20 and Nkx2.5 is essential for cardiogenesis (Takeuchi, Lou et 
al. 2011). 
Furthermore, to check whether Brg1 loss-of-function in the SHF derivatives affects gene 
expression in the tissue arisen from the FHF, we dissected the left ventricle and analyzed the 
expression of Isl1 target genes. As we expected, no major changes were observed in the left 
ventricle of these embryos (Figure 37B), suggesting Brg1 regulates Isl1 target genes 
specifically in the SHF derived tissue. Moreover, to test whether Brg1 generally regulates 
gene expression in OFT and RV, we analyzed the expression of some example genes that are 
not Isl1 targets (Figure 37C). The expression of these genes is not changed with Brg1 
depletion, suggesting that the role of Brg1 in the SHF development is specific (Figure 37C). 
Taken together, the dosage-sensitive interdependence of Isl1 and Brg1, in combination with 
the interactions and co-occupancy of Isl1 and BAF complex members, supports the 
hypothesis that the Brg1-Baf60c complex might regulate gene expression coordinated with 
Isl1 in SHF development. 
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Figure 37 Isl1 works unitedly with Brg1 to regulate its target gene expression 
(A) Relative mRNA expression levels of Isl1/Brg1-Baf60c common targets in dissected OFT and RV of 
wild-type, Isl1-Cre+/-, Isl1-Cre+/-/Brg1+/fl and Isl1-Cre+/-/Brg1fl/fl embryos. Data are mean±SEM, n=4. (B) 
Relative mRNA expression levels of Isl1/Brg1-Baf60c common targets in dissected left ventricle of 
wild-type, Isl1-Cre+/-, Isl1-Cre+/-/Brg1+/fl and Isl1-Cre+/-/Brg1fl/fl embryos. Data are mean±SEM, n=3. (C) 
Relative mRNA expression levels of genes not bound by Isl1 in dissected OFT and RV of wild-type, 
Isl1-Cre+/-, Isl1-Cre+/-/Brg1+/fl and Isl1-Cre+/-/Brg1fl/fl E10.5 embryos. Data are mean±SEM, n=3. 
 
3.5.5 Isl1 recruits the Brg1 complex to its target sequences 
To examine whether Brg1 was directed to Isl1 target sequences via Isl1, we performed Brg1 
ChIP in control and Isl1 KD CPCs followed by qPCR analysis. Knockdown of Isl1 led to a 
significant reduction of Brg1 occupancy at Isl1 targets (Figure 38), suggesting that Isl1 might 
recruit the Brg1 complex to promote chromatin reorganization at its target genes. 
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Figure 38 Brg1 binding at Isl1- bound targets is decreased by Isl1 depletion in CPCs 
ChIP followed with qPCR analysis with Isl1 antibody was done in control and Isl1 KD mESC-derived 
CPCs. Atp1a2 was used as a negative control (n=2). 
 
3.6 Isl1 acts as a pioneer factor in cardiogenesis 
3.6.1 Isl1 binding correlates with sites of open chromatin 
Pioneer transcription factors play critical roles in programming the epigenome and 
instructing lineage specification and differentiation (Zaret and Carroll 2011, Spitz and Furlong 
2012, Soufi, Garcia et al. 2015). To initiate cell programming, pioneer transcription factors 
engage “closed” chromatin covered by nucleosomes and impart competence for 
transcription by chromatin opening. To test whether Isl1 acts as a pioneer factor, we 
analyzed whether Isl1 binding might induce the formation of accessible chromatin in CPCs by 
performing genome-wide analysis of open chromatin landscapes using ATAC (“assay for 
transposase-accessible chromatin”) sequencing (ATAC-Seq) (Buenrostro, Giresi et al. 2013) in 
mESC-derived CPCs. In ATAC-Seq, Tn5 transposase integrates sequencing adapters into 
regions of accessible chromatin, whereas steric hindrance in less accessible chromatin makes 
such transposition less probable (Buenrostro, Giresi et al. 2013). Therefore, amplifiable DNA 
fragments suitable for high-throughput sequencing are preferentially generated at locations 
of open chromatin (Buenrostro, Giresi et al. 2013).  
Comparison of ATAC-Seq data and Isl1 binding profiles revealed a 42% overlap of Isl1 ChIP-
Seq and ATAC-Seq peaks in CPCs. At the promoter proximal regions (TSS +/-10kb) more than 
76% of Isl1 binding sites showed open chromatin (Figure 39A). GO analysis of genes 
characterized by open chromatin at Isl1 binding sites showed enrichment of genes involved 
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in transcriptional regulation, covalent chromatin modification and heart morphogenesis 
(Figure 39B-C), suggesting a role of Isl1 binding in the formation of accessible chromatin 
required for cardiogenesis, similar to other “pioneer factors”. 
 
Figure 39 Isl1 binding correlates with sites of open chromatin 
(A) Overlap of all Isl1 ChIP-Seq and ATAC-Seq peaks (top) or peaks at Transcription Start Sites (TSS) 
+/- 10kb (down) in mESC-derived CPCs. (B) Representative genes and GO terms enriched in genes 
showing open chromatin configuration at Isl1 binding sites in CPCs. (C) Examples of genes bound by 
Isl1, showing open chromatin configuration at Isl1 binding sites in mESC-derived CPCs. Genome 
tracks of Isl1 ChIP-Seq and ATAC-Seq reads of mESC-derived CPCs. 
 
3.6.2 Isl1 and Brg1/Baf60c complex work synergistically to open the chromatin 
during SHF development 
As described in the introduction, the typical activity of a pioneer factor is to bind to the 
closed chromatin; then recruit chromatin remodelers to the binding sites and they work 
cooperatively to open the chromatin. To further investigate how Isl1 opens the closed 
chromatin during cardiogenesis, we hypothesized that Isl1 works together with Brg1/Baf60c 
remodeling complex to reorganize the chromatin landscape at its target genes. To confirm 
our hypothesis, we analyzed whether loss of Isl1 or Brg1 might affect chromatin opening by 
performing ATAC-Seq in E8.5 (6 somites) wild-type, Isl1-/- or Isl1-Cre+/-/Brg1fl/fl embryos. We 
observed 73% overlap of all ATAC-Seq peaks in E8.5 embryos compared to ESC-derived CPCs, 
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while up to 93% overlap at promoter proximal regions (Figure 40A), showing high similarity 
between the open chromatin of in vitro differentiated CPCs to CPCs in early embryos. 
Importantly, we observed significant reduction of chromatin accessibility in Isl1 and Brg1 
knockout embryos at Isl1-ATAC (IA) peaks (Figure 40B-C), whereas chromatin accessibility 
was not affected at ATAC only (A) sites in Isl1 knockout embryos (Figure 40C). In addition, 
the high average ATAC signal at Isl1-ATAC (IA) sites compared to ATAC only (A) sites further 
supports a role of Isl1 in chromatin opening in CPCs (Figure 40C). 
 
Figure 40 Isl1 and Brg1-Baf60c-based SWI/SNF complex shape the chromatin landscape at 
Isl1 target sites in cardiac progenitors 
(A) Overlap of all ATAC-Seq peaks (top) or peaks at Transcription Start Sites (TSS) +/- 10kb (bottom) in 
ESC-derived CPCs and E8.5 embryos. (B) Heat map of tag densities of ATAC-Seq in wild-type, Isl1-/- 
and Isl1-Cre+/-/Brg1fl/fl embryos at TOP1000 Isl1-ATAC (IA) or ATAC only (A) peaks. (C) Average ATAC-
Seq tag intensities in wild-type, Isl1-/- and Isl1-Cre+/-/Brg1fl/fl embryos at Isl1-ATAC (IA) or ATAC only 
(A) peaks. 
 
GO analysis of differential ATAC-Seq peaks in Isl1 and/or Brg1-deficient embryos revealed 
that the Isl1/Brg1 complex plays a key role in activating expression program essential for 
heart development, while repressing nervous system development (Figure 41A-B). 
Importantly, we observed significant overrepresentation of GO terms related to chromatin 
modification in ATAC-Seq peaks decreased in Isl1 knockout embryos, including multiple 
components of the SWI/SNF chromatin remodeling complexes such as Smarcd3 (Baf60c), 
Arid1a (Baf250a), Smarcc2 (Baf170), Dpf3 (Baf45c) as well as Pbrm1 (Baf180) (Figure 41A and 
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41C). In addition, some target genes showed decreased chromatin accessibility only in Isl1 
knockout embryos (Figure 41C, e.g. Dpf3 and Tbx3), suggesting that Isl1 might work together 
with other chromatin modifiers in regulating these genes. In contrast, genes not bound by 
Isl1 did not show changes in chromatin accessibility (Figure 41C, e.g. Myh3). 
 
Figure 41 Isl1 and Brg1-Baf60c-based SWI/SNF complex induces chromatin reorganization 
in cardiac progenitors 
(A) GO terms enriched in ATAC-Seq peaks decreased (top panel) or increased (lower panel) more 
than 2 fold in Isl1-/- versus control embryos. (B) GO terms enriched in ATAC-Seq peaks decreased (top 
panel) or increased (lower panel) in both Isl1-/- and Isl1-Cre+/-/Brg1fl/fl embryos versus control 
embryos. (C) Examples of genes showing decreased ATAC-Seq signal at Isl1 binding sites. Genome 
tracks of Isl1 ChIP-Seq and ATAC-Seq of wild-type, Isl1-/- and Isl1-Cre+/-/Brg1fl/fl embryos are 
presented. Myh3 was shown as a negative control. 
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3.6.3 Isl1 plays a pioneering function in all three cardiovascular lineages 
As described in the introduction, Isl1-positive cardiovascular progenitors are multipotent and 
can differentiate into all three cardiovascular lineages: cardiomyocytes, smooth muscle cells 
and endothelial cells (Moretti, Caron et al. 2006). Analysis of chromatin accessibility at 
promoters of cardiac, smooth muscle and endothelial development/differentiation genes 
revealed decrease in open chromatin at all cardiovascular lineage-related genes in Isl1 and 
Brg1-deficient embryos (Figure 42A-D). Notably the ATAC-Seq signal was highly decreased at 
genes involved in cardiac contraction (Figure 42B). Nevertheless, these data suggest that Isl1 
might play a pioneering function for cardiac cell lineage settlement and requires the Brg1-
based SWI/SNF chromatin remodeling complex. 
 
Figure 42 Isl1 and Brg1-Baf60c complex promote chromatin accessibility in all three 
cardiovascular lineages 
(A-D) Average ATAC-Seq tag intensities at TSS +/- 1kb of cardiac development and differentiation 
genes (A), cardiac contraction genes (B), as well as smooth muscle (C) and endothelial (D) 
development and differentiation genes in E8.5 wild-type, Isl1-/- and Isl1-Cre+/-Brg1fl/fl embryos. 
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3.6.4 Isl1 acts as a pioneer factor independently of Gata4 
The core cardiac transcription factor Gata4 represents a prototypical example of a pioneer 
factor, it binds efficiently to its target sequences on nucleosomal DNA (Cirillo and Zaret 
1999) and induces chromatin reorganization driving heart development and disease (He, Gu 
et al. 2014). To address whether Gata4 binding might affect Isl1 binding or vice versa, we 
first compared the binding sites of Gata4 (Luna-Zurita, Stirnimann et al. 2016) and Isl1 in 
CPCs with ATAC-Seq peaks. Using the published Gata4 ChIP-exo data (Luna-Zurita, 
Stirnimann et al. 2016), we called peaks in each replicate and used high confidence peaks 
found in all three ChIP-Seq replicates for further analysis. This analysis identified 2,417 
common Isl1-Gata4-ATAC peaks, showing that Isl1 and Gata4 often co-occupy at sites 
characterized with open chromatin (Figure 43). In addition, we identified accessible 
chromatin sites bound only by Isl1 or Gata4, supporting the notion that Isl1, similar to Gata4, 
might function as a pioneer transcription factor (Figure 43). 
 
Figure 43 Isl1 acts as a pioneer factor like Gata4 
(A) Overlap of all Isl1 ChIP-Seq, Gata4 ChIP-exo (Luna-Zurita, Stirnimann et al. 2016) and ATAC-Seq 
peaks (top) or peaks at Transcription Start Sites (TSS) +/- 10kb in CPCs. (B) Heatmap (top) and 
aggregation plot (bottom) of mapped reads of Isl1 ChIP-Seq, Gata4 ChIP-exo and ATAC-Seq at ± 2kb 
around peak midpoints of Isl1, Gata4 and ATAC (IGA), Isl1 and Gata4 (IG), Isl1 and ATAC (IA), Gata4 
and ATAC (GA) occupancy. 
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Moreover, ATAC-Seq analysis in E8.5 embryos with loss of Isl1 or Brg1 showed reduction in 
chromatin accessibility in both Isl1-ATAC sites bound or not bound by Gata4 (IGA or IA only), 
supporting the notion that Isl1 acts as pioneer factor also independently of Gata4 (Figure 
44). 
 
Figure 44 Isl1 acts as a pioneer factor independently of Gata4 
Average ATAC-Seq tag intensities at common peaks between Isl1, Gata4 and ATAC-Seq (IGA) in wild-
type, Isl1-/- and Isl1-Cre+/-/Brg1fl/fl embryos (A) or at Isl1 and ATAC-Seq only peaks (IA) (B).  
 
In addition, Gata4 binding was decreased in Isl1 depleted CPCs (Figure 45), however we 
cannot rule out whether Isl1 is necessary for Gata4 association at Isl1 target sites or that 
lower Gata4 occupancy could be due to the decreased levels of Gata4 in Isl1-deficient CPCs 
(Figure 20). 
 
Figure 45 Gata4 occupancy at Isl1- bound sequences is decreased in Isl1 deficient CPCs 
ChIP-qPCR analysis of Gata4 binding at Isl1 target sites in CPCs. Atp1a2 was used as a negative 
control (n=2). 
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3.7 Working model 
Taken together, these data suggest a pioneering function of Isl1 in SHF development. Isl1 
acts as a pioneer transcription factor by binding to closed chromatin and then recruits the 
Brg1-Baf60c-based SWI/SNF complex to its target binding sites. Isl1 works in concert with 
the Brg1-Baf60c-based SWI/SNF complex to confer permissive lineage-specific alterations in 
CPC chromatin landscape, which allow gene expression directly in CPCs or at a later time 
point in cardiomyocytes (Figure 46). Expression changes of Isl1 target genes lead to cardiac 
development defects not only at the early embryonic stages, but also at the later stages 
when Isl1 transcription is turned off.  
 
 
Figure 46 Model of the role of Isl1 in cardiogenesis by controlling epigenetic mechanisms 
and memory 
Isl1 binds to compacted chromatin at genes involved in CPC function, as well as to genes involved in 
cardiomyocyte contraction and structural organization. Isl1 then recruits Brg1-Baf60c complex to the 
binding sites and works cooperatively with the Brg1-Baf60c-based SWI/SNF complex to open up 
chromatin and allow gene expression directly in CPCs, or at a later time point in cardiomyocytes.  
 
 
 
 
 
84 
 
4. Discussion 
The mammalian heart is the first functional organ to develop. Normal cardiac development 
is crucial for embryonic survival due to its critical nature in distributing blood through the 
vessels and the vital exchange of nutrients, oxygen, and wastes both to and from the 
developing baby. Heart development is controlled by a tight spatial and temporal regulation 
of gene networks, including signaling molecules, transcription factors and so on. Accurate 
knowledge of normal cardiac development is essential for proper understanding of 
congenital cardiac malformations that represent the most common congenital anomaly in 
newborns (Schleich, Abdulla et al. 2013), and might help to generate efficient therapies.  
During cardiac development, heart tube elongation occurs by progressive addition of second 
heart field (SHF) progenitor cells to the poles of the heart. Unlike FHF cells, SHF cells show 
continued proliferation and delayed differentiation, and represent a reservoir of multipotent 
cardiac progenitor cells (CPCs) during cardiogenesis (Meilhac, Lescroart et al. 2014). 
Perturbation of SHF development results in congenital heart defects. As described in the 
introduction part, SHF derived cells are involved in most of the common CHDs, especially in 
the outflow tract (OFT) region. These include arterial pole defects resulting from OFT 
hypoplasia or failure of OFT remodeling, especially the OFT alignment and septation defects, 
such as persistent truncus arteriosus (PTA), transposition of the great arteries (TGA), 
overriding aorta (OA), which is usually associated with Tetratolgy of Fallot (TOF) and double 
outlet right ventricle (DORV), in which the divided aorta and pulmonary trunks both exit the 
right ventricle (RV) only, as well as venous pole anomalies including atrial and 
atrioventricular septal defects (Kelly 2012, Neeb, Lajiness et al. 2013). 
The SHF is marked by Isl1 expression (Cai, Liang et al. 2003, Buckingham, Meilhac et al. 
2005). Isl1 plays critical roles in cardiac development which has been demonstrated by a lot 
of studies (Cai, Liang et al. 2003, Moretti, Caron et al. 2006, Moretti, Lam et al. 2007, Bu, 
Jiang et al. 2009, Wang, Li et al. 2016, Quaranta, Fell et al. 2018). However, detailed insights 
into its molecular mode of action underlying Isl1 function in cardiac progenitor cells have not 
been fully elucidated, especially in epigenetic regulation during cardiogenesis. 
In this study, using an Isl1 knockout mouse line and an Isl1 hypomorphic mouse line, well 
established directed cardiac differentiation method and genome-wide profiling of Isl1, 
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binding together with RNA- and ATAC-sequencing of cardiac progenitor cells and their 
derivatives, we uncover a regulatory network downstream of Isl1 that orchestrates 
cardiogenesis. We show that Isl1 binds to and regulates the expression of signaling 
molecules, transcription factors, epigenetic modifiers, and cardiomyocytes 
structural/contraction genes, with critical functions in cardiogenesis. We further identified 
Isl1 as a novel pioneer factor which works in concert with Brg1-Baf60c-based SWI/SNF 
complex to open the “closed” chromatin and orchestrating gene expression programs during 
cardiogenesis. 
 
4.1 Isl1 is critical for SHF development and depletion of Isl1 leads to 
cardiac defects as seen in human CHD patients 
As the Isl1 knockout mouse are lethal at early stage during embryonic development, we 
utilized an Isl1 hypomorphic mouse line which can survive until birth, allowing us to analyze 
the role of Isl1 in SHF derived structures that are dependent on Isl1, as well as the molecular 
regulation of Isl1 during later stages of embryonic heart development. Isl1 hypomoyphic 
mouse embryos showed ventricular and atrial septal defects (VSDs and ASDs) and various 
degrees of OFT abnormalities, including partial outflow tract septation and misalignment or 
common arterial trunk (data done by our collaborators). Similarly, in human patients, 
genetic variations in ISL1 have been associated with susceptibility to ventricular septal defect 
(Lang, Tian et al. 2013) and non-syndromic, complex congenital heart disease (Stevens, 
Hakonarson et al. 2010), whereas ISL1 haploinsufficiency is associated with d-transposition 
of the great arteries (Osoegawa, Schultz et al. 2014).  
Intersection of the RNA-Seq results from Isl1 KO and Isl1 hypomorphic embryos, together 
with Isl1 ChIP-Seq data, identified many novel Isl1 primary targets. Consistent with the 
phenotypes observed in the mouse models, we found an important group of Isl1 target 
genes playing key roles in outflow tract morphogenesis, such as Wnt5a/11, Tgfb2, Jag1, 
Smad6, Pbx3, Msx2, Fog2 (Zfpm2), Tbx1/3/20, Plxna2 (Lin, Lin et al. 2012). In addition, many 
Isl1 target genes are critical for development of the atrioventricular canal and atrial or 
ventricular septation, such as Wnt2, Gata4/6, Tbx5, Nkx2.5 and Hand1/2 (Lin, Lin et al. 2012, 
Bruneau 2013). Moreover, mutations in these genes have been found in human CHD cases. 
For example, TBX20 loss-of-function mutations are present in patients with ToF, PTA and 
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DORV (Pan, Geng et al. 2015, Huang, Wang et al. 2017). Mechanistically, this loss-of-function 
mutation resulted in reduced synergistic activation between TBX20 and NKX2.5 as well as 
GATA4 (Huang, Wang et al. 2017). Multiple mutations in NKX2.5 and GATA4 have also been 
causally linked to various types of CHD, such as ASD, VSD and ToF (McElhinney, Geiger et al. 
2003, Ding, Tong et al. 2015, Mattapally, Nizamuddin et al. 2015). GATA6 mutations are 
found in CHD cases with PTA, VSD or ToF (Kodo, Nishizawa et al. 2009, Meenakshi Maitra 
2010, Wang, Luo et al. 2012). A heterozygous mutation in HAND2 (p.S65I), which 
significantly diminished its transcriptional activity, was identified in a patient with congenital 
ventricular septal defect (VSD) as well (Sun, Wang et al. 2016).  
As described in the introduction, cardiac neural crest cells (CNCCs) migrate to the OFT region 
during cardiac development and play an essential role in OFT septation and alignment, which 
is a very important process and various common types of CHDs are caused by disruption of 
this process. Cells from SHF and CNCCs communicate with each other and work 
cooperatively to form different cardiovascular structures. Semaphorin 3c (Sema3c) is an 
important factor in this communication. During heart development, the OFT myocardium 
secretes Sema3c (ligand) to attract CNCCs, which express Plxna2 (receptor), and promotes 
them to migrate into the OFT (Lin, Lin et al. 2012). Knockout of Plxna2 or Sema3c in mice 
impairs the migration of neural crest cells, leading to PAA defects and PTA (Christopher B. 
Brown 2001, Leonard Feiner 2001). Interestingly, both Sema3c and Plxna2 are Isl1 direct 
targets found in our study and showed decreased levels with Isl1 loss-of-function. Besides, 
Isl1 is also reported to be expressed in a subset of CNCCs (Engleka, Manderfield et al. 2012). 
So, Isl1 may play a role in regulating CNCCs behaviors not only by the interactions between 
SHF and CNCCs, but could also function directly in CNCCs. The role of Isl1 in regulating both 
SHF cells and CNCCs in the OFT may give a better explanation of various OFT defects 
observed in the Isl1 hypomorphic embryos. 
In addition, we also found many genes associated with epithelial to mesenchymal transition 
(EMT) to be downregulated in our Isl1 hypomorphic data and bound by Isl1, such as Wnt5a, 
Bmp4, Tgfb2, Erbb3, Snai1/2, Twist1/2, NFATc2/4 and Msx1/2  (Lin, Lin et al. 2012, von Gise 
and Pu 2012, Bruneau 2013). EMT is an important process during cardiac development. 
Epicardial cells give rise to mesenchymal cells that migrate into the myocardium and 
differentiate into fibroblasts and coronary smooth muscle cells (von Gise and Pu 2012). The 
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atrioventricular cushion mesenchyme forms from an EMT of endocardial cells, further 
leading to the formation of mitral and tricuspid (atrioventricular) valves and cardiac chamber 
septation (Lin, Lin et al. 2012, von Gise and Pu 2012). The cushions in the OFT also arise from 
endocardium through EMT, in combined with CNCCs, contribute to aortic and pulmonic 
(semilunar) valves development and OFT septation (Lin, Lin et al. 2012, von Gise and Pu 
2012). Errors of EMT lead to CHD (von Gise and Pu 2012, Rickert-Sperling, Kelly et al. 2015), 
especially cardiac septal defects and valve defects, as well as OFT defects. In the Isl1 
hypomorphic mice, in addition to ASDs and VSDs, we also observed aortic stenosis, which is 
a narrowing of the aortic valve opening. Thus, disruption of EMT process could be another 
reason for CHD caused by Isl1. 
 
4.2 Isl1 organizes a regulatory gene network driving second heart 
field development 
The analysis of our high-throughput sequencing datasets revealed a genome-wide 
transcriptional regulatory network orchestrated by Isl1 during SHF development. We found 
that Isl1 directly regulates large groups of genes during cardiogenesis. In addition to known 
Isl1 targets, we identified a lot of novel primary downstream targets, many of which have 
been reported to be involved in heart development or are critical for SHF specification and 
expansion, especially signaling molecules and cardiac transcription factors. For example, 
Fgf10, a known Isl1 target, acts as a marker of the anterior SHF (Golzio, Havis et al. 2012, 
Watanabe, Zaffran et al. 2012). Together with Fgf8, Fgf10 promotes the proliferation of the 
cardiac progenitor cells that form the arterial pole of the heart (Watanabe, Zaffran et al. 
2012). Interestingly, Fgf8 was also found to be an Isl1 direct downstream target in our study. 
It is required for SHF expansion, and thus for OFT elongation, septation and subsequent 
ventriculoarterial alignment through a cell autonomous mechanism (Hubert, Payan et al. 
2018, Pérez-Pomares and Kelly 2018). Besides, Wnt2 is a newly identified Isl1 primary target 
in our data. Cell culture studies showed that Wnt2-/- ES cells exhibit impaired cardiomyocyte 
differentiation but enhanced hematopoietic differentiation (Wang, Gilner et al. 2007), which 
is consistent with our finding that Isl1 controls cardiomyocyte lineage commitment, whereas 
inhibits hemopoiesis gene expression. In addition, the forkhead transcription factors Foxc1 
and Foxc2, which play key roles in cardiovascular development, are reported to act upstream 
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of Isl1 in the SHF (Kang, Nathan et al. 2009). In this study, we found Isl1 directly binds on 
both genes in CPCs. This mutual regulation is also seen between other cardiac transcription 
factors, such as Gata4 and Nkx2.5, thus forms the complex transcriptional regulatory 
networks (Figure 6) in cardiogenesis. 
Moreover, we did not observe any change in the expression of Isl1 primary target genes in 
the left ventricle of Isl1 hypomorphic embryos (data not shown), while they were 
significantly changed in dissected right ventricles (Figure 24), suggesting a specific role of Isl1 
in the second heart field. Interestingly, we also found some first heart field genes such as 
Tbx5 and Hand1, also regulated by Isl1 in the embryos (Figure 23 and 24). Since Isl1 has been 
reported to be transiently expressed in CPCs of the first heart field (Laugwitz, Moretti et al. 
2008), we cannot exclude a possibility that Isl1 also plays a pioneer role in the first heart 
filed. In addition, Tbx5 was reported to play an essential role in the pSHF for atrial septation 
(Xie, Hoffmann et al. 2012) and Hand1 was also reported to show expression in the SHF-
derived myocardial cuff (Barnes, Firulli et al. 2010). Given the dynamic nature of cardiac 
gene expression, it cannot be ruled out that at some stages the FHF marker genes transiently 
expressed in the SHF and vice versa, even though they play a primary role in their own heart 
fields. 
Importantly, in our cell culture studies and in vivo analysis, we found highly similar gene 
networks regulated by Isl1. For example, we found Isl1 regulates cardiomyocyte structural 
genes and genes involved in cardiac contraction and sarcomerogenesis in both datasets 
(Figure 19 and 23), suggesting that Isl1 directly controls cardiomyocyte identity, CPC 
differentiation and sarcomeric maturation. Moreover, consistent with our observation in Isl1 
hypomorphic cardiomyocytes with less prominent sarcomere structures, we also observed 
significant decrease of cardiomyocytes structural genes in the Isl1 hypomorphic data at the 
later stages when Isl1 is no longer expressed in the myocardium (Cai, Liang et al. 2003). We 
reason that Isl1 binds to closed chromatin and spawns permissive cardiomyocyte lineage-
specific alterations in the chromatin landscape of CPCs, which enables subsequent 
recruitment of additional regulatory factors activating these genes in cardiomyocytes when 
Isl1 itself is switched off, thereby setting up a lasting regulatory network driving 
cardiogenesis. 
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In addition, data done by my colleague with Isl1 loss-of-function at distinct stages of directed 
cardiac differentiation of mouse ESCs (Wamstad, Alexander et al. 2012) (data not shown) 
further confirm the transient requirement of Isl1 in CPCs for the expression of 
cardiomyocyte structural and contraction genes. Briefly, cardiomyocyte marker genes and 
Isl1 direct targets were significantly downregulated in day10 cardiomyocytes only when Isl1 
was knocked down at day3.7 during the differentiation of mesodermal precursors into 
cardiac progenitors but not at day8 after the appearance of beating cardiomyocytes. Taken 
together, our study supports the requirement of Isl1 in CPCs in setting up a transcriptional 
program to ensure proper cardiomyocyte differentiation. 
 
4.3 Baf60c is a key downstream target of Isl1 
Among the targets of Isl1 identified in our data, one of the targets, Baf60c (Smarcd3), a 
cardiac-specific component of the Brg1-based SWI/SNF chromatin remodeling complex, 
attracted our attention, since epigenetic mechanisms are central to establishment and 
maintenance of transcriptional memory (Jaenisch and Bird 2003, Bernstein, Mikkelsen et al. 
2006, Reik 2007). Baf60c is expressed specifically in the heart and somites in the early mouse 
embryo and Baf60c knockdown embryos by RNAi showed shortened OFT, hypoplastic right 
ventricle and atria, causing lethality at E10.0-E11.0, suggesting a specific role of baf60c in the 
SHF (Lickert, Takeuchi et al. 2004, Lei, Liu et al. 2013). Myofibrillar defects and impaired 
contractile function are found in postnatal mice with Baf60c conditional deletion in 
cardiomyocytes (Sun, Hota et al. 2017). Baf60c was shown to be essential for cardiac growth 
and cardiomyocyte function at several stages of embryonic development, by regulating 
broad networks of genes encoding proteins essential for function of the contractile 
apparatus (Sun, Hota et al. 2017). Consistent with this, Baf60c was further shown to be an 
important modulator of the fundamental program of gene expression essential for cardiac 
structure and function (Sun, Hota et al. 2017). This is highly consistent with our RNA-Seq 
results which showed that Baf60c-activated genes are associated with cardiomyocytes 
structure (sarcomere organization) and function (cardiac muscle contraction), as well as ion 
transport (Figure 31) which is critical in controlling the contractile apparatus (Kuo and Ehrlich 
2015). This is accordant with the reported data in Baf60c−/− embryonic hearts (E10.5 and 
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E12.5) and P7 Baf60cMyh6KO neonatal hearts (Sun, Hota et al. 2017), which identified Baf60c 
targets such as Myl1/3/4/7, Tnni1/2, Casq1 and Tcap, that are also shown in our results. 
As a downstream target of Isl1, Baf60c shares quite a lot of common targets with Isl1 (up to 
43%) in cardiac progenitor cells (Figure 32), including signaling molecules such as Wnt2 and 
Jag1, transcription factors such as Myocd and Hopx, and especially cardiomyocytes 
structural genes such as Myl2/3/4, Tnnt2, Actn2 and Myh6, and cardiac contraction 
associated genes such as Atp1b1, Camk2d, Ryr2 and Tnni1. We found that Baf60c together 
with Isl1 is required for the activation of genes involved in cardiomyocyte contraction, 
sarcomere organization and transcriptional regulation, whereas Baf60c alone activates genes 
participating in ion transport (Figure 31 and Figure 32). This is consistent with the gene 
expression changes observed in Baf60c knockout embryos (Sun, Hota et al. 2017). 
 
4.4 Isl1 works together with Brg1-Baf60c-based SWI/SNF complex 
to regulate gene expression program during cardiogenesis 
Baf60c is a subunit of the Brg1-based SWI/SNF complex, which plays an important role in 
heart development (Hota and Bruneau 2016). Brg1, as the core catalytic subunit in this 
complex, was reported to be involved in cardiogenesis by more and more studies (Bultman, 
Gebuhr et al. 2000, Griffin, Curtis et al. 2010, Hang, Yang et al. 2010, Chang 2012, Wei Li, 
Yiqin Xiong et al. 2012, Alexander, Hota et al. 2015, Qian, Xiao et al. 2017, Hota, Johnson et 
al. 2019). Mef2c-Cre Brg1fl/fl embryos showed hypoplastic outflow tracts and right ventricles 
(Hang, Yang et al. 2010). Accordantly, in our study, using an Isl1-Cre, Brg1-deficient embryos 
showed a shortened outflow tract, a small right ventricle at E9.5 and died by E14.5. 
Consistent with severe SHF structure defects, we observed that the expression of Isl1 target 
genes involved in outflow tract formation and SHF specification (Mef2c, Tbx20, Hand2, 
Smarcd3, and so on) was shown to be impaired in SHF derivatives of Isl1/Brg1 double 
heterozygous embryos, and further decreased in Isl1-Cre+/-/Brg1fl/fl embryos (Figure 23 and 
36). This is quite similar with the publication that the requirement of the balance between 
the dosage of Brg1 and disease-causing cardiac transcription factors, including Tbx5, Tbx20 
and Nkx2.5 in heart development (Takeuchi, Lou et al. 2011). Thus, disruption of a delicate 
balance between Isl1 and Brg1/BAF complex could also be a mechanistic cause of CHDs 
shown in Isl1 haploinsufficiency patients (Osoegawa, Schultz et al. 2014).  
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Moreover, Brg1 interacts with cardiac transcription factors Tbx5, Nkx2.5 and Gata4, and this 
interaction is induced by Baf60c (Lickert, Takeuchi et al. 2004). In our study, we also found 
Brg1 and Baf60c interact with the transcription factor Isl1 in cardiac progenitor cells (Figure 
33). In contrast, Baf60c does not seem to moderate Isl1 binding to the Brg1 complex, since 
we observed similar levels of Brg1 was co-immunoprecipitated by Isl1 in Baf60c KD CPCs 
compared with control (Figure 34). Considering Baf60c as a direct target of Isl1 (Figure 29), 
the loss of Baf60c upon Isl1 depletion may additionally affect the function of Tbx5, Nkx2.5 
and Gata4, as an imbalance between their levels and the Brg1-Baf60c complex, was shown 
to result in impaired cardiac development and transcriptional activation of their targets 
(Takeuchi, Lou et al. 2011). 
The interaction of Isl1 with Brg1/Baf60c led us to think that Isl1 may work cooperatively with 
Brg1 to induce chromatin reorganization and regulate target gene expression in cardiac 
progenitor cells. By comparing the ChIP-Seq data for Brg1 and Isl1, we noticed that they are 
highly co-occupied at Isl1 target sites in cardiac progenitors, especially near the TSS (Figure 
35). Furthermore, they share a large group of common targets, such as Wnt2, Smarcd3, Ryr2 
and Tbx20. (Figure 36 and 37). A newly published study showed that Brg1-activated genes 
are enriched for sarcomere organization and assembly, heart morphogenesis and cardiac 
contraction, with a genome-wide transcriptome analysis in CPCs (Hota, Johnson et al. 2019). 
This is prominently consistent with what we found in our Isl1 KO CPCs (Figure 19) and our in 
vivo data (Figure 23). Furthermore, we observed that Brg1 occupancy on Isl1 target sites was 
decreased with Isl1 loss-of-function (Figure 38). Taken all together, we conclude that Isl1 
might recruit the Brg1 complex to regulate nucleosome structure and expression of its target 
genes. 
 
4.5 Isl1 functions as a pioneer factor during cardiogenesis 
In this study, we showed that Isl1 recruits the Brg1-based SWI/SNF complex to its target sites 
to promote chromatin accessibility, which is the typical working pattern of pioneer factors 
(Figure 10) (Iwafuchi-Doi 2019). Furthermore, Brg1 was reported to initiate cardiac gene 
expression in cardiac precursor cells and maintain the cardiac program to facilitate 
cardiomyocyte differentiation by modulating temporal chromatin accessibility together with 
92 
 
Baf60c and Baf170 (Hota, Johnson et al. 2019). This suggests that Isl1 might works as a 
pioneer factor in organizing the transcription regulation in cardiac development. The classic 
characteristic of pioneer factors is capable of binding closed chromatin and open closed 
chromatin regions. A posdoc in our lab performed nucleosome assembly assays using in vitro 
assembled nucleosomes with recombinant human histones and a DNA fragment containing 
Isl1 motifs within the Ttn promoter, which is bound by Isl1 (Wang, Li et al. 2016) and 
downregulated in Isl1 and Baf60c depleted CPCs (Figure 32), followed with electrophoretic 
mobility shift assays (EMSA), which have been used to identify many pioneer factors (Lai, 
Verhage et al. 2018). She found that Isl1 recognizes its DNA binding motif even when the 
DNA is wrapped around nucleosomes, which enables it to engage its target sites even in 
condensed chromatin. In combination with my data that Nkx2.5, which is supposed not to be 
a pioneer factor, only binds to the free Ttn probe but not to the assembled nucleosomes 
(data not shown), we further demonstrated that the binding of Isl1 to the nucleosomal DNA 
is specific. 
We further performed ATAC-Seq, which is recently used to identify regions of open 
chromatin and assess genome-wide chromatin accessibility (Buenrostro, Giresi et al. 2013), 
in mESC-derived CPCs and in control versus Isl1 and Brg1 knockout embryos, to reveal that 
Isl1 acts as a pioneer factor to alter the chromatin accessibility in cardiac progenitor cells 
together with Brg1, thus modulate cardiomyocyte cell fate. ATAC-Seq analysis combined 
with genome-wide binding analysis of Isl1 revealed that open chromatin regions are 
centered on Isl1 binding sites in CPCs (Figure 39). Furthermore, ATAC-Seq analysis in Isl1 and 
Brg1-deficient embryos together with control samples showed that loss of either Isl1 or Brg1 
led to remarkable decrease of chromatin accessibility at ATAC/Isl1 binding sites (IA), but no 
significant change in ATAC-Seq only sites (A, sites without Isl1 binding) (Figure 40 and 41). In 
combination with the data showing Isl1 recruits Brg1 to its target sites (Figure 38), our data 
confirmed our hypothesis that Isl1 acts as a pioneer factor and works in association with 
Brg1 in shaping the chromatin landscape during cardiogenesis. Intriguingly, some target 
genes showed decreased chromatin accessibility only in Isl1 knockout embryos, such as Dpf3 
and Tbx3 (Figure 41), suggesting that Isl1 might also work together with other chromatin 
remodelers to regulate their expression.  
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A large body of studies have demonstrated that the SWI/SNF complexes undergo 
progressive changes in subunit composition during developmental transitions and that the 
unique subunit composition at each developmental stage correlates with a gene expression 
program that is required for maintaining particular cell state (Wu, Lessard et al. 2009, Ho 
and Crabtree 2010, Toto, Puri et al. 2016). During cardiac differentiation, using 
immunoprecipitation with mass spectrometry, Hota et al. recently determined the dynamic 
composition of BAF complexes during mammalian cardiac differentiation, identifying several 
cell-type specific subunits (Hota, Johnson et al. 2019) (Figure 13) and there is a fine balance 
exists in the composition of the BAF complex (Hota, Johnson et al. 2019). Interestingly, we 
found significant decrease of chromatin accessibility at multiple components of the SWI/SNF 
chromatin remodeling complexes such as Smarcd3 (Baf60c), Arid1a (Baf250a), Smarcc2 
(Baf170), Dpf3 (Baf45c), as well as Pbrm1 (Baf180) in Isl1 knockout embryos, suggesting a 
mechanism by which Isl1 reinforces its function in chromatin reorganization to drive 
cardiogenesis. Ablation of Baf250a, a critical regulatory subunit in SWI/SNF BAF complex, in 
the SHF using Mef2c-Cre leads to persistent truncus arteriosus, trabeculation defects, 
reduced cardiomyocyte proliferation and differentiation, and embryonic lethality around 
E13.0 (Lei, Gao et al. 2012). Baf180 deficiency in mouse embryos causes severe hypoplastic 
ventricle development and trophoblast placental defects, indicating a role of Baf180 in 
cardiac chamber maturation (Doerks, Copley et al. 2002). The cardiac-specific subunits of the 
complex, Baf45c and Baf60c, also play instrumental roles during cardiogenesis and 
cardiomyocyte differentiation (Lickert, Takeuchi et al. 2004, Lange, Kaynak et al. 2008, Sun, 
Hota et al. 2017). Baf170 was reported to facilitate cardiomyocyte differentiation, at least in 
part, via modulating chromatin accessibility (Hota, Johnson et al. 2019). Altogether, these 
data suggest that Isl1 not only works in concert with Brg1-Baf60c-based SWI/SNF chromatin 
remodeling complex in shaping the chromatin landscape of its targets, but also functions in 
the reorganization of the chromatin structure of its subunits during cardiogenesis. 
 
4.6 Isl1 plays a pioneering function independently of Gata4 
During heart development, the complex morphogenetic and molecular events are regulated 
by many transcription factors, acting as a mechanistic link to the transcription apparatus for 
gene activation (Kathiriya, Nora et al. 2015). Gata4 plays a key role in heart development 
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which was revealed by a lot of studies (Kuo, Morrisey et al. 1997{Lun Zhou, 2017 #3171, 
Watt, Battle et al. 2004, Rivera-Feliciano, Lee et al. 2006, Laforest and Nemer 2011)}. It 
represents a prototypical example of a pioneer factor, which binds efficiently to its target 
sequences on nucleosomal DNA (Cirillo and Zaret 1999) and induces chromatin 
reorganization driving heart development and disease (He, Gu et al. 2014). Since Isl1 and 
Gata4 have overlapping expression in heart development (Heikinheimo, Scandrett et al. 
1994), we analyzed whether Gata4 binding affects the pioneering function of Isl1 and vice 
versa. Comparison of Gata4 and Isl1 binding sites in CPCs with ATAC-Seq peaks, using the 
published Gata4 ChIP-exo data (Luna-Zurita, Stirnimann et al. 2016), showed that 41% Isl1 
binding sites which characterized with open chromatin are co-bound by Gata4 (Figure 43A), 
suggesting that Isl1 and Gata4 often co-occupy at target sites with accessible chromatin. This 
is consistent with the finding that Gata4 and Isl1 share common targets in the developing 
heart, such as Hand2 (D.G. McFadden 2000). Furthermore, the ATAC-Seq signal at their co-
occupied sites is higher than the ones they bind alone (Figure 43B bottom and Figure 44), 
suggesting that Gata4 binding reinforces the pioneering function of Isl1 or the pioneer 
functions of Isl1 and Gata4 lead to a synergistic effect on chromatin opening at their 
common target sites. Consistently, transcription of Fgf10 mediated by Isl1 is reported to be 
enhanced by the presence of Gata4 (Golzio, Havis et al. 2012). 
Moreover, we identified 59% of accessible chromatin sites with Isl1 binding are not bound by 
Gata4 (Figure 43), supporting the notion that Isl1 functions as a pioneer transcription factor  
not depending on Gata4 at these binding sites. In addition, the high average ATAC signal at 
Isl1-ATAC (IA) sites compared to ATAC only (A) sites further supports a role of Isl1 in 
chromatin opening in CPCs (Figure 40). Importantly, reduction in chromatin accessibility was 
observed in both Isl1-ATAC sites bound or not bound by Gata4 (IGA or IA) when Isl1 is 
depleted in mouse embryos (Figure 44), supporting our conclusion that Isl1 acts as pioneer 
factor independently of Gata4. Interestingly, we observed that Gata4 binding at Isl1 target 
sites was decreased in CPCs with Isl1 loss-of-function in our study (Figure 45). Since Gata4 is 
found to be a direct downstream target of Isl1 in our study and knockout of Isl1 leads to 
downregulation of Gata4 in both mESC-derived CPCs and in embryonic tissues, the lower 
Gata4 occupancy could be a result of reduced level of Gata4 caused by Isl1 loss-of-function. 
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4.7 Conclusions and perspectives 
In our study, we found that Isl1 is not only indispensable for early stage of cardiogenesis but 
also important for later stages of heart development. Reduced Isl1 level caused various 
types of cardiac phenotype similar with what presented in human CHD patients. Isl1 acts as a 
master transcription factor in SHF development by orchestrating a regulating network 
driving cardiogenesis and functions as a pioneer factor to reorganize the chromatin 
accessibility together with Brg1/Baf60c remodeling complex, to further regulate target gene 
expression and determine cardiac lineage cell fate. 
In our work, we answered the questions we want to address in the objectives, but further 
studies need to be done to better understand the mechanisms underlying the role of Isl1 in 
regulating SHF development. For example, we identified Isl1 works jointly with Brg1 in the 
reorganization of chromatin landscape, but it is not clear how does Brg1 affect Isl1 behavior. 
Studies on Isl1 binding with Brg1 depletion are necessary to prove whether Brg1 affects Isl1 
binding on its target sites or only affects the process of chromatin opening. Besides, we 
suspect that Isl1 may work together with other chromatin remodeling complexes to shape 
the chromatin accessibility at some target genes, it is not clear which chromatin remodeler 
also participates in this process. In addition, to recruit cofactors (transcription factors, 
chromatin modifiers, repressors, and so on) and allow their binding to the open sites is one 
of the typical activities of a pioneer factor as described in the introduction (Figure 10). In this 
study, we identified quite a lot of new Isl1 targets, but it is still not very clear which cofactors 
are recruited to the open sites to work cooperatively with Isl1 in regulating these target 
genes after chromatin landscape reorganization. The identification of additional cofactors of 
Isl1, for example, using mass spectrometry, could help to clarify the clearer regulatory 
pattern. 
During development, a fraction of transcription factors are retained on condensed mitotic 
chromosomes and “bookmark” specific loci, thus facilitating rapid gene reactivation post-
mitosis and providing a transcriptional memory (Bellec, Radulescu et al. 2018, Mayran and 
Drouin 2018). Interestingly, the majority of the known mitotically retained TFs function as 
pioneer factors, such as FOXA1, GATA1 and SOX2 (Caravaca, Donahue et al. 2013, Bellec, 
Radulescu et al. 2018). In our study, we found Isl1 binds a group of cardiomyocytes 
structural genes in CPCs which are supposed to be highly expressed at the later stages of 
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heart development when Isl1 is no longer actively transcribed. As a pioneer factor, further 
studies are needed to address whether Isl1 has a bookmarking function during 
cardiogenesis. To determine whether Isl1 acts as a bookmarking factor in CPCs, mitotic and 
asynchronous subcellular fractionations (Liu, Pelham-Webb et al. 2017) in CPCs will be 
necessary. Expression of Isl1 in both fractions could be detected by WB and performing Isl1 
ChIP-Seq in both fractions would be helpful to determine the binding of Isl1 on specific 
target sites and regulation of Isl1 on different subsets of genes at different cell states. 
In addition, we firstly found Isl1 acts as a pioneer factor in cardiogenesis in this study, it will 
be interesting to determine whether Isl1 also functions as a pioneer factor in other tissues or 
developmental processes of other organs, for example, in the neural system, since Isl1 is 
highly expressed in the neural system (Zhuang, Zhang et al. 2013) and was reported to be 
essential for sympathetic neuron proliferation, differentiation and diversification, as well as 
motor neuron development (Liang, Song et al. 2011, Zhang, Huang et al. 2018). 
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5. Materials and Methods 
5.1 Chemicals used in this study 
Chemicals Source of supply Reference number 
2-Log DNA ladder (0.1-10.0 kb) NEB N3200L 
Agarose Carl Roth 3810.4 
Ammonium persulfate (APS) Sigma A3678-25G 
Ampicillin sodium salt Sigma A99518-25G 
aqueous 30 % acrylamide and bisacrylamide 
stock solution (37.5:1) 
Carl Roth 3029.1 
BSA powder Carl Roth 8076.2 
BSA (used for ChIP) NEB B9000s 
Bromophenol Blue Sigma B0126 
Chloroform Carl Roth 3313.4 
Dimethyl Sulfoxide (DMSO) Sigma D-8779 
Dithiothreitol (DTT) Carl Roth 6908.3 
Dry-milk, non-fat milk BIO-RAD 170-6404 
Ethylene glycol tetraacetic acid (EGTA ) Carl Roth 3054.2 
Ethanol Carl Roth K928.3 
Ethanol Sigma 459844 
Ethidium bromide solution Sigma E1510-10ML 
Formaldehyde Sigma F8775 
Glycerol Carl Roth 3783.1 
Glycine Carl Roth 398.2 
Herculase II Fusion Enzyme with dNTPs Combo Agilent 600677 
H2A/H2B dimers NEB M2508S 
H3/H4 tetramers NEB M2509S 
Igepal Sigma CA-630 
Isopropanol Carl Roth 6752.4 
LB-agar (Lennox) Carl Roth X965.2 
LB-medium (Lennox) Carl Roth X964.2 
LiCl Carl Roth 3739.1 
Methanol Carl Roth 4627.5 
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MgCl2 Sigma M2393-500G 
Nonidet P-40 (NP-40) Fluka 74385 
NaCl Sigma S3014 
Na2EDTA Sigma E5134-250G 
NaH2PO4 · H2O Sigma 53522-1KG 
Na2HPO4 · 12H2O Sigma 04273 
Phenol/Chloroform/Isoamyl alcohol 
 
Carl Roth  A156.1 
Protein A sepharose 6MB GE Healthcare 17-0469-01 
Protein G sepharose 4 fast flow GE Healthcare 17-0618-01 
Proteinase K Sigma P8044 
Paraformaldehyde (PFA) Sigma 15,812-7 
Protease inhibitor cocktail set I  Calbiochem 535142 
Phosphatase inhibitor Cocktail set V Calbiochem 524632 
Phenylmethylsulfonyl fluoride (PMSF) Serva 32395 
Potassium chloride (KCl) Carl Roth 6781.3 
PageRuler Plus Prestained Protein Ladder Thermo Scientific 26619 
Qiazol Qiagen 79306 
RedTaq PCR Reaction Mix 
 
Sigma R2523 
Sodium dodecyl sulfate  (SDS) Sigma L4390-100G 
RNAse inhibitor Applied biosystems N8080119 
Tetramethylethylenediamine  (TEMED) Carl Roth 2367.1 
Triton X-100 Sigma X100-500ML 
Trizol Invitrogen 15596026 
Tris Carl Roth 4855.2 
Tween 20 Sigma P1379 
Urea Carl Roth 2317.2 
β-mercaptoethanol Sigma M3148 
 
5.2 Kits used in this study 
Kit Source of supply Reference number 
Amersham ECL Prime Western Blotting 
Detection Reagent 
GE Healthcare RPN2232 
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GenEluteTM gel extraction kit Sigma NA1111 
GenEluteTM HP plasmid midiprep kit Sigma NA0200 
GenEluteTM HP plasmid miniprep kit Sigma NA0160 
GenEluteTM PCR clean-up kit Sigma NA1020 
High-Capacity cDNA Reverse Transcription Kit Applied Biosystems 4368813 
Nextera DNA Library Prep Kit Illumina 15028211 
Pierce™ BCA Protein Assay Kit Thermo Scientific 23225 
QIAquick PCR Purification Kit Qiagen 28104 
Quant-iT™ PicoGreen™ dsDNA Assay Kit Invitrogen P11496 
RNeasy Microarray Tissue Mini Kit Qiagen 73304 
2x SYBR Green master mix Applied Biosystems 4367659 
 
5.3 Cell culture medium and supplements 
Medium/supplements Source of supply Reference number 
FBS Gibco 10270-106 
DMEM (1x) Gibco 10938-025 
DMEM + Glutamax Gibco 61965-026 
L-Glutamine Gibco 25030-024 
sodium pyruvate Gibco 11360-039 
Penicillin-Streptomycin Gibco 15140-122 
non-essential amino acids Gibco 11140-035 
leukemia inhibitory factor Millipore ESG1107 
mitomycin Sigma M4287 
KnockOut DMEM medium Gibco 10829-018 
KnockOut Serum Replacement Gibco 10828-028 
β-mercaptoethanol Sigma M3148 
X-tremeGENE HP DNA Transfection Reagent Roche 6366236001 
Lipofectamine 2000 Invitrogen 11668019 
Puromycin Gibco A11138-03 
Neurobasal medium Gibco 1103049 
DMEM/F12 Gibco 21331020 
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IMDM Gibco 12440053 
Ham's F12 Nutrient Mix Gibco 11765054 
StemPro™-34 SFM Gibco 10639011 
N2 supplement Gibco 17502-048 
B27 supplement Gibco 17504-044 
B27 supplement without Vitamin A Gibco 12587-010 
Activin A R&D systems 338-AC 
BMP4 R&D systems 314-BP 
VEGF R&D systems 293-VE-010 
bFGF R&D systems 233-FB 
FGF10 R&D systems 345-FG 
7.5% BSA Gibco 15260037 
1-Thioglycerol Sigma M6145 
L-Ascorbic Acid Sigma A4403 
Trypsin-EDTA (1x) 0.05% Gibco 25300-054 
DPBS Gibco 14190-094 
gelatin Sigma G9391 
Poly (2-hydroxyethyl methacrylate) Sigma P3932 
DMSO Sigma D2650 
POLYBRENE Merck TR-1003-G 
 
5.4 Further materials 
Further materials Source of supply Reference number 
15ml Centrifuge Tubes Greiner Bio-One 188271 
50ml Centrifuge Tubes Greiner Bio-One 227261 
5ml Plastic pipet Greiner Bio-One 606180 
10ml Plastic pipet Greiner Bio-One 607180 
25ml Plastic pipet Greiner Bio-One 760180 
6-cm dish (cell culture) Greiner Bio-One 628160 
10-cm dish (cell culture) Greiner Bio-One 664160 
15-cm dish (cell culture) Greiner Bio-One 639160 
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10-cm petri-dish Greiner Bio-One 633180 
6-well plates (cell culture) Greiner Bio-One 657160 
12-well plates (cell culture) Greiner Bio-One 665180 
24-well plates (cell culture) Greiner Bio-One 662160 
48-well plates (cell culture) Greiner Bio-One 677180 
96-well plate F bottom with lid Greiner Bio-One 655180 
96-well plate V bottom with lid Greiner Bio-One 651180 
Forceps (Dumont 5 antimagnetic e) Carl Roth LH66.1 
MicroAMP fast optical 96-well reaction 
plate with barcode 0.1mL 
Applied Biosystems 4346906 
MicroAMP Optical adhensive film Applied Biosystems 4311971 
Reservior VWR 89094-664 
 
5.5 Equipment used in this study 
Equipment Source of supply 
Bacterial incubator 37°C Thermo Scientific 
Binocular microscope M165FC Leica 
Binocular microscope MZ16FA Leica 
Cell culture incubator Thermo Scientific 
Cell culture safety cabinet Thermo Scientific 
Centrifuge HERAEUS Fresco 17 Thermo Electron Corporation 
Centrifuge HERAEUS Multifuge 1S-R Thermo Electron Corporation 
Centrifuge HERAEUS Pico 17 Thermo Electron Corporation 
Cold light source KL2500 LCD Zeiss 
Confocal microscope LSM 700 Zeiss 
Developing machine GE Healthcare 
Fluorescence microscope DM6000B Leica 
Heating block TH 21 HLC BioTech 
Light microscope Wilovert S Hund Wetzlar 
Nanodrop 2000c Spectrophotometer peQLab 
Qubit™ Fluorometer Thermo Scientific 
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Real-Time StepOne Plus Real-Time PCR System Applied Biosystems 
Rocking platform 444-0142 VWR 
Rotator SB3 Stuart 
Scale LC 4800 P Sartorius 
SDS-PAGE apparatus Bio-Rad 
Western Blotting Transfer apparatus Bio-Rad 
Sonifier Sonopuls GM 2070 Bandelin electronic 
Thermal cycler C1000 Touch BIO-RAD 
Thermo block 5436 Eppendorf 
Thermo block MHR 23 HLC BioTech 
UV light source ebq100 Leistungselektronik Jena 
UV light source EL 6000 Leica 
UV-Crosslinker Analytikjena 
Vortexer VF2 IKA®-Labortechnik Staufen 
Water bath cell culture WMB 22 Memmert 
Water bath Julabo U3 Julabo Labortechnik GMBH  
 
5.6 RNA extraction, cDNA synthesis and qPCR 
5.6.1 RNA extraction 
Total RNA from cell or tissue samples was extracted with TRIzol™ Reagent (Invitrogen, 
15596026) for qPCR or with QIAzol Lysis Reagent and RNeasy Microarray Tissue Mini Kit 
(Qiagen, 73304) for RNA-Seq according to the user guides.  
RNA extraction with TRIzol™ Reagent: 
(1) Lyse and homogenize samples in TRIzol™ Reagent: for cells, pipet the lysate up and down 
several times to homogenize; for tissue, add 1 ml of TRIzol™ Reagent per sample and 
homogenize using a homogenizer. Incubate for 5 min at room temperature (RT, 15-25°C). 
Samples can be stored at -80°C for later manipulation or continued to step 2 immediately. 
(2) Add 0.2 ml of chloroform per 1 ml of TRIzol™ Reagent used for lysis. Then securely cap 
the tube and vortex for 15 s.  
(3) Incubate for 2-3 min at RT. Centrifuge the sample for 15 min at 12,000 × g at 4°C. 
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(4) The mixture separates into a lower red phenol-chloroform, and interphase, and a 
colorless upper aqueous phase. Transfer the aqueous phase containing the RNA to a new 
tube. 
(5) Add 1 volume of isopropanol to the aqueous phase. Incubate for 10 min at RT. 
(6) Centrifuge for 10 min at 12,000 × g at 4°C. Total RNA precipitate forms a white gel-like 
pellet at the bottom of the tube. 
(7) Discard the supernatant with a micropipette. 
(8) Wash the pellet in 1 ml of 75% ethanol. 
(9) Vortex the sample briefly. Then centrifuge for 5 min at 7500 × g at 4°C. 
(10) Discard the supernatant with a micropipette. 
(11) Centrifuge the pellet for 5 min at 7500× g at 4°C. Then remove the supernatant 
completely. 
(12) Air dry the RNA pellet for around 10 min. 
(13) Dissolve the pellet in 20-50 µl of RNase-free water. 
RNA extraction with QIAzol Lysis Reagent and RNeasy Microarray Tissue Mini Kit: 
(1) Lyse and homogenize samples in QIAzol Reagent: for cells, pipet the lysate up and down 
several times to homogenize; for tissue, add 1 ml of QIAzol Reagent per sample and 
homogenize using a homogenizer. Incubate for 5 min at RT. Samples can be stored at -80°C 
for later manipulation or continued to step 2 immediately. 
(2) Add 0.2 ml of chloroform per 1 ml of QIAzol Reagent used for lysis. Then securely cap the 
tube and vortex for 15 s.  
(3) Incubate for 2-3 min at RT. Centrifuge the sample for 15 min at 12,000 × g at 4°C. 
(4) The mixture separates into a lower red phenol-chloroform, and interphase, and a 
colorless upper aqueous phase. Transfer the upper phase containing the RNA to a new tube. 
(5) Add 1 volume of 70% ethanol, and mix thoroughly by pipetting up and down. Transfer up 
to 700 µl of the sample to an RNeasy Mini spin column placed in a 2 ml collection tube. Close 
the lid gently, and centrifuge for 15 s at 13,000 rpm at RT. Discard the flow-through. If your 
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sample is more than 700 µl, repeat this step using the remainder of the sample. Discard the 
flow-through. 
(6) Add 700 µl Buffer RW1 to the RNeasy spin column. Close the lid gently, and centrifuge for 
15 s at 10,000 rpm to wash the membrane. Discard the flow-through. 
(7) Add 500µl Buffer RPE to the RNeasy spin column. Close the lid gently, and centrifuge for 
15 s at 13,000 rpm to wash the membrane. Discard the flow-through. 
(8) Add 500 µl Buffer RPE to the RNeasy spin column. Close the lid gently, and centrifuge for 
2 min at 13,000 rpm to wash the membrane. Discard the flow-through. 
(9) Place the RNeasy spin column in a new 2 ml collection tube, and discard the old collection 
tube with the flow-through. Close the lid gently, and centrifuge at full speed for 1 min. 
(10) Place the RNeasy spin column in a new 1.5 ml collection tube. Add 30-50 µl RNase-free 
water directly to the spin column membrane. Close the lid gently. To elute the RNA, 
centrifuge for 1 min at 13,000 rpm. 
(11) Repeat step 10 using another volume of RNase-free water, or using the eluate from step 
10 (if high RNA concentration is required). Reuse the collection tube from step 10. 
Total RNA quality was checked by running an agarose gel in 1× TBE buffer (0.089M Tris, 
0.089M H3BO3, 2 mM Na2EDTA pH 8.0) with RNA mixed with 2× RNA loading buffer (100 μl 
formamide, 40 μl formaldehyde, 20 μl 10× TBE and 2 μl Ethidium bromide). RNA 
concentration was measured by NanoDrop2000/2000c or TECAN spectrophotometers. 
5.6.2 cDNA synthesis 
cDNA synthesis was done with the High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, 4368813) and PCR machine from BioRad (C1000 Touch™ Thermal Cycler). 
Generally, 1 µg total RNA was mixed with 2× RT master mix for each sample. 
2× RT master mix: 
Component Volume 
10× RT Buffer 2 µl 
25× dNTP Mix (100 mM) 0.8 µl 
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10× RT Random Primers 2 µl 
MultiScribe™ Reverse Transcriptase 1 µl 
RNase Inhibitor 1 µl 
Nuclease-free H2O 3.2 µl 
Total per reaction 10 µl 
 
Program used in the thermal cycler for cDNA synthesis: 
 
5.6.3 Quantitative real-time polymerase chain reaction (qPCR) 
qPCR was done with Power SYBR Green PCR Master Mix (Applied Biosystems, 4367659) and 
the qPCR machine from Applied Biosystems (StepOne Plus System). cDNA synthesized from 1 
µg RNA was diluted by 1 to 10 and 1 µl dilution was used for qPCR reaction. 
qPCR reactions were carried out in 10 μl volume:  
Component Volume 
2× SYBR® Green buffer  5 µl 
5 μM primer F stock  0.5 µl 
5 μM primer R stock 0.5 µl 
Template (gDNA/cDNA)           1 µl 
H2O 3 µl 
Total per reaction 10 µl 
 
For qPCR, following thermal cycle condition was used:  
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5.7 Mouse lines 
Isl1 knockout mouse line is a kind gift from Sylvia Evans and the floxed Brg1 mouse line is 
kindly provided by Pierre Chambon and Daniel Metzger. 
5.8 Genomic DNA extraction 
Mice tails or ear tissues were incubated in 200-500 μl lysis buffer with proteinase K over 
night at 55°C with 400 rpm shaking. Next day proteinase K was heat inactivated by 
incubating the samples at 95°C for 10 min. Then the tissue debris was pelleted for 5 min, 
6,000 rpm and supernatant was transferred into new tubes and mixed with equal volume 
Isopropanol to precipitate genomic DNA (gDNA). The samples were centrifuged for 15 min 
(15,000 rpm, 4°C). Then supernatant was removed. Genomic DNA pellet was washed with 
70% EtOH and centrifuged for 5 min with 15,000 rpm at 4°C. Discard the supernatant. The 
pellet was air-dried for 10 min at RT. Finally, dissolve the pellet in 100-300 μl ddH2O. 
Lysis buffer for mouse tails or ear tissues: 
Final concentration Stock Volume of stock for 200 ml solution 
100 mM Tris pH 8.5 1 M Tris pH 8.5 20 ml 
5 mM EDTA 0.5 M EDTA pH 8.0 2 ml 
0.2% SDS 10% SDS 4 ml 
200 mM NaCl 5 M NaCl 8 ml 
H2O  166 ml 
Total volume  200 ml 
Freshly adding proteinase K (10 µg/µl proteinase K stock is 100× for adult tissues and 10× for 
embryonic tails) before using. 
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5.9 Genotyping 
1 μl of gDNA was used in the genotyping PCR reaction (total reaction volume 10 or 20 μl). 
REDTaq® ReadyMix™ PCR Reaction Mix (Sigma, R2523) was used for PCR reactions. 
PCR reaction (take 20 µl reaction system as an example): 
10 µl 2xRedTaq 
1 µl primer1/2/3 
1 µl gDNA 
ddH2O to 20 µl 
Program used in the thermal cycler for genotyping of Isl1 mice: 
 
Program used in the thermal cycler for genotyping of Brg1 mice: 
 
Primers used for genotyping: 
Isl1-F, ACTATTTGCCACCTAGCCACAGCA 
Isl1-(384)-R, AATTCACACCAAACATGCAAGCTG 
Isl1-Cre-Jes-R, CTAGAGCCTGTTTTGCACGTTC 
Brg1_P1 (TH185), GTCATACTTATGTCATAGCC 
Brg1_P2 (TG57), GCCTTGTCTCAAACTGATAAG 
Brg1_P3 (TB82), GATCAGCTCATGCCCTAAGG 
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10× DNA loading buffer for agarose gel electrophoresis (protocol from Takara): 
0.9% SDS 
50% Glycerol 
0.05% Bromophenol Blue 
DNA gel electrophoresis: 
Load the PCR products in 1% agarose gel and run at 145V for 30 min in parallel with DNA 
ladder. Then check the results and take images with a UV gel imaging system. 
5.10 Protein extraction and co-immunoprecipitation (Co-IP) 
mESC-derived CPCs and homogenized embryo tissues were lysed in Co-IP buffer (50 mM Tris 
HCl pH 7.5, 10 mM EGTA, 100 mM NaCl, 0.1% Triton X-100, freshly adding protease inhibitor 
and phosphatase inhibitor) on ice for 15 min; then sonicate for 5-10 s with the tip sonifier. 
Then centrifugation was done at 4°C for 15 min with top speed. Transfer the supernatant to 
a new 1.5 ml tube. Protein concentration was determined with BCA method (Thermo 
scientific, 23225). Protein was then subjected to Co-IP or added with 2× SDS sample buffer 
(125 mM Tris-Cl pH 6.8, 4% SDS, 20% glycerol, 100 mM DTT, 0.02% Bromophenol blue) for 
Western Blot (WB). 
For Co-IP done in mESC-derived CPCs, 5 million cells are used for each sample. For Co-IP 
done in embryos, 30 E8.25-E9.0 mouse embryos are used for each sample. The lysates were 
precleared with Protein-G-Sepharose beads (GE Healthcare, 17-0618) for 1-3 hours at 4°C; 
then incubated with the indicated antibodies overnight at 4°C followed by 1h incubation 
with Protein-G-Sepharose beads (GE Healthcare, 17-0618). Immunoprecipitates were 
washed 3-5 times with lysis buffer, then dissolved in 2× SDS sample buffer; incubated at 95°C 
for 10 min and subjected to standard WB analysis. 
5.11 SDS-PAGE and Western Blot 
Proteins were mixed with 2× SDS sample buffer (125 mM Tris pH 6.8, 4% SDS, 20% glycerol, 
100 mM DTT, 0.02% bromophenol blue) and incubated at 95°C for 10 min. Electrophoretical 
separation was performed with 10-15% SDS-PAGE gels (Bio-Rad). Proteins were transferred 
to nitrocellulose membrane using a wet-blot system (Bio-Rad) for 1-2 hours at 100V 
according to the molecular weight of the protein. Membranes were blocked for 1 hour at 
109 
 
room temperature (RT) with shaking in 5% milk (Bio-Rad) or BSA (Carl Roth) solved in 1× 
TBST buffer (0.242% Tris, 0.8% NaCl, 0.1% Tween-20). The primary antibodies were diluted in 
5% milk or BSA in TBST and incubated with the membrane at 4°C overnight. Blots were 
washed 3 times (shaking for 10 min per washing) at RT with TBST. Secondary antibodies 
were diluted in TBST (1:10,000, HRP-conjugates). The incubation was followed by 3 times 
washing (shaking for 10 min per washing) at RT with TBST. After additional washing steps, 
the blots were developed by adding ECL reagent (GE Healthcare) and imaged with a 
developing system (GE Healthcare). 
Separation gel (5 ml) 
Component Volume  
10% 12% 15% 
ddH2O 1.9 ml 1.6 ml 1.1 ml 
30% aqueous acrylamide solution with 0.8% bisacrylamide (37.5:1) 1.7 ml 2.0 ml 2.5 ml 
Buffer 1.5M Tris, pH8.8 1.3 ml 1.3 ml 1.3 ml 
10% SDS 50 µl 50 µl 50 µl 
10% APS 50 µl 50 µl 50 µl 
TEMED 2 µl 2 µl 2 µl 
 
4% stacking gel (2 ml) 
Component Volume 
ddH2O 1.4 ml 
30% aqueous acrylamide solution with 0.8% bisacrylamide (37.5:1) 0.33 ml 
Buffer 1.5 M Tris, pH 6.8 0.25 ml 
10% SDS 20 µl 
10% APS 20 µl 
TEMED 2 µl 
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1× SDS PAGE running buffer:  
0.125 M Tris base 
0.96 mM Glycin 
0.5% SDS 
1× Transfer buffer: 
25 mM Tris 
0.2 mM Glycin 
10% Methanol (freshly adding) 
10× TBS (pH 7.6): 
2.42% Tris 
8% NaCl 
Primary antibodies used for Co-IP and WB: 
Antibody Host Usage Company 
Isl1 Mouse WB (1 to 10) and Co-IP DSHB, 39.4D5 
Brg1 Rabbit WB (1 to 1000) and Co-IP Millipore, 07-478 
Baf60c Rabbit WB (1 to 500)  a kind gift from Pier Lorenzo Puri 
α-tubulin Mouse WB (1 to 3000)  Sigma, T5168 
IgG Mouse Co-IP CST, 2729 
IgG Rabbit Co-IP Santa Cruz, sc-2025 
 
Secondary antibodies used for WB: 
Antibody Host Dilution Company 
α-mouse HRP donkey 1 to 10,000 Jackson ImmunoResearch, 
715-035-150 
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α-rabbit HRP donkey 1 to 10,000 Jackson ImmunoResearch, 
111-035-003 
 
5.12 Culturing of primary cells and cell lines 
5.12.1 Mouse embryonic fibroblasts (MEFs) 
MEFs are isolated from WT E13.5 mouse embryos. The isolation and culture processes are as 
follows: 
(1) Sacrifice the pregnant mouse.  
(2) Lie down the mouse on its back and swab with 70% ethanol. Using scissors make a cut 
across the belly and cut away the skin to expose the gut. With sterile forceps and scissors, 
dissect out the uterus and place it into a petri dish with sterile PBS.  
(3) Isolate the embryos from the uterus, and release the embryos from the embryonic sacs. 
Transfer embryos to a second petri dish with sterile PBS.  
(4) Remove the embryo heads and limbs and scoop out the liver, intestines and heart with a 
pair of forceps. Transfer the embryo carcass into a sterile 15mL tube with a sufficient volume 
of Trypsin/EDTA to cover the carcasses. Using scissors finely mince the tissue.  
(5) Incubate the tissue for 15 min at 37°C, then pipette the tissue a few times through a glass 
Pasteur pipette to dissociate the tissue. Allow the large pieces of cellular debris to settle. 
Remove the supernatant into a fresh tube and add 50 ml of MEF medium. Transfer to a 10-
cm2 dish. Seed cells from 2-3 embryos/dish. Incubate at 37°C with 5% CO2.  
(6) MEFs should attach and begin to divide in 1-3 days. After 2 days, change the medium. 
When the cells are confluent, usually in 3-4 days, the cultures are ready for freezing. Freeze 
them in MEF medium with 10% DMSO and 10% fetal bovine serum (FBS), at 2×106 cells/vial 
(referred to as P0). Or continue culturing them by splitting them by 1:2 to 1:4 when they are 
very confluent. You can passage them up to P7. 
MEF medium: 
500 ml DMEM high glucose (4.5 g/l) 
6 ml 100× Sodium pyruvate 
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6 ml 100× Penicillin-Streptomycin 
6 ml 100× MEM NEAA 
6 ml 100× L-Glutamine 
50 ml fetal bovine serum 
8 ul β-mercaptoethanol 
Preparing feeders: 
Mitomycin C powder (Sigma, M4287) was dissolved in sterilized ddH2O to get a 
concentration of 1 mg/ml and then filtered by 0.22 µm filter. Add newly prepared mitomycin 
C (10 µg/ml final concentration) to dishes with confluent MEFs. Treat the cells for 2 hours in 
the incubator. Then remove the medium and wash the treated cells for 3 times with PBS. 
Trypsin the cells and freeze them. Store the cells in liquid nitrogen for long term use. When 
you use, thaw the cells by 1 to 1 in MEF medium. 
5.12.2 Mouse embryonic stem cell lines (mESCs) 
E14 Tg(Nkx2.5-eGFP) ES cells (Hsiao, Yoshinaga et al. 2008) were maintained on mitomycin C 
treated mouse embryonic fibroblasts (feeders) in KnockOut ESC medium and cultured at 
37°C with 5% CO2. Split regularly every second day.  
KnockOut ESC medium: KnockOut DMEM medium (Gibco, 10829-018) containing 4.5 mg/ml 
D-glucose, supplemented with 10% KnockOut serum replacement (Gibco, 10828-028), 2 mM 
L-Glutamine (Gibco, 25030-024), 0.07 mM β-mercaptoethanol (Sigma, M3148), 0.1 mM non-
essential amino acids (Gibco, 11140-035), 1 mM sodium pyruvate (Gibco, 11360-039), 100 
U/ml Penicillin-Streptomycin (Gibco, 15140-122) and 1,000 U/ml of leukemia inhibitory 
factor (LIF ESGRO, Millipore). 
5.12.3 HEK293T cell line 
HEK293T cells (ATCC, CRL-11268) were cultured in DMEM medium containing 4.5 mg/ml D-
glucose, plus 10% FBS (Gibco, 10270-106), 2 mM L-Glutamine (Gibco, 25030-024), 1 mM 
sodium pyruvate (Gibco, 11360-039), 100 U/ml Penicillin-Streptomycin (Gibco, 15140-122) at 
37°C incubator with 5% CO2 and split regularly at 80% confluency. 
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5.13 Generation of stable ES cell lines 
HEK293T cells were plated one day before the transfection on 6-well plate. The cells were 
transfected with the following plasmids the next day when they reach around 50% 
confluency:  
975 ng pCMV ΔR8.74 (addgene, 22036, lentiviral packaging plasmid) 
525 ng pMD2.G (addgene, 12259, lentiviral envelope expressing plasmid) 
1.5 µg shRNA/PLKO (lentiviral vectors) 
shRNA targeting sequences: (From shRNA library kept in Max Planck institute for heart and 
lung research) 
Isl1 shRNA-3: CTAACCCAGTAGAGGTGCAAA 
Isl1 shRNA-5: CGGCAATCAAATTCACGACCA 
Baf60c shRNA-1: CGCCTAAAGTTCTCTGAGATT 
Baf60c shRNA-2: GCTGCGCCTTTATATCTCCAA 
Brg1 shRNA-1: GCTGCCAAATACAAACTCAAT 
Brg1 shRNA-2: CCCACGATACAACCAGATGAA 
Transfection was done according to the handbook of X-tremeGENE HP DNA Transfection 
Reagent (Roche, 6366236001). Plasmid: transfection reagent = 1:3. Change the medium to 
DMEM ESC medium (DMEM containing 4.5 mg/ml D-glucose, plus 15% FBS, 2 mM L-
Glutamine, 1 mM sodium pyruvate, 100 U/ml Penicillin-Streptomycin, 0.1 mM non-essential 
amino acids, 0.1 mM β-mercaptoethanol) for the transfected HEK293T cells the next day. 72 
hours after the transfection, virus was harvested by collecting the supernatant and 
centrifuging for 20 min at 4,200 rpm at RT. 0.1-0.2 million ES cells were infected with 2 ml 
virus in ESC medium plus 1,000 U/ml LIF and 8 μg/ml polybrene (Sigma, TR-1003-G) plating 
in one well of 5% Poly (2-hydroxyethyl methacrylate) (Sigma, P3932) coated 6-well plate. The 
next day, plate the infected cells on feeders. One day later, change the medium to KnockOut 
ESC medium. The next day, start the selection with 5 µg/ml puromycin. Two days later, 
change the medium. Now the cells can be harvested to check the knockdown efficiency and 
expanded for further experiments. 
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5.14 Generating Isl1 KO mESC lines by CRISPR-Cas9 technique 
Cas9 plasmid PX459 was obtained from Addgene (plasmid #62988). sgRNAs were 
synthesized and cloned into PX459. mESCs (E14:Nkx2.5-GFP line) were transfected with 
PX459-Isl1 gRNA1 and PX459-Isl1 gRNA2 transiently by using Lipofectamine 2000 
(Invitrogen). After 24 hours of transfection, mESCs were selected with 4 µg/ml puromycin for 
48 hours and plated on feeder cells with 5,000 cells per 6-cm dish. After culture for around 7 
days, clones were picked and screened by PCR. 
gRNA sequences: 
Isl1-gRNA1, CCGATTTAAGCCGGCGGAGT 
Isl1-gRNA2, TCATGAGCGCATCTGGCCGA 
Primers used for screening Isl1 knockout clones: 
primer1, GGCTTAATCCTCTCCTGCGG 
primer2, TTTTTGGTGGATCGCCCATGTC 
primer3, CTTGCCAAGAGTTGGGGTGA 
5.15 Cardiac differentiation 
Directed cardiac differentiation: 
ES cells were differentiated into cardiomyocytes by directed differentiation method 
described in (Wamstad, Alexander et al. 2012). Briefly, undifferentiated ES cells were grown 
on gelatin coated dishes in Neurobasal medium: DMEM/F12 (1:1; Gibco, 1103049 and 
21331020) medium supplemented 2,000 U/ml LIF and 10 ng/ml BMP4 (R&D, 314-BP) for 2 
days and differentiated by aggregation in low attachment petri dishes at a cell density of 
75,000 cells/ml in IMDM: F12 medium (3:1; Gibco, 12440053 and 11765054). After 48h 
aggregates were dissociated and re-aggregated in the presence of Activin A (R&D, 338-AC; 5 
ng/ml), VEGF (R&D, 293-VE-010; 5 ng/ml) and BMP4 (R&D, 314-BP; 0.1-0.8 ng/ml; Bmp4 
concentration empirically determined depending on lot). 40h following the second 
aggregation, aggregates were dissociated and plated as a monolayer in Stempro-34 medium 
supplemented with Stempro34 nutrient supplement (Gibco, 10639011), L-Glutamine (2 mM, 
Gibco, 25030024), L-Ascorbic Acid (Sigma, A4403, 50 µg/ml), VEGF (R&D #293-VE-010; 5 
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ng/ml), bFGF (R&D, 233-FB; 10 ng/ml), and FGF10 (R&D, 345-FG; 25 ng/ml) growth factors. 
We usually obtain around 60-80% of Nkx2.5-GFP+ CPCs using this protocol.  
Nkx2.5-GFP+ cells were FACS sorted at CPC stage for RNA extraction. FACS sorted was done 
by cell sorting core facility in medical faculty Mannheim of Heidelberg University. 
Neurobasal: DMEM/F-12 Growth medium composition for 50 ml 
50% Neurobasal   25 ml 
50% DMEM-F12   25 ml 
0.5× N2 supplement   0.25 ml 
0.5× B27 supplement   0.5 ml  
1× Penicillin-Streptomycin  0.5 ml 
1× L-Glutamin    0.5 ml 
0.05% BSA    0.33 ml (Stock 7.5% BSA) 
1.5×104 M monothioglycerol              0.5 µl 
BMP4                                                       10 ng/ml 
LIF                                                             2,000 U/ml 
Differentiation medium: 50 ml 
75% IMDM (with L-Gln)  37.5 ml 
25% F12 (with L-Gln)   12.5 ml 
0.5× N2 supplement   0.25 ml 
0.5× B27 supplement without VA 0.5 ml 
1× Penicillin-Streptomycin  0.5 ml 
50 µg/ml L-Ascorbic acid  0.5 ml (100× Stock) 
4.5×10-4  M monothioglycerol  2 µl 
Add growth factors when necessary 
Hanging drops: 
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ES cells from control and Isl1 KO Nkx2.5-GFP ESC lines were cultured by hanging drops of 500 
cells per drop in 15 μl ESC medium, in the absence of LIF. After 2 days in the hanging drop 
culture, the resulting embryoid bodies (EBs) were transferred to petri dishes in ESC medium. 
The following time points were used for analysis: day2/3 for mesoderm; day4/5 for CPCs and 
day9/10 for CMs. 
5.16 Chromatin immunoprecipitation (ChIP) 
Cells at different stages of differentiation and tissue from mouse embryos are dissociated to 
obtain single cells suspension. Then cells were fixed with 1% formaldehyde (Sigma, F8775) 
for 10 min at RT. Formaldehyde was quenched with glycine at final concentration of 125 mM 
and washed three times with precooled PBS on ice. Cells were lysed in L1 lysis buffer (50 mM 
Tris pH 8.0, 2 mM EDTA pH 8.0, 0.1% NP-40, 10% glycerol) for 5 min, and then nuclei were 
resuspended in L2 nuclear resuspension buffer (1% SDS, 5 mM EDTA pH 8.0, 50 mM Tris pH 
8.0) after centrifuging 5 min at 3,000 rpm 4°C, followed by shearing. The samples then were 
diluted by 1:10 with DB-dilution buffer (0.5% NP-40, 200 mM NaCl, 5 mM EDTA, 50 mM Tris 
pH 8.0). After preclearing, chromatin was incubated with primary antibody overnight at 4°C 
followed by 1 hour incubation with Protein-A/G Sepharose beads (GE Healthcare). 
Immunoprecipitates were washed four times with NaCl-washing buffer (0.1% SDS, 1% NP-40, 
2 mM EDTA, 500 mM NaCl, 20 mM Tris pH 8.0), followed by three washes with LiCl-washing 
buffer (0.1% SDS, 1% NP-40, 2 mM EDTA, 500 mM LiCl, 20 mM Tris pH 8.0) and three washes 
with TE buffer (Tris pH 8.0 20 mM; EDTA 2 mM), then eluted with EB-extraction buffer (TE 
pH 8.0, 2% SDS). Reverse cross-linking was done by incubation at 65°C overnight with 
shaking. DNA was purified with phenol/chloroform extraction and precipitation. Purified 
DNA was subjected to qPCR analysis or ChIP-Seq. 
Antibodies used for ChIP: 
Isl1: Developmental Studies Hybridoma Bank, 39.4D5 
Brg1: Millipore, 07-478 
Gata4: Santa Cruz, sc-1237 
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5.17 Bioinformatic analysis 
5.17.1 RNA-Seq 
Sequencing was performed on the NextSeq500 instrument (Illumina) using v2 chemistry. All 
RNA libraries result in minimum of 30 million reads per library. All RNA-Seq reads were 
mapped to the mm9 reference genome using the STAR (PMID: 23104886) (-alignIntronMin 
20 -alignIntronMax 500000). Samples were quantified by the use of analyzeRepeats.pl 
(PMID: 20513432) (mm9 -count exons -strand both -noadj). Differential gene expression and 
normalization was performed with DESeq2.Reads per kilobase per millions mapped (rpkm) 
for heatmap was obtained by the use of rpkm.default from EdgeR. The KNIME 2.9.1 platform 
(Konstanz, Germany) was used to filter differentially regulated genes. Heatmaps from the 
RNA-Seq were performed using heatmap.2 from ggplot2 in R. The PCA plots in each RNA-Seq 
set were obtained by the use of prcomp into a custom R-script. RNA-Seq data analysis 
workflow is shown below. 
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5.17.2 ChIP-Seq 
ChIP-Seq reads were mapped to the mouse reference genome mm9 (UCSC assembly) using 
the default settings of bowtie2. Genome-wide distribution of the reads was performed using 
ngs.plot with mm9 Ensembl (version 67) as reference annotation. Peaks for Isl1-ChIP-Seq in 
Embryos and CPCs were called with the use of MACS14 PMID: 18798982  with the parameter 
(p1e8 d80 --nomodel --shiftsize 80). ChIP-Seq peak annotation was performed using 
annotatePeaks.pl (default settings). For data visualizing bam files were converted to BigWig 
files by the use of BamCoverage from deepTools2 (PMID: 24799436) (-b 20 -smooth 40 -e 
150 --normalizeTo1x 2150570000). In Isl1 CPCs ChIP-Seq common peaks between both ChIP-
Seq replicates, were obtained by the use of bedtools intersect (-wa). Venn diagrams were 
generated with BioVenn online tools (PMID: 18925949) and protein coding genes were used 
for all comparisons. ChIP-Seq data analysis workflow is shown below. 
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5.17.3 ATAC-Seq 
Pharyngeal mesoderm and hearts of E8.5 embryos were dissected. Tissues or 50,000 CPCs 
were lysed in 50 µl cold lysis buffer (10 mM Tris-HCl pH 7.4, 10 mM NaCl, 3 mM MgCl2, 0.1% 
Igepal CA-630) and used for ATAC Library preparation using Tn5 Transposase from Nextera 
DNA Library Prep Kit (Illumina #15028211). After centrifugation (10 min, 500 g at 4°C), cell 
pellet was resuspended in the transposition reaction mix (25 µl TD-Buffer, 2.5 µl Tn5, 22.5 µl 
water) and incubated at 37°C for 30 min with gentle mixing. Immediately following the 
transposition reaction, purification was done using MinElute PCR Purification Kit (Qiagen, 
cat# 28004). Amplification of Library together with Indexing was performed as described in 
(Buenrostro, Giresi et al. 2013). Libraries were mixed in equimolar ratios and sequenced on 
NextSeq500 platform using V2 chemistry. The sequencing quality was assessed using FastQC 
(Anders and Huber 2010) (http://www.bioinformatics.babraham.ac.uk/projects/fastqc). 
Reads were mapped with bowtie2 to mm9 mouse genome. Samtools view (-F 1804 -f2) was 
used to remove reads unmapped, mate unmapped, not primary alignment. The 
MarkDuplicates.jar from Picard 1.136 was use to remove PCR artefacts. The mapped reads 
from two samples were merged using bam tools merge program (Barnett, Garrison et al. 
2011). Peaks calling from each repetition was performed with by the use of MACS14 (PMID: 
18798982) (p1e5 -nomodel and -shiftsize 100). Similar to Isl1-ChIP-Seq Bedtools v2.15 
(intersect -wa) (PMID: 20110278) was used to obtain binding sites overlapping in at least 1bp 
each of the repetition. BamCoverage function of deepTools2 (PMID: 24799436) (-b 20 -
smooth 40 -e 150) was used to create normalized bigwig files (reads per genome coverage, 
RPGC). Further bigWigAverageOverBed (https://github.com/ENCODE-DCC/kentUtils) was 
used to quantify the mapped reads on the peaks areas. The quantified matrix was 
normalized using edgeR (PMID: 19910308). Heatmaps and density plots were creating using 
computer matrix followed by plotHeatmap or plotProfile from deepTools2 (PMID: 
24799436). ATAC-Seq data analysis workflow is shown below. 
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For ATAC-Seq analysis three wild-type, three Isl1-/- and three Isl1-Cre+/-/Brg1fl/fl E8.5 (6 
somites) embryos and ESC-derived CPCs from two independent differentiations were used. 
5.17.4 Others 
The Isl1 regulated gene network presented in Results Figure 27 was built by submitting a 
curated list of Isl1 primary downstream targets to the GeneMANIA web based software. The 
network was subdivided into transcription factors, signaling molecules, muscle structural 
and contractile genes and other genes involved in heart development and visualized using 
Cytoscape.  
The taq heatmap was created using ngsplot PMID: 24735413 followed by the use of a home 
script. Bedtools v2.15 (intersect -wa) (PMID: 20110278) was used to find the common 
binding areas among Isl1-ChIP-Seq in CPCs, ATAC-Seq in CPCs and Gata4-ChIP-Seq in CPC 
(GSE72223). Similar settings were using to cross the common areas between Isl1- and Brg1-
ChIP-Seq (GSE116281) and ATAC-Seq in CPCs vs ATAC-Seq in E8.5 embryos. 
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Gene ontology analysis was performed using DAVID Bioinformatics Resources 6.8. The other 
GO term related to cardiac muscle cell differentiation, endothelial cell differentiation and 
smooth muscle cell development/differentiation was obtained from 
(http://amigo.geneontology.org/amigo/landing). Computer matrix followed by plot profile 
from deepTools2 (PMID: 24799436) was used to plot the ATAC-Seq from E8.5 embryos on 
the TSS of the set of genes.  
Brg1-ChIP-Seq (GSE116281) and Gata4-ChIP-Seq (GSE72223) were publically available data. 
Sequencing data (ChIP-Seq, RNA-Seq and ATAC-Seq) have been deposited in the Gene 
Expression Omnibus (GEO) under accession code GSE80383. 
5.18 Primers used in this study 
5.18.1 qPCR primers 
Gene name Sequence of qPCR primers 
qGAPDH_F AACTTTGGCATTGTGGAAGG 
qGAPDH_R GGATGCAGGGATGATGTTCT 
qSox2_F AGAACCCCAAGATGCACAAC 
qSox2_R TCTCGGTCTCGGACAAAAGT 
qNanog_F ACCTGAGCTATAAGCAGGTTAAGA 
qNanog_R GGGATACTCCACTGGTGCTG 
qBry_F AGGGAGACCCCACCGAACGC 
qBry_R CCGGGAACATCCTCCTGCCGTT 
qMesp1_F GTTTAAGCCCGGCCGTCTGCA 
qMesp1_R ATGTCGCTGCTGAAGAGCGGAGA 
qMesp2_F TAGAAAGAGCCGCTGACTCC 
qMesp2_R CTAGGCTCTGGGGACATCTG 
qMef2c_F TCCATCAGCCATTTCAACAA 
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qMef2c_R AGTTACAGAGCCGAGGTGGA 
qIsl1_F ACGTGCTTTGTTAGGGATGG 
qIsl1_R CAAGAAGTCGTTCTTGCTGA 
qHand2_F CGGAGAGGCGGAGGCCTTCA 
qHand2_R CAGGGCCCAGACGTGCTGTG 
qTbx5_F ATGGTCCGTAACTGGCAAAG 
qTbx5_R ACAAGTTGTCGCATCCAGTG 
qTbx20_F GCAGCAGAGAACACCATCAA 
qTbx20_R GTGAGCATCCAGACTCGTCA 
qGata4_F TCTCACTATGGGCACAGCAG 
qGata4_R GCGATGTCTGAGTGACAGGA 
qTnnt2_F ATCCCCGATGGAGAGAGAGT 
qTnnt2_R CTGTTCTCCTCCTCCTCACG 
qMlc2a (Myl7)_F CCCATCAACTTCACCGTCTT 
qMlc2a (Myl7)_R CGTGGGTGATGATGTAGCAG 
qMlc2v (Myl2)_F CTGCCCTAGGACGAGTGAAC 
qMlc2v (Myl2)_R CCTCTCTGCTTGTGTGGTCA 
qTtn_F ACCACCCAACTTCAGTCAGC 
qTtn_R TCCCGGTAGAACTTCACCAC 
qRyr2_F TCTGCCAGGACTGTTTGTCC 
qRyr2_R GACTGAGGAAGGATCAGGGGA 
qBaf60c (Smarcd3)_F GAGATCAGTGCTCTGGACAGT 
qBaf60c (Smarcd3)_R GAGCAGGTCTTGGACGTAGC 
qMyocd_F GCTGAGACTCACCATGACAC 
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qMyocd_R TGGACCTTTCAGTGGCGGTA 
qBrg1_F CACCTACCATGCCAACACTG 
qBrg1_R CGCTTGTCCTTCTTCTGGTC 
qPax7_F CATGGTGGGCCATTTCCACT 
qPax7_R GGCCCGGGGCAGAACTAC 
qTbx18_F AATGAGCTGGATGACCAAGG 
qTbx18_R GGACAGATCATCTCCGCAAT 
qSmyd3_F CTCCGACCCCTTGGCTTAC 
qSmyd3_R TGGCAATTCGGCATTGAGAAC 
qHdac3_F CTCACGCCAGTATCTGGACC 
qHdac3_R CATACGTCAGGAGGTCTGCC 
qMlc1v (Myl3)_F ATCACATACGGGCAGTGTGG 
qMlc1v (Myl3)_R TTGAGCTCTTCCTGTTTTGGC 
qWnt2_F CTGATGTAGACGCAAGGGGG 
qWnt2_R CCTGTAGCTCTCATGTACCACC 
qTpm1_F TCCAGCTGAAAGAGGCCAAG 
qTpm1_R CTTCTGAGAGCTCAGCCCG 
qTmod1_F GAGGATGAAATCCTGGGGGC 
qTomd1_R GGTGGTCTGATCCTTCTGCC 
 
5.18.2 ChIP-qPCR primers 
Gene name Sequence of ChIP primers ChIP 
Hand2_F AATTGCCGAGGTCCTCTTCT Brg1/Gata4 ChIP 
Hand2_R CTCAGAGCCAGCCAACTACT Brg1/ Gata4 ChIP 
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Ttn_F CAGAATATGCAAATCCAGGTGC Brg1/Gata4 ChIP 
Ttn_R CGAGGCATTGGTGAAGACTC Brg1/ Gata4 ChIP 
Ryr2_F TAGGATGGATCTCACTGGATGGT Brg1/Gata4 ChIP 
Ryr2_R AAAGTTAAGCCTTGCCCCACA Brg1/ Gata4 ChIP 
Myocd_F CTGTCAGGCTAGCTGATGATGAA Brg1/Gata4 ChIP 
Myocd_R ATACAACATCTTCCCCTTCACTTCC Brg1/ Gata4 ChIP 
Mlc1v_F GTTCTCGACTCCTCCGGGAA Brg1/Gata4 ChIP 
Mlc1v_R CTCCCCACGTGTCCTTGTC Brg1/ Gata4 ChIP 
Atp1a2_F CGGAAAAGGCTGGGTTAAGT Brg1/Gata4 ChIP 
Atp1a2_R GGGGAGTGGGATTGTTTTCT Brg1/ Gata4 ChIP 
Mef2c_F TCAGTGTCTGCTCCTGCTTC Brg1 ChIP 
Mef2c_R TTCCCTCCACACCTTACTGG Brg1 ChIP 
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